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Development of treatments for rare diseases is challenging due to the limited number
of patients available. Since a substantial proportion of all patients may be included in
the trial, the goal is to treat those patients within the trial as effectively as possible.
This motivates the use of response-adaptive designs which skew allocation towards the
better performing treatment(s) but often reduce the statistical power. Consequently,
this raises the question of how to allocate patients in order to attain a compromise
between these conflicting objectives. This can be formalised as a multi-armed bandit
problem with the dynamic programming and Gittins index solutions considered here.
Dynamic programming is utilised to propose a randomised design for a two-arm
sequential trial with binary outcomes. This design maximises the total number of
patient successes and penalises if a minimum number of patients are not allocated to
each treatment so that sufficient power is achieved. Moreover, the treatment effect
estimator exhibits a very small bias and mean squared error. This design is shown to
be fairly robust to delays, with only a slight reduction in patient benefit. Solutions




A design based upon the Gittins index — which is randomised and orientated to-
wards a patient benefit objective — is proposed for normal outcomes, illustrated in the
multi-armed setting where patients are allocated in blocks. Patient benefit gains are
observed when using this design with a continuous outcome instead of dichotomising
it. These gains persist even when missing data is imputed.
Throughout, we compare the proposed designs to alternative designs via extensive
simulations in a range of scenarios.
This thesis helps bridge the gap between theory and practice by addressing key
issues that have prevented bandit models from being implemented in practice.
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Before any new medical treatment is made available to the public, clinical trials must
be undertaken in humans to ensure that the treatment is safe and efficacious (Pocock,
1983). Such trials are usually divided into the following phases. Phase I trials gen-
erally involve a small number of healthy volunteers, but in some circumstances, e.g.
when testing treatments for a fatal disease, these may be patients who have exhausted
other treatment options. The focus of phase I trials is on the study of the pharma-
cokinetics (i.e. the movement of the treatment through the body), pharmacodynamics
(i.e. the treatment’s effect on the body) and toxicity of a treatment, with the primary
objective being to establish a tolerable dose range. Phase II trials (and onwards) are
performed on patients that have the disease of interest. They are initial efficacy stud-
ies aimed at determining the dose, and frequency of dosing, required to successfully
treat patients (Peace and Chen, 2010). If a treatment is indicated as effective during
phase II, then it proceeds to phase III. These are large-scale, costly confirmatory trials
which usually compare the experimental treatment to a control (standard treatment
or placebo), with the primary objective of confirming the efficacy of the treatment.
After the treatment has been approved, its long-term effects in the wider population
are monitored during phase IV trials.
1
CHAPTER 1. INTRODUCTION AND MOTIVATION 2
In March 2004, the United States Food and Drug Administration (FDA) released
the landmark report, Innovation/Stagnation: Challenge and Opportunity on the Crit-
ical Path to New Medical Products (U.S. Food and Drug Administration, 2004), ex-
pressing concern over the slowdown, instead of the expected acceleration, in innovative
treatments being submitted to the FDA for approval despite advances in biomedical
science. It highlights “an urgent need for improvement in the efficiency and effec-
tiveness of the clinical trial process, including improved trial design” and in par-
ticular, “much more attention and creativity need to be applied to disease-specific
trial design”. Consequently, the FDA released a follow-up document, the Critical
Path Opportunities Report (U.S. Food and Drug Administration, 2006), indicating
that biomarker development and streamlining clinical trials are the two most impor-
tant areas for improving medical product development. Streamlining clinical trials in-
cludes advancing innovative trial designs, such as adaptive designs (Chow and Chang,
2012), which provides the fundamental motivation and underlying theme throughout
this thesis.
Adaptive designs have gained increasing popularity amongst researchers, industry
and regulatory bodies (Lipsky and Lewis, 2013). In particular, this has been demon-
strated by the FDA’s recent release of an updated draft guidance on Adaptive Designs
for Clinical Trials of Drugs and Biologics (U.S. Food and Drug Administration, 2018)
as part of their mission to “modernise clinical trials and advance the development of
safe, effective drugs”. Here, they define an adaptive design as “a clinical trial de-
sign that allows for prospectively planned modifications to one or more aspects of
the design based on accumulating data from subjects in the trial”. In contrast with
the traditional approach adopted in clinical trials, the ability to use information dy-
namically as it accrues to improve efficiency makes adaptive designs a particularly
attractive alternative (Pallmann et al., 2018).
The current gold standard design used in clinical trials is the randomised controlled
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trial (RCT), in which patients are randomised to either the control or experimental
treatment(s) in a pre-fixed, and typically equal, proportion. Although this design
detects a clinically meaningful treatment difference with a high probability, i.e. it
maximises the statistical power of the design under the condition of equal variances
(Atkinson and Biswas, 2014), which is of benefit to future patients outside of the trial,
it lacks the flexibility to incorporate other desirable criteria, such as the participant’s
well-being. As such, a large number of patients within the trial are randomised to
the inferior treatment, which raises ethical issues. This is particularly concerning
in a clinical trial for a rare disease in which a substantial proportion of all patients
with the disease may be included in the trial, and hence the priority should now
be on treating those patients within the trial as effectively as possible (Palmer and
Rosenberger, 1999). This highlights the inherent conflict present in a clinical trial
between individual ethics (doing what is best for the patients within the trial) and
collective ethics (doing what is best for the future target population as a whole), see
e.g. Lellouch and Schwartz (1971). RCTs focus on gathering information, and thus
place emphasis on the latter (Pullman and Wang, 2001).
The justification for a RCT is that there exists a state of equipoise throughout
the trial. Freedman (1987) defines this as a state of genuine uncertainty about which
treatment is superior. However, it may be argued that even if there exists a state of
equipoise at the beginning of a trial, some idea of which treatment is superior is likely
to be obtained as the trial progresses and the data accumulates (the fundamental
concept of an adaptive design).
This motivates the use of a particular type of adaptive design, namely, response-
adaptive designs which take advantage of the accumulating data on patient responses
to skew the allocation probabilities towards the better performing treatments, thus
reducing patient exposure to seemingly inferior treatments (Rosenberger and Lachin,
1993). The aim is to maximise the expected number of successful responses within
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the trial, whilst still maintaining sufficient power. Consequently, this type of design is
well-suited for rare disease trials and small population trials more generally, including
paediatric trials and trials involving subgroups of common diseases, following the re-
cent surge in personalised medicine (e.g. Lee and Wason, 2019), which “leads toward
a fractioning of the target population for each drug” (Zhang et al., 2019). Another
pertinent application area that has been highlighted in the literature is in trials for
highly contagious diseases, where it is hoped that the disease might be eradicated by
the treatment being tested (Berger, 2015). Acute care research, including diseases
with high mortality and no existing treatments (Meurer et al., 2012), is a further ex-
ample where response-adaptive designs may be particularly beneficial (McEvoy et al.,
2016). In contrast to RCTs, response-adaptive designs tend to favour individual ethics
(Pullman and Wang, 2001).
This raises the question of how to design a clinical trial which provides a com-
promise between the collective and individual ethics. This is a perfect example of an
exploration versus exploitation trade-off, which is prevalent in many decision-making
problems, since the fundamental tension is between exploiting treatments that have
performed well (individual ethics) and exploring new treatments in case they are
even better (collective ethics). The formalisation of this problem subsequently be-
came known as the multi-armed bandit problem (MABP) which seeks to balance this
underlying exploration versus exploitation trade-off in order to provide an optimal
allocation rule (Berry and Fristedt, 1985). Dynamic programming (Bellman, 1956)
is one possible method that can be implemented to obtain the optimal solution of
the MABP. However, this approach suffers from the “curse of dimensionality” which
limits its practical applicability, particularly when the number of treatment arms is
large. Remarkably, Gittins and Jones (1974) showed that an optimal solution exists
by decomposing the MABP into smaller sub-problems, thus removing the prohibitive
computational complexity. Moreover, it takes the form of an index policy based on
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what has become widely known as the Gittins index. Both of these solution concepts
will be described in further detail in Section 2.2.3, and will form the foundations of
the methods proposed in Chapters 3–6.
Indeed, across the bandit literature, the use of bandit solutions to optimally de-
sign a clinical trial has been the primary motivation for their study. Gittins (1979)
even states that their “chief practical significance is in the context of clinical trials”.
However, rather ironically, they have never actually been implemented in clinical
practice for reasons which will be discussed in Chapter 2. Nevertheless, in recent
years, there has been some evidence of progress, and response-adaptive randomised
designs based on the MABP, although not optimal, have been implemented in clin-
ical trials (e.g. Barker et al., 2009). Despite these recent advances, bandit theory
and clinical trial practice continue to remain relatively separate entities. Therefore,
the overarching aim of this thesis is to overcome some of the existing practical bar-
riers and thus bridge the gap between bandit theory and clinical trial practice. As
a result, this will contribute to the streamlining of clinical trials in order to improve
medical product development, as identified by the Critical Path Opportunities Report
(U.S. Food and Drug Administration, 2006).
1.1 Outline of Thesis
Chapter 2 aims to introduce the general background information and key concepts
which underpin the main ideas proposed in the subsequent chapters of this thesis.
The relevant literature with regards to both clinical trials and bandit theory will be
outlined in Sections 2.1 and 2.2, respectively, so that the reader is necessarily equipped
for the material that follows.
Chapter 3 utilises the dynamic programming solution of the MABP to propose
a response-adaptive treatment allocation rule in the context of a two-arm sequential
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clinical trial with binary endpoints (i.e. successes or failures) which are assumed to be
available immediately. Chapters 4 and 5 extend this modelling framework to encom-
pass the practical issue of delayed patient responses which significantly increases the
complexity of the problem. In Chapter 6, attention moves to the alternative solution
concept of the MABP, namely, the use of Gittins indices to allocate patients. The
focus is now on continuous endpoints, assumed to be normally distributed with un-
known mean and variance, predominantly in the multi-armed setting where patients
are allocated in blocks rather than sequentially. Additionally, the issue of artifi-
cially dichotomising a continuous endpoint and dealing with missing data is touched
upon. Simulations in the context of real and hypothetical trials are used throughout
to motivate and illustrate the proposed methodology. Chapters 3 and 6 form two
self-contained papers which have been reproduced verbatim from the corresponding
published versions and as such, there is necessarily some overlapping material.
Chapter 7 concludes this thesis by summarising the main contributions and sug-
gesting avenues for further research.
Chapter 2
Background and Literature Review
2.1 Randomisation in Clinical Trials
The concept of randomisation1 was popularised by Fisher (1926) in an agricultural
study (see e.g. Hall, 2007) and was first considered for use in clinical research by
Amberson et al. (1931) who randomised patients to treatments using the outcome of a
coin toss. However, the first iconic RCT is widely recognised as the streptomycin trial
designed by Sir Austin Bradford Hill and conducted by the Medical Research Council
(1948) in which random numbers were used to allocate patients.
Since then, randomisation of patients to treatments has been considered paramount
in comparative clinical trials in order to: (i) generate comparable groups that are sim-
ilar in terms of extraneous factors, except for the intervention of the treatment; (ii)
minimise several types of bias, e.g. treatment allocation bias2, which will ultimately
add validity to the subsequent statistical tests; and (iii) provide a probabilistic basis
for frequentist inference (Rosenberger et al., 2019).
The randomisation methods commonly used in clinical trials can be broadly cat-
1Randomisation in clinical trials may refer to either the random selection of patients from the
population into the trial or the random allocation of patients to treatments within the trial. We use
it exclusively to mean the latter throughout.
2Note that some authors, e.g. Chow and Chang (2012) and Rosenberger and Lachin (2016), use
the term selection bias analogously.
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egorised into two groups, namely, conventional (or fixed) randomisation (in which
the treatment allocation probabilities remain constant throughout the trial, as in
the RCT) and adaptive randomisation (in which the treatment allocation probabil-
ities vary during the trial) (Chow and Chang, 2012). Examples of adaptive ran-
domisation schemes include: treatment-adaptive (or restricted) randomisation which
seeks to balance the sample sizes between treatment groups; covariate-adaptive ran-
domisation which aims to balance covariates of interest between treatment groups
by adapting the allocation probabilities according to patient prognostic imbalance;
response-adaptive randomisation in which the randomisation probabilities change as
patient responses are observed in order to favour the better performing treatments;
and covariate-adjusted response-adaptive (CARA) randomisation which is similar to
response-adaptive randomisation, but now the patient’s covariate profile is also taken
into consideration. In the latter case, since the randomisation probabilities depend on
responses of patients with similar characteristics, such as certain types of biomarkers,
this is an important step towards personalised medicine (see Hu, 2012).
The primary focus of this thesis will be on response-adaptive randomisation meth-
ods. For an overview of the other adaptive randomisation methods, the reader is
referred to Chow and Chang (2012, Chapter 3) or Sverdlov (2015, Chapter 1). CARA
designs are also discussed in Hu and Rosenberger (2006, Chapter 9), Antognini and
Giovagnoli (2015, Chapter 6) and Rosenberger and Lachin (2016, Chapter 10).
2.1.1 Response-Adaptive Randomisation (RAR)
The exact definition of response-adaptive randomisation3 (RAR) varies in the litera-
ture. Some authors, e.g. Rosenberger and Lachin (2016), use it explicitly to refer to
response-adaptive designs that are fully randomised (i.e. non-deterministic) so that
the allocation probabilities are strictly between 0 and 1. Others, e.g. Coad (2008),
3This is sometimes referred to as outcome-, or data-, dependent randomisation within the litera-
ture.
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use it more generally to refer to any design (whether randomised or not) which uses
patient responses to adapt the allocation probabilities towards the most promising
treatment(s). Throughout this thesis, we adopt the former interpretation of RAR.
The ultimate aim of RAR is to allocate more patients to the treatment(s) per-
forming better, thus reducing patient exposure to inefficacious treatment(s), without
sacrificing randomisation. This is more ethically acceptable compared to conventional
randomisation, particularly if a treatment failure represents an extreme, or fatal, out-
come (Pullman and Wang, 2001). Although RAR does not fully eliminate the ethical
problem of randomising patients to inferior treatment(s), it certainly mitigates it by
reducing the probability of allocation to the inferior treatment(s) (Rosenberger and
Lachin, 2016). This can be considered a “necessary evil” which ensures a valid com-
parison between the treatment groups can take place in order to maintain a sufficient
level of power at the end of the trial, and hence provides a compromise between the
collective and individual patient benefit. Consequently, RAR is subject to attack from
both sides of the collective versus individual ethics debate (Tamura et al., 1994) so
remains a very controversial subject within statistical and clinical trial communities
(see Korn and Freidlin (2011); Berry (2011); Lee et al. (2012); Thall et al. (2015);
Hey and Kimmelman (2015) and corresponding commentaries; London (2018)).
Finally, the adaptive designs guideline by the U.S. Food and Drug Administration
(2018) provides an additional pragmatic rationale advocating the use of RAR, namely,
that patients may be more willing to enrol in the trial because RAR improves their
chance of being allocated to the better treatment, therefore increasing speed and ease
of recruitment. This has been demonstrated in various studies; see Tehranisa and
Meurer (2014) and McEvoy et al. (2016), for example, who illustrate that effectively
communicating the randomisation scheme to patients improves their understanding
and leads to an even higher participation rate. Ultimately, implementing RAR could
help alleviate recruitment problems which poses one of the most challenging aspects
CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 10
in the conduct of RCTs (see Sully et al., 2013, for example).
However, RAR may lead to accrual bias in which participants wait until later on
in the trial to enrol since that way, they will have a higher probability of receiving
the superior treatment (Rosenberger, 1996). Further, if there is heterogeneity in
patient enrolment over time, such as the most severely ill patients enrolling as soon
as possible4, then a bias will be introduced which will affect the validity of the results
(see Chappell and Karrison, 2006). One solution is to use CARA randomisation if the
underlying covariates causing the heterogeneity are known in advance (Rosenberger
et al., 2012, Section 4.3). Examples of recent developments in this area include Villar
and Rosenberger (2018) and Villar et al. (2018). Alternatively, one may consider using
block RAR to reduce the bias caused by population drift (see Magirr, 2011; Korn and
Freidlin, 2011, for example).
An important consideration when choosing between conventional randomisation
and RAR is the context of a clinical trial and, more specifically, the patient horizon
(i.e. the total number of patients with the disease of interest both inside and outside
the trial). That is, does the trial include essentially every patient who will have the
condition of interest during a particular time period? Or is there a large number of
patients outside the trial who could gain from the results of the trial? Berry and
Eick (1995) compare the performance of conventional equal randomisation, in which
half of the patients are randomly allocated to each of the two treatment groups, to
four response-adaptive designs. Their main conclusion is that a design employing
equal randomisation is very nearly optimal when the condition is relatively common.
However, if the condition being treated is rare, then response-adaptive designs can
perform substantially better and might be a more suitable alternative. This is because,
in the latter case, a substantial proportion of all patients exhibiting the condition are
included in the trial. Therefore, learning about treatment effectiveness with a view
4This is often referred to as patient (or population) drift.
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to treating patients in the “larger” outside population is much less important. Now,
the primary concern is to treat the patients within the trial as effectively as possible.
A more recent study by Du et al. (2015) obtains similar conclusions when com-
paring equal randomisation with RAR under fixed patient horizons but varying trial
sizes. In particular, they show that equal randomisation is preferred when the number
of patients outside the trial is much larger than the number inside the trial, and RAR
is favoured for large treatment differences or when the number of patients outside the
trial is relatively small.
2.1.2 Examples of RAR Procedures
RAR procedures proposed in the literature generally belong to either one of two main
families, namely, those that are: (i) design-driven, i.e. based on an intuitive rule which
can be completely non-parametric, or (ii) target-driven, i.e. based on an optimal (or
desired) allocation target which depends upon estimated parameters of the assumed
response distribution (Rosenberger and Lachin, 2016, Section 10.3). An example of
each is provided below.
(i) Randomised Play-the-Winner Rule (RPWR)
The most famous (non-randomised) response-adaptive design is the play-the-winner
rule (PWR) which was first introduced in a clinical trial context by Zelen (1969).
For a clinical trial comparing two treatments (A and B) with binary responses (suc-
cess or failure) in which patients enter the trial sequentially, the PWR proceeds as
follows: a success on a particular treatment causes the next patient to receive the
same treatment, whereas a failure on a treatment causes the next patient to receive
the alternative treatment. Suppose the first patient is randomly allocated to either
treatment A or B with probability 0.5, then an example of a response sequence from
a trial employing the PWR is displayed in Table 2.1.1.
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Treatment A Success Success Failure Success Failure ...
Treatment B Failure Success ...
Table 2.1.1: Play-the-winner allocation rule.
A fully randomised version, the randomised play-the-winner rule (RPWR), was
proposed by Wei and Durham (1978) which has the advantage that it is no longer
deterministic (so is less vulnerable to allocation bias, for example). The RPWR has
been the most studied urn model in the RAR literature (Rosenberger and Lachin,
2016) and is easily implemented in two-arm trials with binary responses as follows:
1. Initially, an urn contains u balls of type A and u balls of type B. Therefore,
clinical equipoise is assumed at the onset of the trial.
2. When a patient enters the trial, a ball is drawn randomly from the urn with
replacement. If it is a type i ∈ {A,B} ball, the patient receives treatment i.
3. When a patient’s response is available, the urn is updated as below:
(a) A success on treatment A, or a failure on treatment B, generates an addi-
tional β type A balls and α type B balls in the urn.
(b) Similarly, a success on treatment B, or a failure on treatment A, generates
an additional β type B balls and α type A balls in the urn, where 0 ≤ α ≤ β
are integers.
This rule is denoted by RPWR(u, α, β). Therefore, the urn accumulates more
balls representing the more successful treatment, thus increasing the probability that
a patient will be allocated to the current best treatment. Unlike the PWR, the
allocation probability is now a function of all past allocations and responses (rather
than depending only on that of the previous patient). In particular, it is proportional
to the number of balls of each treatment in the urn.
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Moreover, since sampling is with replacement, delayed responses can be accommo-
dated by simply updating the urn composition when the response becomes available.
Hardwick et al. (2006) refer to this as the delayed RPWR (DRPWR). Two different
DRPWR models are discussed in the literature; these are summarised in Atkinson
and Biswas (2014, Chapter 3). First, Wei (1988) extended the RPWR to incorporate
delayed responses by including another set of indicator variables (in addition to the
treatment allocation and response indicator variables of the RPWR) which determine
whether or not a previous patient’s response has been observed before allocation of
the next patient. Tamura et al. (1994) employ this DRPWR model using response
indicators for a surrogate endpoint instead which is observed sooner than the long-
term endpoint. Bandyopadhyay and Biswas (1996) introduce a second model which
has a slight modification that ensures the denominator of the conditional allocation
probability is free of any random variables. Biswas (1999) compares these two models
showing that they are asymptotically equivalent and there is no significant difference
between their performances. Hence, we will consider the first version of the DRPWR
as a comparator in Chapter 4.
Simulation studies, such as those by Rosenberger et al. (2001b) and Stallard and
Rosenberger (2002), have illustrated that the RPWR may exhibit high variability in
the allocation proportions and a significant reduction in power for certain parame-
ter values.In particular, in a two-arm trial with binary endpoints, if the sum of the
success probabilities is greater than 3/2, then the asymptotic variance of the alloca-
tion proportion depends on the initial urn composition (Hu and Rosenberger, 2003)
and a high variability with reduced power is observed (e.g. Rosenberger et al., 2001b,
Table 1). In contrast, when the sum of the success probabilities is strictly less than
3/2, the asymptotic variance is independent of the initial urn composition and as
such, the RPWR has a smaller variability and larger power. This is illustrated in
Coad and Rosenberger (1999, Table 1) in which the power values of the RPWR are
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very similar to those attained by conventional randomisation, or Rosenberger and Hu
(2004, Table 2). An alternative type of urn model which has the same limiting allo-
cation proportion as the RPWR but exhibits far less variability is the drop-the-loser
rule proposed by Ivanova (2003). Note that the theoretical relationship between the
power and variability of a RAR procedure has been derived in Hu and Rosenberger
(2003), confirming that the average power is a decreasing function of the variability
(see also Hu and Rosenberger, 2006, Chapter 2).
The practical consequences of using an allocation rule that is too variable are
demonstrated by the infamous extracorporeal membrane oxygenation (ECMO) trial
(Bartlett et al., 1985) in which the high variability of the RPWR led to an extreme
imbalance in the allocation (Hu et al., 2009a). In particular, the investigators chose to
use the RPWR(1, 0, 1) design, that is, the urn contained one ball of each type initially
and an ECMO (control) ball was added each time a patient survived on ECMO
(control) or failed on the control therapy (ECMO). The first patient was randomly
allocated to ECMO and survived. The second patient was randomly allocated to the
control and died. Hence, this meant that the odds of the next patient being randomly
allocated to ECMO were 3:1. All subsequent patients thereon received ECMO by
chance and survived. The trial terminated after 12 patients; one control patient who
had died and 11 ECMO patients, all of whom survived.
Although the study of Bartlett et al. (1985) provided encouraging evidence for the
efficacy of ECMO, the results were not convincing due to the very limited comparative
data and have since generated much controversy. Unfortunately, this has contributed
considerably to the limited application of RAR methods in practice. However, the
ECMO trial is atypical of adaptive designs in general and should not constitute a
reason to neglect adaptive designs in future modern clinical trials (Rosenberger, 1999).
Ultimately, the Bartlett et al. (1985) ECMO trial highlights the need for caution when
replacing conventional randomisation with adaptive schemes.
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(ii) Doubly Adaptive Biased Coin Design (DBCD)
The RPWR above possesses a purely myopic structure which means that each patient
is allocated to the treatment that is currently performing the best. As we have seen
from the ECMO trial, this can result in unfortunate randomisation sequences when
applied in practice. The RPWR is not based on any formal optimality criterion and
cannot target any pre-specified allocation proportion (Atkinson and Biswas, 2014),
so we now turn attention to the second major family of RAR procedures; those that
can target some desired, often optimal, allocation proportion. A general approach
for deriving the optimal allocation proportion is based on the framework proposed in
Jennison and Turnbull (2000, Chapter 17); this is discussed further within the RAR
context in Hu and Rosenberger (2006, Chapter 2) and Atkinson and Biswas (2014,
Chapter 8).
One example is the doubly adaptive biased coin design (DBCD) originally pro-
posed for the two-treatment case by Eisele (1994) and further generalised to the
multi-treatment case by Hu and Zhang (2004). This design is based on Efron’s (1971)
biased coin design and is “doubly adaptive” because it depends on both the current
allocation proportion and the current estimate of the target allocation proportion
(rather than just the former, as in Efron’s biased coin design). The basic idea is to
define an allocation function, g, from [0, 1]×[0, 1] to [0, 1] (satisfying certain regularity
conditions) which, for every patient, maps the actual allocation proportion and esti-
mated target proportion, so far, to the randomisation probability for the next patient.
Since this function involves unknown parameters of the response distribution, which
are sequentially updated using the incoming data, these designs require a pre-run of
conventional randomisation in order to obtain the initial parameter estimates.
Hu and Zhang (2004) introduced the following allocation function for the two-
CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 16




y(y/x)α+(1−y)((1−y)/(1−x))α if 0 < x < 1,
1− x if x = 0, 1,
(2.1.1)
where α ≥ 0 is a tuning parameter that controls the variability of the allocation
proportions (as it increases, the variability decreases), x denotes the current allocation
proportion and y the current estimated target.
Suppose that the response distribution depends on the unknown parameter vec-
tor θ, and ρ(θ) is the target proportion of patients to be allocated to treatment A.
Assuming that we have observed j patient responses, NAj of which are from treat-





, where ρ(θ̂j) is the estimated target allocation based on the first j
patient responses. When α = 0 and θ̂j is the maximum likelihood estimator of θ,
this reduces to the sequential maximum likelihood procedure (Melfi and Page, 2000),
i.e. allocating with probability equal to ρ(θ̂j).
The DBCD has the advantage that it can be used to target any desired allocation
proportion and can be applied to continuous, as well as binary, responses (Hu and
Zhang, 2004). Moreover, relative to other RAR procedures (such as the RPWR),
it exhibits a smaller variability of the allocation proportions (as shown in Hu and
Rosenberger (2003), for example). Hu et al. (2009b) proposed an alternative to the
DBCD — the efficient randomised adaptive design (ERADE) — which can also adapt
to any desired allocation proportion but is asymptotically best5 so has even lower
variability.
An example of an optimal allocation target for a binary response trial which min-
imises the expected number of treatment failures for a fixed variance of the test
5Asymptotically best procedures attain the lower bound on the asymptotic variance of the allo-
cation proportions (for a particular allocation target); see Hu et al. (2006) for details. The drop-the-
loser rule (mentioned on p.14) is an example of an asymptotically best procedure.
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statistic is provided in Rosenberger et al. (2001b). Zhang and Rosenberger (2006)
propose a corresponding version for continuous responses which minimises the total
expected response from all patients within the trial (when a smaller response is more
desirable to patients). They compare several DBCD procedures theoretically and by
simulation for trials with continuous outcomes and conclude that the DBCD targeting
the optimal allocation is the best to use in practice. Biswas et al. (2007) illustrate that
this target allocation proportion is not suitable for normally distributed outcomes in
general since it cannot be calculated for negative means. A correction is provided
by Biswas and Bhattacharya (2009) which is the version we will implement in Chap-
ter 6 (described therein). A limitation of this optimal allocation proportion is that
it is not easily extended to the multi-armed case. However, other target allocation
proportions comparing multiple treatments have become increasingly prevalent in the
literature; examples include Tymofyeyev et al. (2007), Zhu and Hu (2009) and Jeon
and Hu (2010). Methods for finding allocation targets are also discussed in the book
by Antognini and Giovagnoli (2015).
2.1.3 Bayesian Adaptive Randomisation (BAR)
So far, the RAR procedures discussed have fallen within the frequentist paradigm
which is the standard statistical approach to designing and analysing clinical trials
(Berry et al., 2011). We now turn our attention to the alternative, and increasingly
popular, Bayesian approach which is perfectly suited to online learning and thus lends
itself naturally to the adaptive design framework. Under this approach, the unknown
parameters of the response distribution are assumed to be random and follow some
prior distribution. The incoming data is used to determine the corresponding posterior
distribution, according to Bayes’ Theorem, and hence the allocation probabilities
(which are based on some function of the posterior distributions) are updated. For a
thorough overview of Bayesian adaptive methods applied to the design and analysis
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of clinical trials, the reader is referred to the book by Berry et al. (2011).
(i) Thompson Sampling (TS)
The idea of incorporating RAR within a Bayesian framework, commonly referred to
as Bayesian adaptive randomisation (BAR), originates from Thompson (1933) who
suggested randomising a patient to a treatment based on its posterior probability of
being better than the alternative treatment. A sampling method using this concept
later became known as Thompson Sampling (TS). Although seemingly attractive,
this posterior probability is very variable (particularly earlier in the trial when not
much data has been attained) and can lead to more patients being allocated to the
inferior treatment. Moreover, using the posterior probability to allocate patients can
result in extreme imbalance and hence low statistical power. Thall and Wathen (2007)
therefore introduce a tuning parameter to stabilise the allocation probabilities; this
is the version we will implement and describe in Chapter 6, where it will be used
as a comparator in both the two-arm and multi-arm settings. Other ways to avoid
extreme imbalance, e.g. by imposing bounds on the allocation probabilities so they do
not converge to 0 or 1, are discussed in Du et al. (2015). In multi-arm trials, where
there is a shared control group, the power of the trial can be preserved by protecting
allocation to the control group (see e.g. Trippa et al., 2012; Villar et al., 2015a; Viele
et al., 2020). In this case, the adaptive randomisation scheme is applied amongst
the experimental treatments but the allocation to the control is fixed and determined
independently. An example now follows.
(ii) Trippa et al. Procedure (TP)
Trippa et al. (2012) proposed a BAR design which is similar to that of TS since
sampling is again from the posterior distribution of the unknown parameters. How-
ever, instead of computing the posterior probabilities that arm k is the best (as in
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TS), it allocates patients based on the posterior probabilities that each experimental
arm is better than the control arm (k = 0), given the current observed data, i.e.
P(µk > µ0 | data) for k = 1, . . . , K. Assume that the trial is composed of j blocks
(or stages) testing K experimental treatments against a shared control, where µk
represents the unknown parameter of the response distribution (e.g. the population
mean of treatment k if responses are normally distributed, or the success probability
of treatment k if responses are binary) and nk,j patients have been allocated to treat-
ment k by block j, then the probability of allocating treatment k to patients in block




















)}ηj if k = 0, (2.1.3)









k=0 nk,j. For information on the selection
of these tuning parameters, refer to Wason and Trippa (2014) or the online Appendix
of Trippa et al. (2012). The fundamental idea is that they tune the exploration
versus exploitation trade-off inherent in the randomisation procedure. For example,
when γj = 0, then the patients in block j will be randomly allocated to each of the
experimental arms with identical probabilities, i.e. equal, fixed randomisation, which
makes sense during the initial exploratory stage of the trial (j = 1) when no responses
have yet been observed. However, during later stages of the trial, larger values of γ
are preferable in order to exploit the information contained in the observed responses
by giving rise to larger allocation probabilities to the better arms. At the extreme,
as γ → ∞, patients would be randomly allocated to either the best experimental
treatment or the control arm only. Thus, the chosen value of γ needs to lie between
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these two extremes.
The purpose of the expression for π̄0,j is to protect allocation to the control arm
(and thus preserve power) since if the difference between the number of patients on
the control, n0,j, and the number of patients on the most commonly used experimental
arm, max(nk,j)
K
k=1, is too large, then the allocation procedure will try to compensate
for this by allocating a larger number of patients to the control arm to make the size
of these two groups more comparable.
We will implement the TP with allocation probabilities as defined in (2.1.3) in
Chapter 6 to be used as a comparator in the multi-armed setting.
BAR schemes, such as TS and TP, have become increasingly popular in practice
(see Biswas et al., 2009; Lee et al., 2010) and have been implemented in several
real-life trials, particularly cancer trials, to allocate more patients to treatments that
have performed well for similar patients (Wason et al., 2015). Notable examples
include the I-SPY 2 (Barker et al., 2009), BATTLE (Kim et al., 2011) and BATTLE-
2 (Papadimitrakopoulou et al., 2016) trials. These trials utilise designs that match
patients with the most appropriate treatment for them according to their biomarker
profiles and are thus geared towards personalised medicine (Zhou et al., 2008). The
BAR design that is implemented in the BATTLE-2 trial is described in Gu et al.
(2016). For brief reviews of the I-SPY 2 and BATTLE trials, see Berry et al. (2011,
Chapter 4).
Another type of Bayesian adaptive design is a bandit allocation rule which utilises
prior information on the unknown parameters in combination with the accruing pa-
tient observations to ascertain the optimal treatment allocation at each stage of the
trial (see e.g. Hardwick and Stout, 1991; Zhang et al., 2019). Bandit rules are cen-
tral to the methods proposed in this thesis and therefore we provide the fundamental
concepts in the following section.
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2.2 Bandit Models
2.2.1 The Multi-Armed Bandit Problem (MABP)
The multi-armed bandit problem (MABP) owes its name to its resemblance to the
situation faced by a gambler with a choice between several slot machines (or “one-
armed bandits”). It is a sequential decision problem in which, at each time, a player
must decide which bandit to operate next in order to maximise their total expected
winnings (reward) over the whole time horizon. Do they operate one which has
performed well in the past so has the largest posterior mean of winning, i.e. exploit,
or one with a larger posterior variance which therefore has the potential to perform
even better, i.e. explore? Considering only the former leads to a myopic, or one-step-
look-ahead, policy which seeks solely to maximise the immediate reward and is not
necessarily globally optimal (Berry and Fristedt, 1985). All of the rules discussed in
Section 2.1.2 were of this form.
The MABP, however, provides a mathematical formulation of this inherent ex-
ploitation versus exploration trade-off 6 which aims to balance these competing goals
and maximise the total reward in order to obtain an optimal policy. This policy
accounts for the fact that gaining new information could potentially lead to greater
rewards in the future. Consider any situation which requires a decision to be made,
e.g. choosing which chocolate bar to purchase in a shop, and notice that this trade-
off is prevalent in most real-life decision-making problems (see Cohen et al., 2007),
irrespective of the context, as reflected in Whittle’s (1982) statement that the MABP
“embodies in essential form a conflict evident in all human action”. This therefore
makes the MABP an extremely useful and important problem to solve, and explains
why it has attracted so much attention from a wide range of disciplines; see Git-
tins et al. (2011, Chapter 9) and Lattimore and Szepesvári (2019, Section 1.2) for
6Depending on the context, other terminologies for this trade-off may instead be adopted, e.g.
earn versus learn.
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examples.
The application area that we will be focussing on throughout this thesis is the
design of clinical trials and, more specifically, how to allocate patients to treatments7
(or arms) in order to optimise some pre-determined performance criterion. Attention
will be centred around a patient benefit criterion, such as maximising the number of
successful responses8 from patients within the trial or, equivalently, the proportion
of patients allocated to the superior treatment (if it exists), but there are many
other objectives that one may wish to optimise over. Interestingly, the problem of
sequentially allocating patients within a clinical trial provided the initial impetus for
the study of MABPs, first posed by Thompson (1933) and subsequently developed by
Robbins (1952), in which the term “bandits” did not yet even appear.
The classic MABP formulation assumes that any arm which is not selected re-
mains passive, that is, it does not change state or produce any reward. An important
generalisation relaxes this assumption so that passive arms can also change state, and
more than one arm can be activated at any decision time, if appropriate. This gives
rise to so-called restless bandits, introduced by Whittle (1988), which substantially
extends the modelling power of MABPs so that they can be applied to a much wider
variety of practical problems. For example, the restless bandit framework can incorpo-
rate finite horizons (unlike the classic MABP which assumes an infinite horizon) and
delayed feedback, both of which are particularly relevant to the clinical trial setting
and hence will be considered in this thesis. Restless bandits are discussed in further
detail in Gittins et al. (2011, Chapter 6).
7Note that the terms “treatments”, “arms” and “bandits” may be used interchangeably.
8Within the Biostatistics literature, the term patient response is often used to imply a patient
success. However, throughout this thesis we refer to it in its most general sense to mean either a
success or a failure.
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2.2.2 Markov Decision Processes (MDPs)
MABPs are typically modelled as Markov decision processes (MDPs), which are ex-
tensions of Markov processes to include a set of decisions (or actions) and associated
rewards at each stage. Therefore, to formulate an MDP, the following quintuple must
be defined: decision epochs, states, actions, transition probabilities and rewards. A
detailed description of these are provided in Puterman (2014, Chapter 2) and sum-
marised briefly below. Decision epochs t are simply the points in time at which deci-
sions are made and will be referred to as “time t”, where t ∈ T ≡ {0, 1, . . . , T} , T ≤
∞9. The states at time t, zt, contain all of the information required to be able to
choose an action a from the set of available actions A. In the clinical trial context, the
state represents one’s state of knowledge about the effectiveness of the correspond-
ing treatment (which is updated once the patient’s response has been observed), and
an action corresponds to allocating a patient to a treatment. These actions can be
deterministic (if they are selected with certainty) or randomised (in which case each
action is selected with some probability, e.g. Cheng and Berry (2007)). In the clinical
trial context, it is desirable for actions to be randomised, that is, patients should be
randomly allocated to treatment arms, for the reasons outlined in Section 2.1. De-
terministic actions would enable the treatment allocation sequence to be predicted,
and therefore unmasked, if the state of the trial was known. In Chapter 3, we explore
this issue further, showing how randomisation can be introduced and what effect this
has on the behaviour of the proposed RAR design. As a result of the action taken at
time t, at: (i) the system transitions to a new state at time t + 1, zt+1, according to
the transition probability P(zt+1 | zt, at), and (ii) some reward Rat(zt) accrues which
provides the basis for evaluating the chosen action. The transition probabilities and
rewards at each t depend only on the current state and action chosen in that state,
thus giving rise to a Markovian (“memoryless”) system.
9Note that although decisions are not made at decision epoch T , it is included here for complete-
ness so that the final state of the system can be evaluated (Puterman, 2014, Section 2.1.1).
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The time horizon, T , of an MDP can be finite or infinite. In the latter case, rewards
are usually discounted by introducing a discount factor d ∈ (0, 1) which ensures
that the total reward obtained is finite. To complete the Markov decision problem
formulation, an optimality criterion (or objective) needs to be specified which is partly
determined by the time horizon. Assuming an infinite horizon and following Bellman
(1956), the typical objective of the classic MABP is to maximise the expected total
discounted reward over the infinite horizon, which is discussed in Gittins et al. (2011,
Chapter 2) and Puterman (2014, Chapter 7). An alternative objective, however, is to
consider the (long-run) average expected reward over the infinite horizon (Puterman,
2014, Chapter 8).
In finite horizon problems, which will be the focus of this thesis, interest is in the
expected (discounted) total reward (Puterman, 2014, Chapter 4). Suppose that the
system is in state z at time t and Eπ represents the expectation under policy10 π ∈ Π
(where Π is the set of past-measurable11 policies), then the expected total discounted
reward over the remainder of the time horizon T − t is





∣∣∣ zt = z] , (2.2.1)
where au denotes the action that is chosen at time u (u = t, . . . , T ) under policy π and
Rau(zu) is the reward received from all arms when action au is taken. In the classic
MABP formulation, when actions are deterministic and rewards are immediate, this
is simply the reward from the arm corresponding to the chosen (or active) action.
Note that in the finite horizon case, rewards are not necessarily discounted as in the
infinite horizon case. The undiscounted finite horizon objective, which is equivalent
to substituting d = 1 into (2.2.1) and sometimes referred to as uniform discounting
10A policy is any rule that determines which action to take given the information available in state
z at time t, i.e. it is a mapping from states to actions.
11The action prescribed by a past-measurable policy at time t does not depend on what happens
after t. This is also known as history-dependent (Puterman, 2014) or non-anticipating (Jacko, 2019b).
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(e.g. Wang, 1991b; Hardwick and Stout, 1991), is the most pertinent in many appli-
cations (Jacko, 2019b). This includes the clinical trial setting, in which case there
is: (i) a finite horizon since there is a pre-determined finite number of patients in the
trial, and (ii) uniform discounting since each patient response carries the same weight
(Hardwick, 1995). Therefore, throughout this thesis, attention is restricted to the
finite horizon problem with the principal objective being to maximise the expected
total reward in (2.2.1) which, as previously mentioned, in the clinical trial setting
translates to maximising the expected total patient benefit. A thorough examination
of the finite horizon bandit problem from a statistical and theoretical perspective,
within the clinical trial setting, is provided in the book by Berry and Fristedt (1985)
(which includes an extensive annotated bibliography).
Maximising the expected total reward over the specified time horizon T gives rise
to the optimal policy12; Section 2.2.3 below discusses how this can be obtained. Note
that throughout this thesis, it is assumed that T is the total number of patients
inside the trial, n. However, one may also wish to incorporate what happens after
the trial, in which case T would represent the total number of patients both inside
and outside the trial, N , so that the optimal criterion is defined for the entire patient
population instead. Such a criterion is considered in Berry and Eick (1995), Cheng
and Berry (2007) and Zhang et al. (2019), for example, where it is assumed that the
patients outside the trial will receive the treatment that performed best during the
trial. Thus, the number of successes expected after the n patients in the trial have
responded is taken to be the size of the remaining population, N − n, multiplied
by the maximum current estimate of the treatment success rates. An example of
this type of optimal response-adaptive allocation procedure, formulated as a two-arm
bandit problem, is the robust Bayes (RB) procedure which is described and compared
to other randomisation procedures in Berry and Eick (1995). A toy example of the
12The existence of an optimal policy for a finite horizon MDP is shown in Berry and Fristedt
(1985, Chapter 2).
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RB procedure, illustrating how the patients in a trial should be allocated in order
to maximise the expected number of patient successes over N , is presented in Berry
and Stangl (1996, pp. 25–29) when n = 7 and N = 100. More recently, Zhang et al.
(2019) implemented the optimal design of Berry and Eick (1995) to investigate how
the size of the patient horizon affects the power and patient benefit trade-off. This
procedure hinges on the method of dynamic programming which is described in the
following section.
2.2.3 Solution Methods to the MABP
Two possible solution methods to the MABP are now discussed. The first — dynamic
programming — is an exact approach, giving rise to a Bayes-optimal solution (see
Jacko, 2019b, Section 7.2) and will be used to implement the methods proposed in
Chapters 3–5. The alternative index-based solution, however, yields a near-optimal
approximation and will be utilised in Chapter 6.
In contrast with most RAR procedures in the literature, including those introduced
in Section 2.1.2, bandit solutions have the advantage that they look-ahead, or are
forward-looking, since they balance the myopic goal with future rewards (Hu and
Rosenberger, 2003). In other words, they maximise not only the immediate reward
but the cumulative reward, which takes account of all possible future rewards.
(i) Dynamic Programming (DP) Approach
Since MABPs can be formulated as MDPs, they are, in principle, amenable to solution
by the standard dynamic programming (DP) technique which was developed by Bell-
man (1956) (and popularised in the classic book by Bellman (1957)). Informally, this
approach involves breaking the problem down into a series of smaller sub-problems,
each of which are solved (and the solution stored) to yield the complete solution to
the original problem. Decomposing the problem in this way and storing the solutions
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of the sub-problems so that they can be re-used reduces the computational burden
considerably.
More formally, DP is based upon calculation of a value function, Ft, which rep-
resents the best possible value of the objective in (2.2.1), i.e. the maximum expected
total reward, over the set of all policies π for every possible state at time t. When











∣∣∣ zt = z] .
A fundamental property of the value function is that it satisfies the following







P(z′ | z, a)Ft+1(z′)
}
for 0 ≤ t ≤ T − 1, (2.2.2)
where P(z′ | z, a) is the transition probability of moving from state z at time t to
some new state z′ at time t+1 under action a, and A is the action space containing all
available actions. Intuitively, the Bellman equation expresses a relationship between
the value of a state and the value of its successor states, which is the essence of DP.
It is helpful to notice that equation (2.2.2) comprises of two parts: (i) the immediate
reward Ra(z) received by choosing action a when in state z, plus (ii) the expected
(discounted) future reward earned from the successor states as a result of taking this
action. The second term contains the product of the probability of being in state z′
at time t+ 1 if action a is taken, and the expected total reward obtained if policy π is
followed from time t+ 1 to T when the “new” starting state is z′. The idea is that, in
every state, the action which maximises the expected combination of immediate and
13This was originally termed the functional equation by Bellman (1957). Alternative names also
include the fundamental equation of dynamic programming (Berry and Fristedt, 1985); the dynamic
programming equation (Gittins et al., 2011); the optimality equation (Puterman, 2014), etc.
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future rewards is chosen. In finite horizon problems, no action is taken at time t = T
and so the final decision occurs at time T −1. Therefore, the terminal reward at time
t = T is a function of the state only, that is, FT (z) = R(z). This is sometimes referred
to as the salvage (or scrap) value in the operational research literature (Puterman,
2014). Although the terminal reward is usually 0, there are instances when this is
not the case, e.g. if an artificial terminal reward (i.e. penalty) is introduced to avoid
certain states (as in Chapter 3) or the reward is not obtained immediately (as in
Chapters 4 and 5).
The ultimate optimisation problem is to find the maximum expected total reward
over the entire time horizon when t = 0 for a given initial state z0 = z, that is, F0(z).
By calculating this value, the policy that gives rise to it, namely, the complete optimal
policy π∗, is also found and can be expressed as π∗(z0) ≡ arg max
π∈Π
Vπ0 (z). Note that
the initial state z0 is usually a very natural choice and has just one possibility, as in
the clinical trial setting when there are no observations before the start of the trial at
time t = 0. However, in some applications, the initial state may be less obvious and
could take, for example, a set over some distribution.
When the horizon is finite, this can be solved exactly using backward induction, in
which the value function is evaluated recursively by first determining the maximum
expected reward (together with the corresponding actions) at the final time period14
of the decision process for all possible states. Proceeding towards the penultimate
period, the maximum expected reward for every possible state is again calculated,
but this time incorporating the information just obtained for the subsequent period
as well. Continuing backwards in time until the start of the problem at time t = 0
allows the optimal reward F0(z0), along with the corresponding optimal policy (or
policies), to be determined for every state at every point in time.
More formally, the backwards induction algorithm can be summarised as follows:
14A period (or stage) represents the time between two consecutive decision epochs.
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1. Let t = T and FT (z) = R(z) for all z = zT ,


















P(z′ | z, a)Ft+1(z′)
}
,
3. If t = 0, stop. Otherwise, repeat Step 2.
At the end of the algorithm, F0(z) will contain the maximum expected discounted
sum of rewards received by following policy π∗(z) from state z = z0.
Thus, when implementing this algorithm computationally, two multi-dimensional
arrays, indexed by state, need to be created: (a) the value F containing the maximum
expected total reward for the corresponding combination of states, and (b) the optimal
policy π∗ containing the actions which give rise to these values.
An illustrative example of the backward induction algorithm applied to the finite
horizon two-armed bandit problem of optimally allocating patients in a clinical trial,
i.e. when T = n, is provided in Appendix 3.6.1 of Chapter 3. See also the example
provided in Berry and Stangl (1996, pp. 25–29) which includes accompanying figures
to demonstrate how backwards induction is used to optimally allocate patients over
the entire patient horizon, i.e. when T = N .
The DP approach requires a considerable amount of computational power and
memory to calculate and store the solution, even for relatively small problems. For
example, consider the problem of allocating patients in a clinical trial of size T = n
with two treatments (A and B) available and binary responses (success or failure).
At each time t, there will be four possibilities (success on A, failure on A, success
on B or failure on B) and hence, 4n possible paths which need to be enumerated
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in order to determine the optimal policy15. As the number of arms increase, the
size of the problem grows exponentially; a phenomenon referred to as the curse of
dimensionality (Bellman, 1961). See Villar et al. (2015a, Figure 1) which illustrates
how the computational requirements of DP rapidly increase with T , even for a small
number of arms. Furthermore, Zhang et al. (2019, Section 3.3) find that “with three
arms and sample sizes of 100, it becomes infeasible”. For this reason, DP is often
thought to be of limited applicability in practice. However, with the advancement in
modern day computers, DP methods can be used to solve MDPs with millions of states
(Sutton and Barto, 2017) and the survey by Jacko (2019b) shows that DP solutions
are tractable for much larger horizons than are commonly believed. For example,
the author develops a package which computes the DP design in a few minutes for
T ≈ 1000, a few hours for T ≈ 2000 or a few days for T ≈ 4000 (refer to Jacko (2019a)
for details of implementation).
When the dimension of the state space is too large to deem exact DP methods
suitable, the value function can be approximated using a heuristic algorithm instead.
A plethora of such algorithms (e.g. TS discussed in Section 2.1.3) prevail the bandit
and operational research literature, and many fall under the umbrella term of approx-
imate dynamic programming (ADP), but we do not go into details here since they are
beyond the scope of this thesis. The interested reader is referred to Powell (2011) for
an accessible introduction to ADP.
Some of the most popular bandit algorithms have been evaluated within a clinical
trial context by Kuleshov and Precup (2000) to determine whether they constitute
effective adaptive trial strategies. Simulation studies showed that they all performed
similarly. In particular, they successfully treated at least 50% more patients, resulted
in fewer adverse effects and greater patient retention compared to fixed randomisation,
but had more difficulty identifying the superior treatment. Even though the bandit
15In the clinical trial context, the policy is synonymous to the allocation rule, or design, that
specifies which treatment arm each patient receives.
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algorithms received delayed feedback (since the response was observed 13 days after
administration of the treatment), this had minimal impact on their effectiveness.
In addition, it is worth noting that patient dropout was interpreted as a treatment
failure which is a common assumption in trials with a binary response, and we discuss
a possible way to deal with this for continuous responses in Chapter 6. See Kaibel and
Biemann (2019) for another simulation study comparing a range of bandit algorithms
with fixed randomisation, but this time for normally distributed outcomes.
A further impediment to the use of the DP design in clinical trial practice is that “it
is difficult to describe and cumbersome to communicate” (Berry, 1978). Therefore, an
alternative solution which both reduces the computational difficulties and is simpler
to communicate is now discussed below.
(ii) Index-Based Approach
A key breakthrough for the infinite horizon MABP was provided by Gittins and
Jones (1974), who showed that instead of solving the K-dimensional MDP (where
K is the number of arms), an optimal solution can be found by decomposing this
into K one-dimensional optimisation problems (where the computational cost now
increases linearly with K rather than exponentially). Remarkably, it was shown that
the optimal policy obtained by backward induction is equivalent to an index policy.
That is, an index can be computed separately for each arm as a function only of
its current state, such that the optimal policy is always to continue the arm with
the largest current index. This was originally called the dynamic allocation index by
Gittins (1979) and subsequently named the Gittins index by Whittle (1980), which
is how we will refer to it hereafter (and how it widely appears in the literature). The
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∣∣∣ zk0 = zk] , (2.2.3)
where τ is a stopping time and Rk(zkt ) is the immediate reward obtained from allocat-
ing arm k when in state z at time t. Here, the rewards are geometrically discounted16
(which is the second most frequently considered discount sequence in the literature
(Berry and Fristedt, 1985)). Note that the numerator in equation (2.2.3) represents
the expected total discounted reward up to τ , whilst the denominator represents the
expected total discounted time up to τ . Thus, the Gittins index is interpreted as the
maximum expected reward per unit of discounted time when starting from the initial
state.
For a given discount factor d, the method of calculating these indices is described in
Gittins (1979) and Gittins et al. (2011, Chapter 7). In addition to Bernoulli endpoints,
Gittins indices have been derived for a variety of others, including: normal (with known
(Jones, 1970) and unknown variance (Jones, 1975)), multinomial (Glazebrook, 1978)
and exponential (Amaral, 1985). Tables containing the calculated Gittins index values
are provided in Gittins et al. (2011). Since the Gittins index is independent of K,
the relevant table can be used for all possible trials, which reduces the computational
requirements even further (Villar et al., 2015a).
When using Gittins indices to solve the K-armed MABP in a clinical trial context,
the Gittins index theorem no longer applies because the horizon is finite and hence,
the solution obtained will not be optimal. However, although not optimal, it can still
be used to approximate the optimal policy when applied with a truncated horizon
T < ∞ instead, and, as Bather (1981) stated, “the principle can still be effective”.
We now provide some examples, both past and present, of treatment allocation rules
16Berry and Fristedt (1985, Theorem 6.2.1) show that for the classical MABP, Gittins indices are
optimal only if the discount sequence is geometric.
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that are based on Gittins indices, and outline what remains to be done in the future
to increase their desirability of being applied in practice.
Robinson (1983) was the first to consider the relative merits of Gittins indices for
a finite horizon. In particular, sequential allocation rules based on Gittins indices for
a Bernoulli two-armed bandit problem using discount factors 0.99, 0.995 and 0.9999
were compared against three different adaptive rules (as well as equal allocation). The
appropriate choice of d remained unclear to the author, although he did comment that
“for medical applications, it should be near one”. Berry and Fristedt (1985, pp. 249-
250) queried the choice of discount factor and suggested that a more reasonable choice
may be 1 − 1/T , which was also suggested by Wang (1991b). As with most of the
early literature on response-adaptive allocation rules for Bernoulli responses, these
comparisons were based on two criteria: expected successes lost17 (a measure of the
patient benefit; the smaller, the better) and the error probability (the probability
that the inferior treatment has the higher proportion of successes). Simulation results
showed that the Gittins index rules had slightly larger error probabilities, but con-
siderably smaller expected successes lost, than equal allocation, even when there was
a substantial delay in observing the response. Moreover, the author commented that
this rule is easy to use given the availability of tables for the indices, and performs
well for a wide range of model parameters.
Hardwick and Stout (1991) and Hardwick (1995) also consider an allocation rule
based on approximations to the Gittins indices using its lower bounds18 (which are
easier to compute) and compare it to the optimal rule based upon the DP solution
to the finite horizon two-armed bandit problem. They show that their proposed rule
satisfies both power and patient benefit criteria adequately, thus providing a good
compromise. Therefore, as Hardwick (1995) points out, the Gittins lower bound (or
17Note that minimising the expected successes lost is equivalent to maximising the expected num-
ber of successes (which is the criterion we will consider).
18The general expression for the lower bound given an arbitrary prior distribution is provided in
Berry and Fristedt (1985, Example 5.4.6).
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modified bandit) allocation rule “has a special appeal for clinical trial applications
since it can be viewed as offering an ethically equitable mechanism for balancing
outcomes of present and future patients”.
Wang (1991b) advocates the use of Gittins indices as “a promising choice to use
in clinical trials” and consequently proposes an adaptive allocation rule using Gittins
indices with discussion on the appropriate choice of discount factor. In particular,
he suggests that although a reasonable choice of d is 1 − 1/T , it is not the best way
to use Gittins indices to approximate the optimal solution and ideally, the discount
factor should get smaller as fewer patients remain in the trial. Therefore, he rec-
ommends choosing the discount factor dynamically, based on the number of patients
remaining in the trial, which he refers to as the dynamic Gittins index (DGI) alloca-
tion. Simulation results comparing the DGI with the optimal solution obtained using
DP for small trial sizes (up to T = 20) reveal that the difference between DGI and
the optimal policy is negligible in terms of the expected total number of successes
received. Moreover, he concludes that if the disease is rare, in which case the focus is
on treating patients in the trial as effectively as possible, then Gittins indices should
be used. Alternatively, if the disease is common, he suggests using the least failures
rule, i.e. the limit case of the Gittins index rule as d→ 1 (Kelly, 1981).
In another paper by Wang (1991a), it is shown that introducing a constraint pa-
rameter into the Gittins index rules significantly reduces the error probability incurred
when using Gittins indices to allocate patients. Wang (1991a) also generalises these
rules to the case when the response distribution is unknown. This constrained Gittins
index rule is further explored by Coad (1991b, 1995) in the normal response setting
and implemented in Chapter 6 of this thesis as a comparator method (where a de-
scription of the method is provided). Coad (1992) also studied the effect of linear
time trends on sequential allocation rules based on Gittins indices and considered
analysing the data in blocks (as we do in Chapter 6) as a means of ameliorating the
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effect of time trends.
An important extension of the Gittins index was introduced by Whittle (1988) who
proposed a heuristic rule, known as the Whittle index, as a solution to the multi-armed
restless bandit problem (see Section 2.2.1). This reduces to the Gittins index in the
classic case when passive bandits remain frozen. Although the Whittle index policy
is not optimal in general, Weber and Weiss (1990) proved that it is asymptotically
optimal under certain conditions. Refer to Gittins et al. (2011, Chapter 6) for further
details. In Chapter 3, the Whittle index policy is considered as a comparator instead
of the Gittins index because the corresponding MABP is restless due to the following
reasons: (i) the horizon is finite and so the number of patients in the trial remaining
to be treated is included as a state variable (which changes for all arms at each t,
regardless of the action taken), and (ii) actions are randomised meaning that more
than one arm can change state during a time period, thus removing the one-to-one
correspondence between the action and arm chosen that exists in the deterministic
case. Moreover, the Gittins index theorem only applies when actions are deterministic.
The relative advantages and disadvantages of using Gittins and Whittle index
policies for the classic and restless Bernoulli MABP, respectively, as potential patient
allocation rules are discussed at length in the paper by Villar et al. (2015a). In the
former case, the horizon is truncated and in the latter case, the finite horizon Bernoulli
MABP is reformulated as an equivalent infinite horizon restless MABP. Simulation
results, in both the two-armed and multi-armed settings, show that the index-based
policies perform extremely well with respect to the patient benefit criteria, and start to
skew patient allocation towards the superior arm earlier than the alternative adaptive
designs considered. The increase in the expected number of patient successes relative
to the other designs considered was most pronounced in the multi-armed case. How-
ever, they suffer from a severe reduction in power which severely hinders their use in
practice. Therefore, the authors suggest a modified version of the Gittins index rule
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— the controlled Gittins approach — which protects allocation to the control group
in a similar vein to the aforementioned TP in Section 2.1.3(ii), and thus improves the
power. A similar approach is considered in Chapter 6.
The performance of the Gittins and Whittle index rules, amongst others, is fur-
ther explored in Villar (2018) through both exact and simulated calculations, with a
particular focus on their application to rare disease trials. Although the Gittins and
Whittle index policies behave similarly, the Whittle index is shown to always outper-
form the Gittins index in terms of the expected proportion of patients allocated to
the best arm. Moreover, simulation results in the two-armed case show that both the
Gittins and Whittle index rules are almost identical to the optimal rule obtained by
DP, with the sub-optimality gap increasing slightly in the multi-armed case.
All of the aforementioned index-based allocation rules are deterministic which is a
major barrier to their implementation in practice. Although semi-randomised index-
based rules have been proposed in the literature, e.g. Glazebrook (1980); Bather (1980,
1981), in which random perturbations are added to the index value, they are not fully
randomised since they are not expressed in terms of allocation probabilities. Villar
et al. (2015b), however, present a fully randomised design using Gittins indices —
the forward-looking Gittins index (FLGI) — which is applied to blocks of patients,
rather than individuals. Simulation results show that the FLGI continues to increase
the number of patient successes significantly compared to alternative adaptive ran-
domised designs (including TS and TP described in Section 2.1.3), yet fails to meet
the required power level. This design is discussed further in Chapter 6 where it forms
the foundations of the method proposed. An extension of the FLGI to incorporate
binary covariates has also been suggested by Villar and Rosenberger (2018) which is
beyond the scope of this thesis but forms an ongoing area of research.
With the exception of the constrained Gittins index, the above index-based alloca-
tion rules focus only on the Bernoulli bandit problem and examples of applying them
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to endpoints other than binary within the clinical trial setting are limited. A recent
example, however, is provided by Smith and Villar (2018) who investigate Gittins
index-based allocation rules for the case when the outcome is normally distributed
with known variance. The results support that the Gittins index-based designs achieve
the largest patient benefit relative to alternative designs used in clinical trial practice,
especially in the multi-armed case, at the expense of a power reduction.
2.3 Summary
Despite index-based allocation rules being: computationally feasible for multi-armed
trials and large T ; easy to implement; appealing to use if patient benefit within the
trial is a primary concern (as in rare diseases); conceptually simple to summarise to
clinicians and patients etc. due to the intuitive nature of always allocating the arm
with the largest index, which is paramount since “if a scheme is impracticable then,
no matter what its theoretical advantages happen to be, it will not be used” (Upton
and Lee, 1981), they are yet to be implemented in clinical trial practice.
Moreover, bandit rules in general have been proposed and studied in the literature
for many years so their theoretical properties are very well understood and, as already
mentioned, their initial motivation was in the design of clinical trials, which makes
us question why they have never been applied in practice. As a result of reviewing
the pertinent literature, several possible reasons for this have been identified, the
main findings of which are now summarised and used to provide the impetus for the
methods proposed in the subsequent chapters.
• Patient responses need to be available immediately, or at least before the next
patient is allocated. This only applies to a small proportion of clinical trials, e.g.
some rare disease or paediatric trials, or if the treatment is fast-acting. How to
obtain a solution to the exploration versus exploitation trade-off in the presence
CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 38
of delayed responses, however, is possibly the greatest challenge for both bandit
literature and clinical trial practice. Consequently, Chapters 4 and 5 attempt
to tackle this problem for the DP approach.
• The allocation of patients to treatments following a bandit rule that is optimal
with respect to patient benefit is deterministic and most of the bandit literature
deals with non-randomised procedures (Rosenberger and Hu, 2004; Rosenberger
and Lachin, 2016). Chapter 3 concentrates on introducing randomisation into
the DP solution of the two-armed Bernoulli bandit problem, whereas Chapter 6
randomises groups of patients based on probabilities determined by the Gittins
index, resulting in a fully randomised Gittins index-based allocation rule.
• Bandit allocation rules result in insufficient statistical power to detect a signifi-
cant treatment difference at the end of the trial. This is a severe limitation from
a practical perspective, even if the issue is mitigated in the rare disease setting
(since there are comparatively few patients outside the trial), which is where
these designs are deemed to be most applicable19. Note, however, that this is
not limited to bandit rules, it extends to all RAR procedures because it is not
possible to maximise both patient benefit and power simultaneously (Hu and
Rosenberger, 2003). Therefore, interest is in utilising ways which can improve
the power of bandit-based solutions. In the two-arm case of Chapter 3, as well
as randomising the allocation probabilities, a constraint is introduced into the
value function to avoid extreme imbalance which leads to low power. In the
multi-armed case of Chapter 6, we adopt the effective approach identified in the
literature of applying the index rule only to the experimental arms whilst fixing
allocation to the control arm (see e.g. Viele et al., 2020).
• Bandit allocation rules typically exhibit other undesirable frequentist proper-
19For example, in the Discussion of Bather (1981), Prof. D. Berry comments that “the primary
hope for future applications [of bandit rules] lies in small clinical trials involving rare diseases”.
CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 39
ties, such as a lack of type I error control and biased estimates of the treat-
ment effects. However, it is again important to note that this is a problem
with (response-) adaptive rules more generally due to the dependence structure
induced in the resulting observations (Rosenberger and Lachin, 2016). Inves-
tigating methods to minimise the bias of the resulting estimates is beyond the
scope of this thesis, but the reader is referred to the following literature: Coad
and Ivanova (2001); Bowden and Glimm (2008); Carreras and Brannath (2013);
Robertson (2016); Bowden and Trippa (2017); Robertson and Glimm (2019),
and references therein. See also Robertson and Wason (2019) for a recently
proposed procedure which guarantees strong control of the error rate for RAR
trials.
• Most of the relevant research has focused on the simplest context of a two-armed,
sequential trial with Bernoulli responses. This is somewhat restrictive in the
clinical setting where other endpoints are also of interest, and increasingly more
trials are including multiple arms to improve efficiency in response to the Criti-
cal Path Opportunities Report (U.S. Food and Drug Administration, 2006), see
e.g. Wason and Jaki (2016, 2018). In Chapter 6, we propose and evaluate a
Gittins index-based design for normal outcomes (with unknown variance) in
multi-armed trials. Moreover, we move from the fully sequential setting to the
group sequential setting in which patients are randomised in groups at a finite
number of interim analyses.
Chapter 3
A Bayesian Adaptive Design for
Clinical Trials in Rare Diseases
3.1 Introduction
Before any new medical treatment is made available to the public, clinical trials must
be undertaken to ensure that the treatment is safe and efficacious. Development of
treatments for rare diseases is particularly challenging due to the limited number of
patients available for experimentation.
The current gold standard design is the randomised controlled trial, in which
patients are randomised to either the experimental or control treatment in a pre-
fixed proportion. Its main goal is to learn about treatment effectiveness with a view
to prioritising future patients outside of the trial. Although this design can detect a
significant treatment difference with a high probability, i.e. it maximises the statistical
power, which is of benefit to future patients, it lacks the flexibility to incorporate other
desirable criteria, such as the trial participant’s well-being. As such, a large number of
patients within the trial receive the inferior treatment. This is particularly concerning
for rare disease trials in which a substantial proportion of all patients with the disease
40
CHAPTER 3. A BAYESIAN ADAPTIVE DESIGN FOR CLINICAL TRIALS 41
may be included in the trial. Moreover, there will be fewer patients available outside
of the trial to benefit from the learning. Therefore, in this case, the priority should
be on treating those patients within the trial as effectively as possible.
This motivates the use of response-adaptive designs for clinical trials involving
rare diseases in which the accruing data on patient responses are used to skew the
allocation towards the superior treatments, thus reducing patient exposure to inferior
treatments. Although it does not fully eliminate the ethical problem of randomising
patients to the inferior treatment, it certainly mitigates it by reducing the probability
of allocation to the inferior treatment, if it exists.
Berry and Eick (1995) compare the performance of the traditional design, in which
half of the participants receive treatment A and the other half receive treatment B,
to four response-adaptive designs. They conclude that if the condition being treated
is rare, then response-adaptive methods can perform substantially better and might
be a more suitable alternative.
Despite the long history in clinical trials methodology, very few response-adaptive
designs have actually occurred in practice and applications thus far have been dis-
appointing (Rosenberger, 1999). This is largely attributable to the extracorporeal
membrane oxygenation (ECMO) trial by Bartlett et al. (1985) which employed the
randomised play-the-winner rule, a response-adaptive design described briefly in Sec-
tion 3.21.
The problem of designing a clinical trial which aims to identify the superior treat-
ment (exploration or learning) whilst treating the trial participants as effectively as
possible (exploitation or earning) is a natural application area for bandit models,
a type of response-adaptive design. Bandit models seek to balance the exploration
versus exploitation trade-off in order to obtain an optimal allocation policy which
maximises the expected number of patient successes over a finite number of patients.
1See also Section 2.1.2.
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As such, they present an appealing alternative to the traditional approach used in
clinical trials. Across the bandit literature, the use of bandit models to optimally
design a clinical trial is often referred to as the primary motivation for their study
(Gittins, 1979). However, to the best of our knowledge, they have never been im-
plemented in real clinical practice for reasons including lack of randomisation and
biased treatment effect estimates. Moreover, in contrast to the traditional approach
taken in clinical trials, bandit models exhibit very low power since it is not possible
to maximise both power and patient successes simultaneously. For a discussion of
the benefits and challenges of bandit models in clinical trial practice, see Villar et al.
(2015a).
In this chapter, we propose a novel bandit-based design which provides a very
appealing compromise between these two conflicting objectives and addresses some of
the key issues that have prevented bandit models from being implemented in clinical
trial practice. We modify the optimal design, which aims to maximise the expected
number of patient successes, in such a way that we overcome its limitations without
having a significant negative impact on the patient benefit.
The modifications involve incorporating randomisation into a currently determin-
istic design, which was considered by Cheng and Berry (2007), and adding a constraint
which forces a minimum number of patients on each treatment. These are described
in Sections 3.2.2 and 3.2.3, respectively, building on the standard dynamic program-
ming approach presented in Section 3.2.1. In Section 3.4, we compare our design
to alternative designs via extensive simulations in several scenarios in the context of
a recently published phase II clinical trial of isotonic fluid resuscitation in children
with severe malnutrition and hypovolaemia (Akech et al., 2010). We evaluate each
design’s performance according to the measures set out in Section 3.3. We summarise
the main conclusions in Section 3.5 and highlight areas for future research.
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3.2 Methods
In this section, we introduce different methods for allocating patients to treatments
in a clinical trial. For simplicity of exposition, we consider a two-armed clinical trial
with a binary endpoint and a finite number of patients within the trial, n. Patients
enter the trial sequentially over time, one-by-one, and each patient is allocated to
either treatment A or B on arrival. We assume that n is fixed but that the sample
sizes for treatment groups A and B, denoted by NA and NB respectively, are random,
where NA + NB = n. Let X and Y denote the patient’s response (either a success
or failure) from treatments A and B respectively, which we model as independent
Bernoulli random variables. That is,
X ∼ Bernoulli(1, θA) and Y ∼ Bernoulli(1, θB), for 0 ≤ θA, θB ≤ 1,
where θA and θB are the unknown success probabilities of treatments A and B re-
spectively. Further, assume that each patient’s response from the allocated treatment
becomes immediately available2.
The fixed randomised design randomises patients to either treatment A or B with
an equal, fixed probability, i.e. 50% in a two-armed trial. This will act as a reference
to which each of the response-adaptive designs described below will be compared
against.
One of the most well-known response-adaptive designs is the randomised play-
the-winner (RPW) rule, a type of urn model, proposed by Wei and Durham (1978).
This design is very intuitive and applies specifically to clinical trials comparing two
treatments with binary responses. Initially, an urn contains u balls of type A and
u balls of type B. When a patient is recruited, a ball is drawn randomly from the
urn with replacement; if it is a type A ball, the patient receives treatment A and if
2Note that we relax this assumption in Chapters 4 and 5.
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it is a type B ball, the patient receives treatment B. After each patient’s outcome is
observed, a decision about the urn composition is made depending on the observed
result. Thus, a success on treatment A, or a failure on treatment B, generates an
additional β type A balls and α type B balls in the urn. Similarly, a success on
treatment B, or a failure on treatment A, will generate an additional β type B balls
and α type A balls in the urn, where 0 ≤ α ≤ β are integers. In this way, the
urn accumulates more balls representing the superior treatment, thus increasing the
probability that a patient receives the current best treatment. Note that the RPW
rule is myopic (as are most response-adaptive designs) in the sense that it uses all of
the past observations to treat the next patient as if this were the last patient in the
trial.
3.2.1 Optimal Design using Dynamic Programming (DP)
The RPW rule described above is not constructed based on any formal optimality cri-
terion so we now turn our attention to an alternative approach which utilises dynamic
programming. With this approach, prior information on the unknown parameters is
used in conjunction with the incoming data (and the number of remaining patients in
the trial) to determine the optimal treatment allocation for every patient of the trial.
Note that we use t to denote both time and the last patient treated in this model
since they are analogous, that is, at time t we have treated t patients. The trial time
is therefore bounded by 0 ≤ t ≤ n.
Since the treatment effects take values between zero and one, it is sensible to assign
the parameters independent Beta prior distributions
θA ∼ Beta(sA,0, fA,0) and θB ∼ Beta(sB,0, fB,0) for 0 ≤ θA, θB ≤ 1,
where sA,0 (fA,0) and sB,0 (fB,0) represent the prior number of successes (failures)
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on treatments A and B, respectively. Since this is a conjugate prior with respect
to the Bernoulli likelihood function, the posterior distribution follows another Beta
distribution with parameters summarising the relevant information from the trial to
date (that is, the combination of the initial prior plus the accumulated data). At time
t ≥ 1, after observing sA,t (fA,t) successes (failures) on treatment A, and sB,t (fB,t)
successes (failures) on treatment B, the posterior distribution is expressed by
θA | sA,t, fA,t ∼ Beta(sA,0+sA,t, fA,0+fA,t) and θB | sB,t, fB,t ∼ Beta(sB,0+sB,t, fB,0+fB,t),
where sA,t + fA,t + sB,t + fB,t = t for t ≥ 1. Therefore, it will only be necessary to
update the parameters of these distributions as the trial progresses. For simplicity,
let the prior information and data combined be denoted as




is the posterior probability (i.e. the current belief ) of success for
treatment j given the prior information and data up to patient t.
Let δj,t, for t = 0, . . . , n− 1, be the binary indicator variable representing whether
patient t+ 1 is allocated to treatment j ∈ {A,B}, where
δj,t =
 1, if patient t+ 1 is allocated to treatment j,0, otherwise. (3.2.2)
Using the jargon of dynamic programming, δj,t is the reward for every successfully
treated patient, and thus
s̃j,t
s̃j,t+f̃j,t
· δj,t is the expected (one-period) reward, where
expectation is taken in the Bayesian sense, i.e. according to the current belief.
Let Π be the family of admissible designs (i.e. allocation policies) π, which are
those such that
∑
j δj,t = 1 for all t since only one treatment is allocated per patient.
Let Ft(sA, fA, sB, fB) be the value function representing the maximum expected total
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reward, i.e. the maximum Bayes-expected number of successes, in the rest of the trial
after t patients have been treated when the combined information is (sA, fA, sB, fB),
that is,











∣∣∣∣∣∣ s̃A,t = sA, f̃A,t = fA, s̃B,t = sB, f̃B,t = fB
 .
Note that this depends on the total number of patients n even though we do not
state it explicitly to simplify the notation.
The ultimate optimisation problem is to find an optimal design which maximises
the expected total reward, i.e. the Bayes-expected number of successes, over the set
of all policies in the whole trial for a given prior at time t = 0, namely,
F0(sA,0, fA,0, sB,0, fB,0). (3.2.3)
The problem summarised in equation (3.2.3) is known as a finite-horizon Bayesian
Bernoulli two-armed bandit problem which can be solved exactly using dynamic pro-
gramming methods, giving rise to an optimal adaptive treatment allocation sequence.
Specifically, one can implement a backward induction algorithm which starts with the
last patient, patient n, and proceeds iteratively towards the first patient. Details of
this algorithm can be found in the Appendix 3.6.13.
Suppose that t < n. If treatment A is allocated to the next patient, then the
expected total reward, i.e. the Bayes-expected number of successes, for patients t+ 1
3See also Section 2.2.3(i).
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to n under an optimal policy is
FAt (sA, fA, sB, fB) =
sA
sA + fA




· Ft+1(sA, fA + 1, sB, fB).
Alternatively, if treatment B is allocated to the next patient, then the expected
total reward, i.e. the Bayes-expected number of successes, for patients t+1 to n under
an optimal policy is
FBt (sA, fA, sB, fB) =
sB
sB + fB




· Ft+1(sA, fA, sB, fB + 1).
Therefore, the value function satisfies the following recurrence known as the prin-
ciple of optimality,
Ft(sA, fA, sB, fB) = max
{
FAt (sA, fA, sB, fB), FBt (sA, fA, sB, fB)
}
, for 0 ≤ t ≤ n− 1,
Fn(sA, fA, sB, fB) = 0, otherwise . (3.2.4)
Unlike most response-adaptive designs, this is not a myopic allocation rule. In-
stead, all possible sequences of treatment allocations and responses are enumerated,
and the sequence that maximises the expected number of patient successes over the
finite planning horizon is selected (Hu and Rosenberger, 2006). As such, this approach
is computationally intensive and suffers from the curse of dimensionality (Bellman,
1961). However, we provide an efficient algorithm for the optimal DP design, im-
plemented in the programming language R; the computational times are shown in
Table 3.6.1 of the Appendix 3.6.1.
The computational complexity of the dynamic programming methods to solve this
problem is the main motivation behind the implementation of simpler index-based
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solutions which circumvent the aforementioned problem of dimensionality. One such
solution, which we include as a comparator, is the Whittle index (WI) proposed by
Whittle (1988). This can be applied when the horizon is finite, which is the case with
a clinical trial since there are a finite number of patients in the trial. It is derived from
a relaxation of problem (3.2.3), allowing the multi-armed problem to be decomposed
into single-armed problems in which the states are augmented, adding the number
of patients remaining to be treated as an additional state. Although the WI is a
heuristic solution, it has been found to be near-optimal in several cases. See Villar
et al. (2015a) for a detailed review of the WI as a potential patient allocation rule in
a clinical trial.
It is shown in Villar et al. (2015a) and Villar et al. (2015b), and further illustrated
by our results, that optimal designs which achieve the highest patient benefit suffer
from very low power. Moreover, optimal designs are completely deterministic (Cheng
and Berry, 2007) which means there is a risk of introducing various sources of bias
into the trial, e.g. selection bias (Blackwell and Hodges, 1957). Both of these factors
contribute to making the optimal design unsuitable to implement in clinical trial
practice. Therefore, in the rest of this section we focus on modifications to the DP
design which address these shortcomings, i.e. its determinism and low power, while
improving over a fixed randomised design in terms of patient benefit measures, such
as overall response.
3.2.2 Optimal Design using Randomised Dynamic Program-
ming (RDP)
Randomisation is a critical component in the design of clinical trials, not least to min-
imise the bias and confounding in order to achieve the desired accuracy and reliability
(Chow and Liu, 2014). Therefore, a natural first step is to modify the optimal design
by forcing actions to be randomised; see Cheng and Berry (2007). This is achieved by
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assigning a probability to the allocation rule at each stage. In particular, we define
the following actions so that each treatment has a probability of at least 1−p of being
allocated to each patient, where 0.5 ≤ p ≤ 1 for two-armed trials and will be referred
to as the degree of randomisation. Note that p = 0.5 and p = 1 correspond to fixed,
equal randomisation and the DP design, respectively.
(i) Action 1 (a = 1): The next patient receives treatment A with probability p and
treatment B with probability 1− p.
(ii) Action 2 (a = 2): The next patient receives treatment B with probability p and
treatment A with probability 1− p.
The associated expected total reward under this new action definition changes,
along with the corresponding value function. Specifically, the expected total reward,
i.e. the Bayes-expected number of successes, for patients t+ 1 to n when a = 1 is now
given by
F1t (sA, fA, sB, fB) = p · FAt (sA, fA, sB, fB) + (1− p) · FBt (sA, fA, sB, fB),
and analogously when a = 2,
F2t (sA, fA, sB, fB) = (1− p) · FAt (sA, fA, sB, fB) + p · FBt (sA, fA, sB, fB).
Thus, in contrast to that shown in (3.2.4), the value function satisfies
Ft(sA, fA, sB, fB) = max
{
F1t (sA, fA, sB, fB), F2t (sA, fA, sB, fB)
}
, for 0 ≤ t ≤ n− 1,
Fn(sA, fA, sB, fB) = 0, otherwise.
We refer to this design as the randomised dynamic programming (RDP) design
hereafter.
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Preferably, we would like p to be as close to one as possible so that the action
that allocates to the superior treatment with probability p is as effective as possible.
However, this would entail that sometimes, by chance, the inferior treatment is sam-
pled too few times or not at all. The possibility of this undesirable event occurring
makes this design unsuitable to implement in practice as it results in low power and
estimates with large biases.
3.2.3 Optimal Design using Constrained Randomised Dy-
namic Programming (CRDP)
In order to circumvent having few or no observations on a treatment, we modify the
optimal design further by adding a constraint to ensure that we always obtain at
least ` observations from each treatment arm, where ` is a fixed predefined value and
will be referred to as the degree of constraining. To do this, we add a penalty to
the reward function for every combination of the states that give rise to fewer than `
observations on a treatment arm at the end of the trial.
We formulate this model as a Markov decision process with the following elements:
(i) Let zt = (s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ) be the vector of states representing all the
information that is needed in order to choose an action for patient t, where
s̃A,t, f̃A,t, s̃B,t, f̃B,t are as defined previously in (3.2.1), and ñ = n − t is the
number of patients in the trial remaining to be treated.
(ii) The action set, A = {1, 2}, is composed of Action 1 (a = 1) and Action 2 (a = 2)
as defined in Section 3.2.2.
(iii) The expected (one-period) reward under action a is given byRa(s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ).
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If we are not at the end of the trial (ñ ≥ 1), then




+ (1− p) · s̃B,t
s̃B,t+f̃B,t
, if a = 1,
(1− p) · s̃A,t
s̃A,t+f̃A,t
+ p · s̃B,t
s̃B,t+f̃B,t
, if a = 2.
Otherwise, if we are at the end of the trial with no more patients left to treat
(ñ = 0), then
R(s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ = 0) =
 −n, if sA,t + fA,t < ` or sB,t + fB,t < `,0, otherwise,
where −n is the penalty chosen because it is a large negative value which will
cause the algorithm to avoid the undesirable states.
(iv) The non-zero transition probabilities, P(zt+1 | zt, a), representing the evolution
of the states from patient t to t + 1 under a = 1 and a = 2 are given as follows
(where w.p. means “with probability”).
When a = 1:
zt+1 =

(s̃A,t + 1, f̃A,t, s̃B,t, f̃B,t, ñ− 1) w.p. p · s̃A,ts̃A,t+f̃A,t ,
(s̃A,t, f̃A,t + 1, s̃B,t, f̃B,t, ñ− 1) w.p. p · f̃A,ts̃A,t+f̃A,t ,
(s̃A,t, f̃A,t, s̃B,t + 1, f̃B,t, ñ− 1) w.p. (1− p) · s̃B,ts̃B,t+f̃B,t ,
(s̃A,t, f̃A,t, s̃B,t, f̃B,t + 1, ñ− 1) w.p. (1− p) · f̃B,ts̃B,t+f̃B,t .
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When a = 2:
zt+1 =

(s̃A,t + 1, f̃A,t, s̃B,t, f̃B,t, ñ− 1) w.p. (1− p) · s̃A,ts̃A,t+f̃A,t ,
(s̃A,t, f̃A,t + 1, s̃B,t, f̃B,t, ñ− 1) w.p. (1− p) · f̃A,ts̃A,t+f̃A,t ,
(s̃A,t, f̃A,t, s̃B,t + 1, f̃B,t, ñ− 1) w.p. p · s̃B,ts̃B,t+f̃B,t ,
(s̃A,t, f̃A,t, s̃B,t, f̃B,t + 1, ñ− 1) w.p. p · f̃B,ts̃B,t+f̃B,t .
We refer to our proposed design as the constrained randomised dynamic program-
ming (CRDP) design hereafter.
3.3 Simulation Set-Up
We implement all of the above designs in several two-arm trial scenarios via simu-
lations which will now be discussed, along with the performance measures that we
use to compare and evaluate each design. The scenarios created are motivated by a
recently published trial, as reported by Akech et al. (2010), which evaluated the effect
of two different resuscitation treatments for children aged over six months with severe
malnutrition and shock. The aim of the trial was to recruit 90 eligible patients, where
45 would be randomly assigned to group 0 (low dose hypotonic fluid: HSD/5D) and
45 to group 1 (Ringer’s Lactate: RL). The original trial allocated patients between
the two arms with a fixed and equal randomisation probability of 0.5. The primary
response outcomes were binary and available at eight and 24 hours after randomisa-
tion (resolution of shock by 8/24 hours). For this trial, 61 children were recruited,
26 received arm 0 and 29 received arm 1. At the end of the trial, the success rates
observed in groups 0 and 1 at eight hours were 32% and 44%, respectively, and at 24
hours were 22% and 44%, respectively. Although these differences were not statisti-
cally significant, the relatively quickly observed primary endpoint, the life-threatening
nature of the disease, and the fact that patient recruitment is challenging, makes this
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trial an ideal motivating scenario for testing our proposed design.
Assuming that we begin the trial (at t = 0) in a state of equipoise, that is, a state
of genuine uncertainty about which treatment is superior, we let sA,0 = fA,0 = sB,0 =
fB,0 = 1, reducing this to a uniform prior.
We consider the following hypothesis
H0 : θA = θB versus H1 : θA 6= θB,
which will be tested using Fisher’s exact test (Routledge, 2005) for comparing the
success probabilities of two binomial distributions. Fisher’s exact test is probably
the most common choice for binary outcomes and a small sample size. This test is
a conditional test (conditioning on the marginals), which increases the discreteness
and thus the conservatism of the test (Kateri, 2014). This means that the observed
rejection rate is often far below the nominal significance level. Therefore, we set the
nominal significance level to 0.1 throughout so that the observed type I error value
will be closer to 0.05.
Alternatively, we could have followed a Bayesian inference procedure. However,
in a clinical trial context a traditional hypothesis test is expected (due to both this
being a common practice and because of regulatory requirements). Also, since all the
simulations included in this chapter use an uninformative prior, the impact of using a
Bayesian estimator instead of the sample proportion for point estimation and decision
making would be negligible.
In order to create a comprehensive picture of our proposed design, we run our
simulations for a range of combinations of the success probability parameters θA and
θB. Specifically, we consider θA = 0.2 against θB = (0.1, 0.2, . . . , 0.9), and similarly
for θA = 0.5 and 0.8. In the following, we focus on the scenario where θA is fixed
at 0.5 for all θB ∈ (0.1, 0.9) since the patterns observed for the other cases are very
similar.
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Furthermore, we repeat the simulations for different total sample sizes. The results
for n = 75 are reported throughout because this shows a good range of power values
across all scenarios and clearly highlights the differences between each design, thus
enabling us to make better comparisons. The results for n = 25, 50 and 100 are shown
in Figures 3.6.3–3.6.5 of the Appendix 3.6.7.
We evaluate the performance of these designs by simulating 10,000 replications of
each trial and taking the average values over these runs.
3.3.1 Performance Measures
In addition to the operating characteristics, such as the power and type I error rate,
we also consider the ethical performance of each design since this is one of the major
advantages of response-adaptive designs over traditional fixed designs. Specifically,
the criteria we focus on to assess the performance of each design are:
1. Power. The proportion of times we correctly reject H0 in the 10,000 trial
replicates, i.e. the probability of making the correct decision at the end of the
trial, so we want this to be high. This provides an informative measure of how
well a test performs. This is calculated when θA 6= θB.
2. Type I error rate. The proportion of times we incorrectly reject H0, i.e. the
probability of making the incorrect decision at the end of the trial, so we want
this to be low. This is calculated when θA = θB.
3. Percentage of patients allocated to the superior treatment arm. This
measures the ethical performance of each design, which we wish to maximise.
4. Average bias of the estimator. This provides a measure of the bias ex-
hibited by the treatment effect estimator, where we define treatment effect as
the treatment difference, ∆̂ = θ̂A − θ̂B. The estimator of θA and θB is simply
the sample proportion θ̂A = sA,n/NA and θ̂B = sB,n/NB, respectively. This is
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the observed proportion of successes in either treatment group by the end of
the trial (at time t = n). The average bias of this estimator is defined to be
the difference between the estimated success probability difference and the true
success probability difference, that is,
Bias(∆̂) = E(∆̂−∆) = E(θ̂A − θ̂B)− (θA − θB) . (3.3.1)
5. Mean squared error (MSE) of the estimator. The MSE provides a measure






which can be expressed in terms of the bias and variance of the estimator as,
MSE(∆̂) = Bias(∆̂)2 + Var(∆̂). (3.3.2)
3.4 Simulation Results and Design Comparison
We compare our proposed design to the alternative designs outlined in Section 3.2
based upon the performance measures highlighted in Section 3.3.1. We set p = 0.9
as the degree of randomisation and ` = 0.15n as the degree of constraining in our
proposed CRDP design, which we believe yields robust design characteristics for many
scenarios of interest and could be used as a quick rule of thumb. Alternatively, ` could
be heuristically determined as the minimum sample size per arm required to attain a
power of (1 − γ) in a fixed randomised design, where (1 − γ) ≤ (1 − β) and (1 − β)
is the power level obtained by a fixed randomised trial of size n. In the following two
paragraphs, we describe a more formal heuristic approach to determine p and ` when
higher precision is needed to trade-off power and patient benefit.
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We tried a range of values for ` ∈ (0.05n, 0.50n) (where 0.50n corresponds to
fixed equal randomisation) and found that as ` increases, the power of the design
increases hyperbolically, while the percentage of patients allocated to the superior
treatment decreases linearly. This is illustrated in Figure 3.6.1 of the Appendix 3.6.3.
We recommend choosing ` ∈ (0.10n, 0.15n) because for values of ` < 0.10n, the power
is insufficient, and for values of ` > 0.15n, the very small gains in power do not
outweigh the considerable reduction in the percentage of patients allocated to the
superior treatment.
Similarly, we tried a range of values for p ∈ (0.5, 1) (where p = 0.5 and p = 1 cor-
respond to fixed equal randomisation and the DP design, respectively) and observed
that there is a decrease in power, but a large increase in the percentage of patients
allocated to the superior treatment as p increases from 0.5 to 0.9; see Tables 3.6.2–
3.6.5 in the Appendix 3.6.4 which illustrate this for the RDP design (i.e. without the
constraint). We take p = 0.9 since this produces a good balance between the power
and patient benefit across a wide range of scenarios and sample sizes.
3.4.1 Power and Type I Error
Figure 3.4.1 illustrates the changes in statistical power, and type I error rate, for
each design across a range of scenarios in a study with 75 observations (where the
result for θA = θB corresponds to the type I error rate). It can be seen that fixed
randomisation attains the highest power for all scenarios, whereas that of the DP
and WI designs is drastically reduced, even for large treatment differences. This is
what we would expect since it is not possible to maximise both power and patient
successes simultaneously and, unlike the fixed design, the DP design aims to maximise
the expected number of successes within the trial. Therefore, although the DP and
WI designs are able to identify the superior treatment arm, they are unable to do so
with sufficient statistical significance. We can see that the power of these designs lies
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below 0.3 for all θB ∈ (0.1, 0.9), confirming that they are severely underpowered. As
a result, they are clearly unsuitable to implement in practice.
Figure 3.4.1 also shows that once randomisation is incorporated into the DP design
to form RDP, there is a substantial improvement in power compared to the DP and
WI designs, which even exceeds the 0.8 level (illustrated by the upper dashed line)
for some scenarios. Our proposed CRDP achieves even better power, with its power
values lying much closer to those for the fixed design than the other bandit designs.
The obvious patterns, such as the power increasing with the size of the treatment
difference for each design, are apparent in Figure 3.4.1. Furthermore, additional
evaluations for other sample sizes show similar patterns and can be seen in Figure
3.6.3 of the Appendix 3.6.7.
Turning our attention to the type I error rates, we see that the type I error rate of
both the DP and WI designs lies markedly below the nominal significance level at 0.1
(illustrated by the lower dashed line on Figure 3.4.1) and is therefore greatly deflated
for both designs. However, all of the other designs attain similar, higher observed
type I error rates which are much closer to the nominal significance level and thus
have better controlled type I error rates.
3.4.2 Patient Benefit
Figure 3.4.2 shows the percentage of patients (out of a total of 75) that receive the
superior treatment within the trial. Note that when θA = θB, we define treatment A
as the superior treatment for illustrative purposes and all designs show that approxi-
mately 50% of patients receive the superior treatment in this case, as expected.
The DP and WI designs perform the best, resulting in the highest percentage of
patients receiving the superior treatment. This is not at all surprising considering
they are designed to maximise the expected total reward (patient successes) within
the trial in order to satisfy the patient benefit criterion.



































































Figure 3.4.1: The changes in power and type I error for each design when n = 75,
θA = 0.5 and θB ∈ (0.1, 0.9). The upper dashed line at 0.8 represents the desired
power level, and the lower dashed line at 0.1 represents the nominal significance level.
At the other extreme, by design, the fixed randomised design allocates only 50%
of the patients to the superior treatment in every scenario. Although the RPW rule
does outperform the fixed design in terms of the patient benefit, the percentage of
patients that are on the superior treatment is still much lower compared to all of the
other designs. It is useful to note that the limiting allocation proportion of patients
on treatment A for the RPW rule is given by (1−θB)/(2−θA−θB) (Wei and Durham,
1978).
Figure 3.4.2 shows that the RDP and CRDP designs perform very well and the
percentage of patients receiving the superior treatment is still sufficiently high, with
the CRDP line lying slightly below the RDP line due to the addition of the constraint.
The largest difference between CRDP and DP is approximately 10%, which occurs
at either end of the plot when the size of the treatment difference is at its largest.
Moreover, our proposed CRDP design allocates a maximum of approximately 21% and
35% more patients to the superior treatment than the RPW rule and fixed design,
respectively, which occurs when θB = 0.1.
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For all designs (excluding the fixed), Figure 3.4.2 shows that the percentage of pa-
tients allocated to the superior treatment increases with the magnitude of the treat-
ment difference, with the higher values occurring at the tails of the graph which
correspond to the larger treatment differences. Furthermore, similar patterns are




































































Figure 3.4.2: The percentage of patients on the superior treatment arm for each design
when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9).
3.4.3 Bias
Figure 3.4.3 shows the average bias of the difference in the sample proportions as an
estimator for the treatment effect, as defined by (3.3.1), in a study with 75 obser-
vations. We see that the fixed randomised design produces the best result in terms
of the bias, with its associated estimator attaining zero bias for all scenarios, as it
should.
At the other extreme, the DP and WI designs exhibit the largest statistical bias
with a maximum absolute value of 0.2 occurring when θB = 0.9. Therefore, the
corresponding estimates following such bandit designs will be biased due to the un-
derlying dependence structure induced in the resulting observations. This is reflected
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in Table 3.4.1 which directly reports the raw estimates of the success probabilities,
θ̂A and θ̂B. Table 3.4.1 shows that in the DP design, the estimate of the success
probability for the inferior arm is substantially underestimated. The estimate for the
superior arm is also underestimated, but less than for the inferior arm, particularly
when the treatment difference is relatively small. This implies that the estimate of
the treatment difference, ∆̂, is generally overestimated. Since bandit designs allocate
fewer patients to the inferior treatment, this may partially explain why the estimate
corresponding to this arm is worse than that of the superior arm because there are
fewer observations to base the inference on.
Once randomisation is incorporated into the DP design, we see from Figure 3.4.3
that the bias is drastically reduced across all scenarios, with a maximum absolute
value of 0.027 which is 85% smaller than the worst-case bias of the other bandit
designs. Moreover, our proposed CRDP design performs even better than the RDP
and further reduces the bias of the treatment effect estimator. In fact, the bias values
for our proposed CRDP are very close to zero for all scenarios with a maximum
bias value of only 0.014 which is 93% smaller than the worst-case bias for the DP
design. As such, the bias following our proposed CRDP is negligible compared to the
very large bias exhibited by the other bandit designs and hence, the treatment effect
estimator following our proposed CRDP design is essentially mean-unbiased. Again,
this is reflected in Table 3.4.1 which shows that in our proposed CRDP design, θ̂A and
θ̂B are now much closer to their true values. Moreover, there is a large improvement
in the estimate of the success probability for the inferior arm compared to the DP
design since it is now only slightly underestimated.
Note that we can clearly see from Figure 3.4.3 that all designs correctly attain a
bias of zero when θA = θB. Similar results for different n are provided in Figure 3.6.5
of Appendix 3.6.7.
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Figure 3.4.3: The average bias of the treatment effect estimator when n = 75, θA = 0.5
and θB ∈ (0.1, 0.9).
True Fixed DP CRDP
θA θB θ̂A (s.e.) θ̂B (s.e.) θ̂A (s.e.) θ̂B (s.e.) θ̂A (s.e.) θ̂B (s.e.)
0.500 0.100 0.500 (0.083) 0.100 (0.050) 0.498 (0.062) 0.057 (0.096) 0.499 (0.064) 0.097 (0.085)
0.500 0.200 0.500 (0.083) 0.201 (0.065) 0.493 (0.080) 0.119 (0.132) 0.496 (0.070) 0.187 (0.105)
0.500 0.300 0.500 (0.083) 0.301 (0.075) 0.474 (0.118) 0.191 (0.156) 0.489 (0.084) 0.275 (0.109)
0.500 0.400 0.500 (0.083) 0.401 (0.080) 0.434 (0.162) 0.279 (0.176) 0.475 (0.098) 0.364 (0.107)
0.500 0.500 0.500 (0.083) 0.500 (0.082) 0.386 (0.192) 0.389 (0.192) 0.462 (0.105) 0.464 (0.106)
0.500 0.600 0.500 (0.083) 0.600 (0.080) 0.340 (0.216) 0.518 (0.193) 0.461 (0.111) 0.575 (0.099)
0.500 0.700 0.500 (0.083) 0.699 (0.075) 0.303 (0.240) 0.652 (0.172) 0.472 (0.123) 0.689 (0.080)
0.500 0.800 0.500 (0.083) 0.800 (0.065) 0.290 (0.266) 0.780 (0.129) 0.484 (0.136) 0.797 (0.058)
0.500 0.900 0.500 (0.083) 0.900 (0.049) 0.291 (0.290) 0.895 (0.074) 0.493 (0.147) 0.900 (0.039)
Table 3.4.1: The estimates of success probabilities, θ̂A and θ̂B, and corresponding
standard errors (s.e.) for the success probabilities of treatments A and B, respectively,
compared to their true values θA and θB. These results correspond to the scenario in
which n = 75, θA = 0.5 and θB ∈ (0.1, 0.9).
3.4.4 Mean Squared Error
Figure 3.4.4 shows the mean squared error (MSE) of the treatment effect estimator,
as defined by (3.3.2), for a study with 75 observations. The fixed randomised design
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results in the smallest MSE, with values fairly constant and close to zero for all
scenarios.
The DP and WI designs exhibit the largest MSE values, with the MSE of the WI
design exceeding those of the DP design for all scenarios. This is a direct consequence
of the large bias observed in Figure 3.4.3. Moreover, these designs experience the
largest increase in MSE as θB increases from 0.1 to 0.7, after which point they remain
fairly constant. Specifically, as θB increases from 0.1 to 0.7, the MSE jumps from
0.016 to 0.141 for the WI design, and from 0.015 to 0.133 for the DP design. We also
notice from Figure 3.4.4 that the associated MSE plots for the DP and WI designs
are not symmetric about θB = 0.5. This is a result of the variance of the estimator
increasing markedly as θB increases from 0.1 to 0.6, in addition to the bias for the DP
and WI being much larger for larger values of θB.
Once randomisation is incorporated into the DP, the MSE is reduced for all sce-
narios, from a worst-case value of 0.141 in the WI design to a worst-case value of
0.032 in the RDP design which is a 77.3% improvement. Moreover, our proposed
CRDP design improves the MSE values even further, with a lower and upper bound
of 0.011 and 0.026, respectively. The majority of the MSE values lie around 0.030
for the RDP design and 0.020 for our proposed CRDP design. In contrast to the
steep curves of the DP and WI designs, the MSE values associated with the RDP
and CRDP designs remain fairly constant (as with the fixed and RPW designs), thus
giving rise to the relatively flat curves visible in Figure 3.4.4. Furthermore, we see
that the curve corresponding to our proposed CRDP lies fairly close to the curve for
the fixed design. Thus, the MSE values of the treatment effect estimator following
our proposed CRDP design are comparable to those of the fixed design, staying close
to zero for all scenarios, and are a huge improvement on those exhibited by the DP
and WI bandit designs.
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Figure 3.4.4: The mean squared error (MSE) of the treatment effect estimator when
n = 75, θA = 0.5 and θB ∈ (0.1, 0.9).
3.4.5 Overall Performance
Figure 3.4.5 shows a star plot for each design against power, patient benefit, average
bias and MSE of the treatment effect estimator in a trial with 75 patients when
θA = 0.5 and θB = 0.2. The most desirable values lie towards the outer edge of the
star plot with the least favourable values towards the centre. Figure 3.4.5 summarises
the key features of each design showing that the fixed design performs very well with
respect to power, average bias and MSE but poorly with respect to patient benefit,
whilst in contrast the DP design performs poorly with respect to power, average bias
and MSE but very well with respect to patient benefit. Our proposed CRDP design,
on the other hand, has values lying near to the outer edge of the star plot for power,
average bias, MSE and patient benefit, thus showing that it performs well with respect
to all of the performance measures. Table 3.6.6 in Appendix 3.6.6 reports additional
combined measures that complement Figure 3.4.5 to compare the designs.



















Figure 3.4.5: Star plot showing the performance of each design with respect to power,
patient benefit, absolute average bias and MSE of the treatment effect estimator when
n = 75, θA = 0.5 and θB = 0.2. The best value achieved for each performance measure
is depicted at the outer edge. (Note that the absolute average bias and MSE axes
have been inverted so that the smaller (favourable) values are towards the outer edge,
unlike the power and patient benefit axes which have their larger values towards the
outer edge.)
3.4.6 CRDP Patient Allocation
Figure 3.4.6 shows the average allocation probability to the superior treatment B
under the CRDP design for every patient t in a trial with 75 patients when θA = 0.5
and θB = 0.7. This figure illustrates how the CRDP design adaptively allocates
patients between the two treatments over time. The average allocation probability to
a superior arm grows steadily through the trial towards the degree of randomisation
selected (p = 0.9), but without reaching it in this scenario. As the trial approaches
the treatment decisions for its final 15 patients, this probability markedly oscillates in
order to satisfy the degree of constraining. This indicates that an important number
of allocations to the inferior arm under the CRDP design tend to occur by the end
of the trial rather than at the beginning of it4. Figure 3.4.7 also illustrates this point
4Note that this could circumvent the problem of accrual bias mentioned in Section 2.1.1.
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Figure 3.4.6: Probability of allocating a patient to the superior treatment B for CRDP
when θA = 0.5 and θB = 0.7 in a trial of size n = 75.
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Figure 3.4.7: Patient allocations for CRDP when θA = 0.5 and θB = 0.7 in a trial of
size n = 75 for five different trial realisations. Upper dots represent allocations to the
superior treatment B while lower dots represent allocations to the inferior treatment
A.
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3.5 Discussion
In this chapter, we evaluate different methods for allocating patients to treatments.
The DP design performs very well when considering patient benefit compared to
traditional fixed randomisation. However, this method suffers from an extremely low
power to detect a significant treatment difference, biased estimates of the treatment
effect and a large MSE. Moreover, it is completely deterministic and thus at risk of
many possible sources of bias.
At the other extreme, fixed randomisation performs very well in terms of the
statistical criteria, exhibiting high power, unbiased estimates of the treatment effect
and small MSE. However, it allocates a large proportion of patients to the inferior
treatment arm. This is particularly detrimental for rare, and fatal, diseases in which
a substantial proportion of patients exhibiting the disease may be included in the trial
and therefore the priority should be to treat these patients as effectively as possible.
We propose modifications to the DP design which overcome its current limitations
and offer patient benefit advantages over a fixed randomised design by randomising
in an optimal way and forcing a minimum number of patients on each arm. Our
formal, mathematical approach grounded in decision theory creates a continuum of
designs, with DP and fixed randomisation at the extremes, which offers freedom in
choosing the most appropriate balance by fixing a degree of randomisation and a
degree of constraining. This greatly increases the prospects of a bandit-based design
being implemented in real clinical trial practice, particularly for trials involving rare
diseases and small populations where the fixed randomisation approach is no longer
the most appropriate design to use and is often not feasible due to the small sample
sizes involved.
Our proposed CRDP design, with suggested degree of randomisation p = 0.9 and
degree of constraining ` = 0.15n, seems to perform robustly in a range of simulated
scenarios (not all of which are reported here). The power is only slightly lower than
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with fixed randomisation, while almost as many patients are randomised to the su-
perior treatment as in the DP design. Hence, this design strikes a very good balance
in terms of the patient benefit and power trade-off, providing both power and ethical
advantages, which acknowledges that clinical trials are multiple objective experiments.
The average bias and MSE of the treatment effect estimator following our proposed
CRDP design are very low. It is well known that selection results in biased estimators
(see e.g. Bauer et al., 2010). This is also true for group-sequential trials which are,
however, routinely used in practice nowadays because the benefit from these designs
can outweigh the bias incurred, particularly in the case of rare diseases. In order
to make this assessment, it is important to determine the magnitude of the bias (as
well as the benefits of the design) and hence the evaluations provided are essential for
these novel methods to be applied in a real-life trial. In cases where the magnitude
of the bias could be considered excessive, there exists a bias-corrected estimator that
can be used (which comes at the price of a notably increased variability); see Bowden
and Trippa (2017). Coad and Ivanova (2001) also study the bias of the maximum
likelihood estimators of the success probabilities following several response-adaptive
designs in the two-arm, binary response case.
In this chapter, we consider a two-armed trial with binary endpoints for simplicity,
yet the principles used easily extend to multi-arm trials. An area of further work is to
generalise the proposed design so it can be applied to other endpoints. In addition,
a natural extension of this work is to modify the heuristic WI policy in a similar
way as we have with the optimal DP design since index policies are conceptually
more intuitive (we allocate the patient to the treatment with the highest index), and
hence easier to communicate and be understood by clinicians. Moreover, the WI is
potentially very important for the extension to more than two treatment arms since
the DP quickly becomes computationally intractable while the WI is still feasible
(Villar et al., 2015a).
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In our proposed design, each patient’s response is used to inform the subsequent
allocation decision. This relies on the assumption that patient responses become
available before the next patient receives treatment (which would be the case if patient
responses were quickly observed, for example). In many clinical trial settings, this is
unrealistic because often a treatment takes a substantial length of time to induce a
response and so it is very likely that the accrual rate will exceed the response rate.
However, in a rare disease setting, the accrual rate is likely to be relatively slow with
some patients being recruited over several years, and hence this assumption would
be reasonable. Further research is required to address the problem of incorporating
delayed responses into bandit-based designs which would increase the generalisability
of our proposed design5.
Moreover, our proposed design can only be applied to relatively small-scale trials
since the underlying backwards induction algorithm suffers from the curse of dimen-
sionality (Bellman, 1961) and currently attains its practical limit at n = 200. Again,
this is not an issue for a rare disease setting in which the number of patients available
for participation in the trial is limited, or clinical trials involving children, for exam-
ple, in which recruitment is challenging (Hampson et al., 2014). In fact, many phase
II trials have no more than 200 patients, even in common diseases.
Additional extensions of this work include considering the effect of changing the
prior distribution assigned to the unknown success probabilities. For example, a Beta
prior with carefully chosen parameters could alternatively be used if the investigator
wishes to reflect a greater amount of knowledge or a bias in favour of a particular
treatment, without increasing the complexity of the problem. See Hampson et al.
(2014) in which the unknown model parameters of the prior distribution are deter-
mined by eliciting expert opinion and incorporating historical data from a related
trial.
5See Chapters 4 and 5.
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3.6 Appendix
3.6.1 Backward Induction Algorithm
• If t = n, there is nothing to do because all n patients have already been
treated and their outcomes observed. Thus, Fn(s̃A,n, f̃A,n, s̃B,n, f̃B,n) = 0 ∀
s̃A,n, f̃A,n, s̃B,n, f̃B,n.
• If t = n− 1, there is only one patient left to treat and interest is in determining
which treatment to allocate to this patient ∀ s̃A,n−1, f̃A,n−1, s̃B,n−1, f̃B,n−1 that
sum to n− 1. There are two possibilities:
– If treatment A is allocated to the remaining patient, then we compute the
expectation













is the probability of a failure if treatment A
is allocated.
– Alternatively, if treatment B is allocated to the remaining patient, then
we compute the expectation













is the probability of a failure if treatment B
is allocated.
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Interest is in choosing the optimal allocation such that
Fn−1(s̃A,n−1, f̃A,n−1, s̃B,n−1, f̃B,n−1) =
max{FAn−1(s̃A,n−1, f̃A,n−1, s̃B,n−1, f̃B,n−1), FBn−1(s̃A,n−1, f̃A,n−1, s̃B,n−1, f̃B,n−1)}.
Thus, if FAn−1(s̃A,n−1, f̃A,n−1, s̃B,n−1, f̃B,n−1) > FBn−1(s̃A,n−1, f̃A,n−1, s̃B,n−1, f̃B,n−1),
then it is optimal to allocate the remaining patient to treatment A, and vice
versa. If they are equal, then both treatments are optimal choices.
• The next step is if t = n − 2, i.e. when there are two remaining patients to be
allocated. To determine which treatment to allocate to patient n− 1, there are
two possibilities:
– If treatment A is allocated to patient n − 1, then we compute the expec-
tation












0 + Fn−1(s̃A,n−2, f̃A,n−2 + 1, s̃B,n−2, f̃B,n−2)
)
.
– Similarly, if treatment B is allocated, then we compute the expectation
















These steps are just iterations, and can be expressed more succinctly in the general
CHAPTER 3. A BAYESIAN ADAPTIVE DESIGN FOR CLINICAL TRIALS 71
form as follows.
If treatment A is allocated to the next patient, then the expected number of
successes for patients t+ 1 through n under an optimal policy is










· Ft+1(s̃A,t, f̃A,t + 1, s̃B,t, f̃Bt).
On the other hand, if treatment B is allocated to the next patient, then the
expected total reward under an optimal policy is










· Ft+1(s̃A,t, f̃A,t, s̃B,t, f̃B,t + 1).
Therefore, F satisfies the recurrence
Ft(s̃A,t, f̃A,t, s̃B,t, f̃B,t) = max
{




Table 3.6.1 illustrates the computational speed of the backwards induction algorithm
to compute the allocation policy of the DP design on a standard laptop with 16 GB
of RAM. The maximum trial size that can be computed on a standard laptop using
R is 215. Although trials of sizes larger than 215 are very unlikely to occur in a rare
disease context, computations of the DP design are feasible on a standard performance
workstation (1 TB of RAM) for 215 < n < 600. Trials of a size up to 3500 patients
would be feasible with today’s number one supercomputer (with 1.3 PB of RAM).
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n EPS Run Time RAM
10 0.60218 0.01s 0.1 MB
30 0.63066 1s 6.2 MB
50 0.63993 6s 47.7 MB
70 0.64485 24s 183.2 MB
90 0.64799 1m:04s 0.56 GB
110 0.65020 2m:22s 1.1 GB
130 0.65186 4m:37s 2.1 GB
150 0.65316 8m:03s 3.86 GB
200 0.65547 25m:20s 11.9 GB
Table 3.6.1: Expected proportion of successes (EPS) when sA,0 = fA,0 = sB,0 =
fB,0 = 1, i.e. EPS = F0(1, 1, 1, 1)/n, run time in minutes (m) and seconds (s) and
RAM memory requirements of the DP design on a standard laptop.
3.6.3 Choosing the Degree of Constraining, `
Figure 3.6.1 illustrates the non-linearity of the power, based on which we recommend
` = 0.15n in our proposed CRDP design.
















Figure 3.6.1: The effect of changing the degree of constraining, `, on the power and
percentage of patients on the superior treatment when θA = 0.2 and θB = 0.8 for the
constrained DP design (without randomisation). The left and right dashed vertical
lines correspond to ` = 0.10n and ` = 0.15n respectively, where n = 75 in this case.
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3.6.4 Choosing the Degree of Randomisation, p
Tables 3.6.2–3.6.5 illustrate the effect of varying degrees of randomisation for a range
of different scenarios, based on which we recommend p = 0.9 in our proposed CRDP
design.
p Bias MSE Type I Error EPS % on superior
0.5 0.000 0.004 0.035 0.200 50.0
0.6 -0.002 0.004 0.034 0.200 50.1
0.7 -0.001 0.005 0.027 0.200 50.2
0.8 0.000 0.005 0.022 0.200 50.0
0.9 0.000 0.006 0.008 0.200 50.2
1.0 0.001 0.008 0.000 0.200 49.7
Table 3.6.2: The effect of changing the degree of randomisation, p, on the perfor-
mance measures when n = 75 and θA = θB = 0.2 for the RDP design (without the
constraint).
p Bias MSE Power EPS % on superior
0.5 -0.001 0.004 0.428 0.300 50.0
0.6 -0.002 0.005 0.406 0.315 57.3
0.7 -0.003 0.006 0.355 0.329 64.5
0.8 -0.007 0.007 0.289 0.344 71.4
0.9 -0.018 0.010 0.183 0.356 77.9
1.0 -0.058 0.017 0.021 0.368 83.6
Table 3.6.3: The effect of changing the degree of randomisation, p, on the performance
measures when n = 75, θA = 0.2 and θB = 0.4 for the RDP design (without the
constraint).
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p Bias MSE Power EPS % on superior
0.5 -0.001 0.004 0.938 0.400 50.0
0.6 -0.002 0.005 0.935 0.437 59.1
0.7 -0.002 0.007 0.910 0.473 68.2
0.8 -0.005 0.009 0.830 0.509 77.3
0.9 -0.015 0.015 0.636 0.544 86.0
1.0 -0.089 0.03 0.070 0.577 94.2
Table 3.6.4: The effect of changing the degree of randomisation, p, on the performance
measures when n = 75, θA = 0.2 and θB = 0.6 for the RDP design (without the
constraint).
p Bias MSE Power EPS % on superior
0.5 -0.001 0.004 1.000 0.500 50.0
0.6 -0.001 0.005 1.000 0.557 59.6
0.7 -0.001 0.007 0.999 0.615 69.2
0.8 -0.004 0.010 0.995 0.672 78.8
0.9 -0.009 0.019 0.937 0.730 88.3
1.0 -0.100 0.043 0.118 0.786 97.6
Table 3.6.5: The effect of changing the degree of randomisation, p, on the performance
measures when n = 75, θA = 0.2 and θB = 0.8 for the RDP design (without the
constraint).
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3.6.5 CRDP Patient Allocation: Other Scenarios
Figure 3.6.2 complements Figure 3.4.6 to show average allocation probabilities of our














































































































































































































































































































Figure 3.6.2: Probability of allocating a patient to treatment B for CRDP when
θA = 0.5 and θB = {0.5, 0.6, 0.8, 0.9} in a trial of size n = 75 estimated over 10,000
simulations.
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3.6.6 Combined Performance Measures
Table 3.6.6 summarises the performance of the four key features (power, average bias,
MSE and patient benefit) per design by showing the following measures: (i) sum of the
distance of each key feature from the best achievable value (SDis), (ii) the maximum
difference among each of the four key features from the best achievable value (MD),
(iii) sum of the deviations of each key feature from the fixed randomisation design
(SDev).
Design SDis MD SDev
CRDP 32.925 24.7 53.513
RDP 36.936 29.7 63.009
DP 74.439 72.3 95.494
WI 73.307 73.2 113.695
RPW 30.714 29.7 11.801
Fixed 40.512 50.0 0
Table 3.6.6: The summary measures of performance in terms of the four key features.
SDis: sum of the distance of each key feature from the best achievable value; MD:
maximum difference among each of the key features from the best achievable value;
SDev: sum of the deviations of each key feature from the fixed randomisation de-
sign. Note that these should be treated with some caution since the key features are
measured on different scales.
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3.6.7 Results for Other Sample Sizes
Figures 3.6.3–3.6.5 complement Figures 3.4.1–3.4.3, respectively, to compare the per-
























































































































































































































































Figure 3.6.3: The changes in power and type I error for each design when θA = 0.5
and θB ∈ (0.1, 0.9) for varying sample sizes. The upper dashed line at 0.8 represents
the desired power level, and the lower dashed line at 0.1 represents the nominal
significance level.










































































































































































































































































Figure 3.6.4: The percentage of patients on the superior treatment for each design
when θA = 0.5 and θB ∈ (0.1, 0.9) for varying sample sizes.
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Figure 3.6.5: The average bias of the treatment effect estimator when θA = 0.5 and
θB ∈ (0.1, 0.9) for varying sample sizes.
Chapter 4
Extension to Delayed Responses
4.1 Introduction
In Chapter 3, each patient’s response is used to inform the subsequent allocation de-
cision which relies on the assumption of immediate patient responses or, more specif-
ically, that a patient’s response is available before the next patient enters the trial.
Most response-adaptive designs in the literature are typically formulated under this
assumption (Cheung et al., 2006; Biswas et al., 2008, Section 3.7). Although this
may be appropriate for some clinical contexts, such as trials of surgical interventions
(Rosenberger and Lachin, 2016, Chapter 12), trials for diseases with a slow recruit-
ment rate (e.g. rare diseases) or rapidly observed endpoint (e.g. acute diseases), it is
unrealistic in many clinical trial settings (e.g. oncology trials). This is because, not
only may a treatment take a substantial length of time to induce a response, but there
may also be an administrative delay in obtaining the response (Pocock, 1983) or im-
plementing the adaptation to the allocation probabilities which, as Wason et al. (2019)
discusses, “will reduce the efficiency advantage of an adaptive approach in exactly the
same way as using an outcome that takes longer to observe”. As a result, responses
from all of the previously allocated patients may not be available before allocation of
80
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the next patient; we will refer to these responses, or patients, as being in the pipeline1.
One simple approach is to base the allocation decision only on the currently observed
data and ignore the pipeline data. However, this can lead to biased parameter es-
timates and incorrect allocation decisions (Xu and Yin, 2014). Another possibility
is to wait until all of the treated patients have responded before allocating the next
patient(s), but this is impractical since the trial will take much longer (Wason et al.,
2019). Moreover, it is unethical to withhold treatment from trial participants (Yin,
2012, Chapter 7). Even though it has long been highlighted that “useful methods
must have treatment assignment rules that do not require instantaneous observations
and reporting” (Simon, 1977), the problem of how (response-)adaptive designs can be
adjusted to incorporate delayed responses remains an important research question.
Several authors have illustrated the effect of delayed responses on particular response-
adaptive designs (predominantly urn models), either by simulation, e.g. Robinson
(1983); Rosenberger and Seshaiyer (1997); Rosenberger (1999); Ivanova and Rosen-
berger (2000); Kuleshov and Precup (2000); Karrison et al. (2003); Zhang and Rosen-
berger (2006, 2007); Wason et al. (2019), or theoretically, e.g. Bai et al. (2002) for
urn models; Hu et al. (2008) for the doubly adaptive biased coin design. However,
few have provided potential solutions to accommodate for the delay (which has been
pointed out in many papers, e.g. Hardwick et al. (2006); Caro and Yoo (2010); Chick
et al. (2017)). The inability of most response-adaptive designs to account for the
delay has long been cited as one of the greatest limitations and barriers to their im-
plementation in practice (see Simon, 1977; Armitage, 1985; Zhang and Rosenberger,
2006; Villar et al., 2015a,b; Smith and Villar, 2018; Ahuja and Birge, 2019). Sverdlov
et al. (2012), for example, describe it as “a major stumbling block in implementing
adaptive designs”, and Rosenberger et al. (2012, Section 4) list it as one of the main
1The pipeline includes those patients who have been allocated to a treatment but have not yet
responded. This is consistent with the terminology used in related literature, e.g. Hampson and
Jennison (2013); Chick et al. (2017).
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criticisms of RAR. As such, there is a strong interest amongst the statistical and
clinical trial community in whether RAR methods can be extended to accommodate
delayed responses (see e.g. the comment made by D. S. Coad in the Discussion of the
paper by Hampson and Jennison (2013)).
Consequently, the main objective of this chapter is to take a step towards address-
ing this problem by not only exploring the impact of delayed responses on the designs
introduced in Chapter 3, but also proposing a method which can utilise the pipeline
information in the adaptations. First, we outline some of the few existing designs
that do adjust for delays.
Eick (1988b) introduces a model for a bandit problem with delayed responses in the
context of a two-armed clinical trial where the distribution of one arm is known, thus
referred to as a one-armed bandit, and the other has a geometric response time. The
DP solution is presented and compared to the optimal solution (designed to maximise
expected total patient lifetime) for the immediate response case. These results have
been further extended by Wang (2000) and Wang (2002). Another paper by Eick
(1988a) proves the existence and optimality of the Gittins index for the one-armed
delayed response bandit when the discount factor is less than 1/2.
Biswas and Coad (2005) comment that “most of the available literature on adap-
tive designs overlooks possible delays in responses” and suggest how delays can be
incorporated into their proposed multi-armed adaptive design for continuous multi-
variate responses.
Hardwick et al. (2006) consider a two-armed trial with Bernoulli responses in
which patients arrive via a Poisson process and their response times are assumed to
follow independent exponential distributions. The objective function of interest is to
maximise the expected number of patient successes during the trial. Therefore, they
model this problem as a two-armed bandit with delay which, in theory, is amenable
to solution by DP to yield the optimal design. However, as discussed in Chapter
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2, this approach is already computationally intensive and the additional complexity
caused by the delay increases this even further. They discuss two alternatives based
on the recursive DP equations: the first was computationally infeasible at the time of
publication, therefore they present a second solution which reduces the computational
requirements. In this chapter, we take a similar approach to Hardwick et al. (2006)
by proposing, and implementing, a design for the delayed response bandit based on
the DP equations, yet there are some important differences which will be highlighted
in Chapter 5.
Xu and Yin (2014) propose a two-stage non-parametric fractional scheme based
on RAR to address the issue of delayed response by treating unobserved outcomes as
censored and calculating their fractional contribution to the response probability. See
also Chick et al. (2017) for another, more recent, example of a design for a two-armed,
sequential trial adjusted for delayed responses based on a Bayesian decision theoretic
model.
This chapter is organised as follows. In Section 4.2, we begin by exploring the
impact of fixed and random delays in responses on both the optimal DP response-
adaptive design and the constrained randomised variant (CRDP) introduced in Chap-
ter 3, which we will jointly abbreviate as (CR)DP from hereon for convenience. We
compare it to the delayed randomised play-the-winner rule (DRPWR), described in
Section 2.1.2, which is well-studied in the literature and is the rule most often sug-
gested for delayed response settings (Hardwick et al., 2006).
Similarly to Chick et al. (2017), the remainder of this chapter will focus on the
case where there is a fixed number of patients in the pipeline at each stage and
we will suggest two approaches to account for this delay in Section 4.3, along with
corresponding simulation results. The first is an intuitive approach based on altering
the time horizon used (see Section 4.3.1), and the second extends the MDP model
defined in Chapter 3 by introducing another state variable (see Section 4.3.2). Finally,
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the main conclusions are concisely summarised in Section 4.4.
A fixed number of pipeline patients at each stage will be imposed when the time
between two consecutive allocations (i.e. the time period) is constant and patients
are followed up at a fixed time after treatment (e.g. Facey, 1992; Whitehead, 1993).
Although a patient response may occur at any time, in binary response trials (consid-
ered in this chapter), interest is only in if it has occurred by the specified follow-up
time. Other examples leading to a fixed delay in response are due to administrative
delays, such as staff availability, resource limitations, time taken to obtain the results
(e.g. patients may require a blood test to determine whether the treatment has been
successful, the results of which may only be available one week later), time taken to
update and implement the adaptations, etc. (Pocock, 1983; Wason et al., 2019). In
the literature, other authors (including Langenberg and Srinivasan, 1981, 1982; Chick
et al., 2017) have also formulated delayed response models based upon the assump-
tions of a constant time period and fixed time until response. Furthermore, focusing
on the fixed delay model is a natural first step which will aid in the development of a
solution for more complex delay structures, such as when the number of patients in
the pipeline is instead random (as in Chapter 5).
4.2 The Effect of Delayed Responses on (CR)DP
4.2.1 Trials with a Fixed Delay
In this section, we focus on a deterministic delayed response model which assumes
that there is a constant time between allocations and a fixed delay of length d > 0
between allocating a patient to a treatment and observing their outcome. As a result,
we will know exactly how many patients are in the pipeline at each stage in the trial
which, for t ∈ {d+ 1, . . . , n}, will remain of fixed length equal to d.
In order to explore the impact of delayed responses when applying the (CR)DP
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designs, we use simulation to evaluate its performance in a range of scenarios for
different delay lengths. By first understanding the impact of a delayed response, we
can then take steps to modify the design accordingly. Moreover, as Wason et al. (2019)
point out, “it is important that theoretical work that proposes and promotes adaptive
designs clearly lays out any reduction in their reported efficiency benefits when there is
substantial delay in outcome evaluation”. We pay particular attention to the scenario
in which θA = 0.5 ∀ θB ∈ (0.1, 0.9) and n = 75 so results are consistent with, and
comparable to, those reported in Chapter 3. Since more interest is in what happens
for shorter delays, as this is where the most marked changes in performance of these
designs occur, the results are illustrated for d = 0, 5, 15, 25, 50 and 75. Furthermore,
from a practical viewpoint, “adaptive allocation has no benefit when there are long
delays” (Berry and Stangl, 1996, Chapter 4) because there is little, or no, chance to
adapt the allocation, thus it would be inappropriate to employ an adaptive design
in this setting. The reason for including the results for no delay is so we can clearly
evaluate how the delayed responses are affecting the performance measures relative to
the base case. Further, recall that d = 75 corresponds to fixed, equal randomisation.
The results illustrated in Figure 4.2.1 correspond to changes in the performance of
the CRDP design, and analogous results for the DP design are displayed in Figure
4.5.1 of the Appendix 4.5. We include results for the DP design to show how the
delay affects the design in the absence of the randomisation and constraining.
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Figure 4.2.1: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the CRDP
design when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different fixed delay lengths
(estimated over 100, 000 simulations).
Power. The top left plot in Figure 4.2.1 illustrates the changes in statistical
power for CRDP, with the results for θA = θB corresponding to the type I error rates.
The most notable observation is that the power increases with delay length. This is
what we expect because as the length of the delay increases, the adaptation is slowed
and the closer the design is to pure randomisation meaning there is less imbalance
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between the treatment arms (and hence a greater power). However, the observed
changes in power are only small, even for a considerable increase in the delay length.
For example, when θB = 0.1, the change in power from the “worst” case (i.e. when
d = 0) to the “best” case (i.e. when d = 75) is approximately 10%, on average.
As mentioned previously, we see that the larger changes in power happen for
shorter delays, with negligible changes as the delay length increases from 50 to 75,
for example. The obvious patterns, such as the power increasing with the size of the
treatment difference, are evident for all delay lengths. In terms of the type I error
rates, we see that they are seemingly well controlled since they lie close to the nominal
significance level at 0.1.
Patient benefit. The top right plot in Figure 4.2.1 illustrates the changes in the
percentage of patients allocated to the superior treatment, i.e. the patient benefit,
for CRDP. When θA = θB, the design allocates approximately 50% of patients to the
superior treatment whatever the delay length, as expected. In general, we observe
that the number of patients in the trial receiving the superior treatment decreases as
the delay length increases. Again, this is not surprising since a longer delay means
that there are fewer responses available to update the allocation probabilities, and
the longer the equal randomisation phase at the start of the trial. This also confirms
what has been noted in the literature; for example, in a Technical Report on two-
armed bandit strategies by Berry (1976, Section 6), it was mentioned that “there is a
decrease in the maximal expected proportion of success when there is response delay”.
Consider the scenario in which θA = 0.5 and θB = 0.1. For the case of no delay,
approximately 83% of patients in the trial are allocated to the superior treatment and
for a delay of length 25, approximately 73% of patients are allocated to the superior
treatment. Thus, we only lose roughly 10% of the patient benefit in this case (which
is not a huge price to pay for a delay which causes one third of the information to be
excluded). Furthermore, compared to standard randomisation (illustrated by the pink
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line in Figure 4.2.1), the gain in patient benefit is still considerably higher. Even for a
delay length of 50 (two thirds of the trial size), there are still worthwhile gains, relative
to equal randomisation, with approximately 10% more patients being allocated to the
superior treatment.
Bias. The bottom left plot of Figure 4.2.1 shows the changes in the average bias
of the treatment effect estimator ∆̂ = θ̂A− θ̂B (where θ̂A = sA,n/NA and θ̂B = sB,n/NB
are the observed proportions of successes on treatment A and B, respectively, by the
end of the trial). We observe that, in general, the bias decreases as the delay length
increases (with some slight discrepancy for delay lengths of 0 and 5). This pattern
can be seen more clearly in the corresponding plot for the DP design (Figure 4.5.1 of
the Appendix 4.5). The decrease in bias seems sensible since the values of sA,n, sB,n,
NA and NB will be varying with delay length. As an example, consider the scenario
in which θA = 0.5 and θB = 0.1. For shorter delays, there will be fewer patients
allocated to the inferior treatment (arm B) so that NB < NA. As a result, θ̂B will
be underestimated, which is shown in Chapter 3, so the treatment effect estimator,
∆̂, will be larger, leading to a larger bias. Alternatively, as d → 75, then NB → NA
until eventually NB ≈ NA when d = 75, i.e. as the delay increases, there will be less
imbalance between the two treatment arms. Therefore, θ̂A and θ̂B will be closer to
their true values, hence giving rise to a smaller bias. Note that it will be useful to
look at the values of the raw estimates of θA and θB in Table 4.2.1 to support this.
It is also worth noting that the bias values for a delay of 50 are very close to those
for equal randomisation, i.e. they are lying close to zero across all scenarios.
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True CRDP with delay 5 DRPWR with delay 5
θA θB θ̂A θ̂B θ̂A − θ̂B Bias θ̂A θ̂B θ̂A − θ̂B Bias
0.500 0.100 0.499853 0.096223 0.403630 0.003630 0.496576 0.097737 0.398840 -0.001160
0.500 0.200 0.497806 0.188783 0.309024 0.009024 0.496257 0.196250 0.300007 0.000007
0.500 0.300 0.491774 0.278339 0.213435 0.013435 0.495755 0.295181 0.200574 0.000574
0.500 0.400 0.480684 0.369758 0.110926 0.010926 0.495331 0.394947 0.100384 0.000384
0.500 0.500 0.470749 0.470066 0.000684 0.000684 0.494164 0.494433 -0.000269 -0.000269
0.500 0.600 0.469279 0.579858 -0.110578 -0.010578 0.492965 0.594547 -0.101582 -0.001582
0.500 0.700 0.477296 0.691518 -0.214222 -0.014222 0.490896 0.695328 -0.204432 -0.004432
0.500 0.800 0.487732 0.797777 -0.310045 -0.010045 0.487573 0.796879 -0.309306 -0.009306
0.500 0.900 0.495412 0.899759 -0.404347 -0.004347 0.480832 0.898330 -0.417498 -0.017498
True CRDP with delay 25 DRPWR with delay 25
θA θB θ̂A θ̂B θ̂A − θ̂B Bias θ̂A θ̂B θ̂A − θ̂B Bias
0.500 0.100 0.499554 0.097617 0.401938 0.001938 0.497334 0.097964 0.399370 -0.000630
0.500 0.200 0.497649 0.193748 0.303900 0.003900 0.497083 0.196814 0.300270 0.000270
0.500 0.300 0.493642 0.288373 0.205269 0.005269 0.496828 0.296256 0.200572 0.000572
0.500 0.400 0.488466 0.384723 0.103742 0.003742 0.496502 0.396201 0.100300 0.000300
0.500 0.500 0.484371 0.484043 0.000329 0.000329 0.496184 0.496505 -0.000321 -0.000321
0.500 0.600 0.483978 0.588435 -0.104456 -0.004456 0.495625 0.596536 -0.100910 -0.000910
0.500 0.700 0.487662 0.693864 -0.206202 -0.006202 0.494818 0.697139 -0.202321 -0.002321
0.500 0.800 0.492379 0.797834 -0.305455 -0.005455 0.494015 0.798157 -0.304142 -0.004142
0.500 0.900 0.496040 0.899640 -0.403599 -0.003599 0.492782 0.898929 -0.406147 -0.006147
Table 4.2.1: The success probability estimates, θ̂A and θ̂B, for treatments A and B,
respectively, compared to their true values, θA and θB, following CRDP and DRPWR
with a fixed delay. These results correspond to the scenarios in which n = 75, θA = 0.5
and θB ∈ (0.1, 0.9) for a fixed delay of 5 (upper table) and 25 (lower table).
Mean squared error. The bottom right plot in Figure 4.2.1 shows that the mean
squared error (MSE) of the treatment effect estimator decreases as the delay length
increases across all scenarios. Since the MSE depends on the bias, this pattern could
simply be due to the bias values decreasing with delay, but after plotting only the
variances of the treatment effect estimator (not included here), which follow exactly
the same pattern as the MSE plots, this confirms that the variability of the estimator
does indeed decrease with delay.
A further interesting observation is that for longer delays, the MSE (and vari-
ance) plots become more symmetric around θB = 0.5, yet for shorter delays, the
MSE/variance of the estimator begins to slightly increase again after θB = 0.8 (see
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delay lengths of 0, 5 and 15, for example, on the MSE plot in Figure 4.2.1).
Similar patterns of results are observed for the DP design in Figure 4.5.1 of the
Appendix 4.5, but the changes with delay length are much more pronounced due to
the lack of randomisation and constraining in the design meaning a greater level of
imbalance can occur. Consider the first scenario in which θB = 0.1. When the delay is
25 (one third of the trial size), there is a loss of approximately 15% in patient benefit
relative to the optimal value attained in the no delay case. However, the percentage
of patients on the superior treatment is still approximately 30% larger than equal
randomisation. In terms of the power, a delay of 25 increases it by nearly as much
as 80% relative to when there is no delay. Moreover, it lies very close to the power
obtained by equal randomisation. For a delay of 15, the percentage of patients on
the superior treatment is reduced by only around 8%, but the power is increased by
approximately 66%. Therefore, by introducing a delay in response, although the DP
design is no longer optimal with respect to patient benefit, it still allocates a con-
siderably large percentage of patients to the superior treatment whilst achieving a
substantially improved power.
Note that the scale of the bias and MSE plots for the DP is much larger than that
used for the corresponding plots for the CRDP.
Comparison to DRPWR
In this section, we explore how the most commonly proposed rule for such problems,
the DRPWR (see Section 2.1.2), compares to the (CR)DP designs for a range of
delay lengths. We focus on two scenarios, with and without a treatment difference,
to illustrate the differences between the performance measures of these designs. Note
that plots corresponding to Figure 4.2.1 for just the DRPWR are provided in Figure
4.5.3 of the Appendix 4.5.
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(i) Scenario 1: θA = 0.5 and θB = 0.1
Power. The first plot in Figure 4.2.2 illustrates the changes in power as the delay
length, d, increases. We have already identified that the power of the (CR)DP design
increases with delay, however this plot gives a much clearer visualisation of the rate
of this increase. In particular, we see that it increases hyperbolically with the largest
changes occurring for shorter delay lengths and practically no change occurring as d
increases from 40 to 75.
In contrast, the length of the delay does not seem to affect the power of the
DRPWR, which remains fairly constant for all delay lengths. The power of the RPWR
is already high when there is no delay, because it does not create enough imbalance
between the two treatments, and thus there is little room for improvement.
Comparing designs for this particular case, we see that although the DRPWR
attains the highest power for delays up to around 45 (at which point all of the designs
converge), the CRDP design still performs very well, whereas the power of the DP
design is insufficient and lies below 80% for delays up to length 15. For example,
when the delay is 5, the power of DRPWR and CRDP is above 90% but for DP, it is
close to 50%.
Patient benefit. The second plot in Figure 4.2.2 shows how the percentage of
patients allocated to the superior treatment varies as d increases. Similarly to the
(CR)DP, as the delay length increases, the DRPWR allocates fewer patients to the
superior arm. Again, this plot allows us to visualise the rate of this decrease much
more clearly. For DP, we observe that the percentage of patients allocated to the
superior treatment decreases linearly at a relatively constant rate compared to the
CRDP which decreases at a slower rate, and the DRPWR which decreases at a much
slower rate than both (CR)DP designs. Further, (CR)DP allocates substantially more
patients to the superior treatment than the DRPWR, most markedly for shorter delay
lengths. For example, Figure 4.2.2 shows that when d = 5, DP and CRDP allocate
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approximately 30% and 20% more patients, respectively, to the superior arm than
DRPWR.
Bias. The third plot in Figure 4.2.2 illustrates the changes in the average bias of
the treatment effect estimator as the delay length varies. We have already identified
that, generally, the bias of the (CR)DP design decreases with delay, and this plot
shows that this happens for shorter delays up to around d = 30, after which point the
bias fluctuates very closely around 0. Moreover, the bias values decrease at a much
quicker rate for the DP design. In contrast, the bias values following the DRPWR
appear to be fairly robust to changes in delay, remaining close to 0 for all delay lengths,
with a very slight decrease evident as d increases.
Note that the scale of this plot is very small and although the DRPWR appears to
perform slightly better with respect to bias for shorter delay lengths, the differences






















● ● ● ●














































































Figure 4.2.2: The changes in power, % of patients on the superior treatment and the
average bias of the treatment effect estimator for (CR)DP and DRPWR as the length
of the fixed delay increases, when n = 75, θA = 0.5 and θB = 0.1 (estimated over
100, 000 simulations).
(ii) Scenario 2: θA = θB = 0.5
Corresponding plots when there is no treatment difference are shown in Figure
4.2.3. Here, we notice that the differences in the performance measures of the (CR)DP
and DRPWR are much less pronounced, as expected.
The first plot illustrates the changes in type I error rates for the (CR)DP and
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DRPWR as the delay increases. We observe that the overall trend of the type I error
rate appears to decrease with d for all designs, although more so for the (CR)DP design
than the DRPWR. Further, the type I error rates for the DRPWR are consistently
smaller, albeit very slightly, than those for (CR)DP (with delay) until around d = 60,
after which they perform similarly.
Since the treatments have the same success rates, the percentage of patients al-
located to either treatment behaves accordingly, that is, close to 50% irrespective of
the design or delay length. Similarly, the bias values lie very close to 0 for all delay
























































































































Figure 4.2.3: The changes in type I error, % of patients on the superior treatment
and the average bias of the treatment effect estimator for (CR)DP and DRPWR as
the length of the fixed delay increases, when n = 75, θA = θB = 0.5 (estimated over
100, 000 simulations).
4.2.2 Trials with a Random Delay
The assumption of a fixed delay in Section 4.2.1 is not very realistic in a clinical trial
context where the length of the delay may vary from patient to patient. Thus, in this
section, we relax the assumption of a fixed delay, and consider a simple stochastic
delayed response model in which patients still arrive sequentially, at a constant rate,
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but the length of time to observe a response is now random2. As a result, in contrast
to Section 4.2.1, the number of patients in the pipeline at any stage of the trial is also
random.
We use a Bernoulli random variable with probability r to determine which patients
in the pipeline have responded at each stage in the trial. If a patient has responded,
we record their observation, update the states accordingly and remove this patient
from the pipeline. Otherwise, if the patient has not yet responded, they remain in the
pipeline and we simply proceed to allocate the subsequent patient based on whatever
information is currently available.
Recall that a geometric distribution models the number of independent and identi-
cally distributed Bernoulli trials before the first success. Therefore, using a Bernoulli
random variable at each stage to determine whether there has been a patient response
is equivalent to assuming a geometric response time. If Yi denotes the response time,
or equivalently the delay length, of patient i = 1, . . . , n, then Yi ∼ Geometric(r), with
probability mass function given by (1 − r)tr for t = 0, 1, . . . and 0 < r ≤ 1. Note
that Eick (1988b) also considered a geometric response time when investigating the
one-armed bandit problem with delay.
We will now vary the success probability r, i.e. the probability of a patient respond-
ing at each stage, in order to explore the impact of random delays on the (CR)DP
designs. So that the results are presented similarly to those in Section 4.2.1 for the
fixed delay case, we will illustrate the performance measures for different expected
delay lengths. Since the expected value of a geometric random variable Yi is given
by E(Yi) = (1 − r)/r, to do this, we will choose values of r = 1/(1 + E(Yi)) such
that E(Yi) = 0, 5, 15, 25, 50, 75 and 100 for each i. Note that we include an expected
2Although it is not typical in clinical trial practice to have a binary endpoint that is randomly
observed, we use it purely for the purpose of illustrating the effect of random delays on (CR)DP
since it is more intuitive to interpret a random delay as being the random time from allocation to
response. This set-up is also used in Hardwick et al. (2006). However, the equivalent — but more
realistic — reformulation in terms of random arrivals with a fixed follow-up time is considered in
Chapter 5.
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delay length of 100 here to demonstrate that, in the random delay case, the (CR)DP
gives rise to different performance measures for expected delays greater than the trial
size, i.e. 75. This is in contrast to the fixed delay case in which, for all delays ≥ 75,
(CR)DP mimics equal randomisation and thus behaves the same.
Figure 4.2.4 is the analogue of Figure 4.2.1 but for the random delay case. The
overall trends observed for the performance measures as the expected delay lengths
increase are similar to those for the fixed delay case. However, we see that there
are some immediate differences as a result of the additional variability incurred by
the random delay. In particular, the top right plot of Figure 4.2.4 shows that the
percentage of patients allocated to the superior treatment appears to be much larger
for the random delay case (explained below). The bias and MSE values are also larger
when the delay is random, and there is little difference in the power as the expected
delay length increases. These observations are due to a mixture of reporting averages
and the fact that there is inherent variability in the results that goes beyond that of
simulation error, owing to the underlying random nature of the delay.
The corresponding plot illustrating the effect of a random delay on the performance
of the DP design is shown in Figure 4.5.2 of the Appendix 4.5.
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Figure 4.2.4: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the CRDP
design when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different expected random delay
lengths (estimated over 100, 000 simulations).
Comparison to Fixed Delay
We now compare the performance measures of the (CR)DP with a fixed delay versus
(CR)DP with a random delay for a specific scenario in which θA = 0.5 and θB = 0.1
(see Figure 4.2.5). Note that this comparison is fair in the sense that we have cali-
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brated the random delays so that we expect them to be the same length, on average,
as the fixed delays. However, it is not fair in the fact that one has variability whilst
the other does not. Thus, we use this comparison purely for illustrative purposes to
highlight the differences that can occur as a result of the delay being random rather
than fixed. Figure 4.2.5 shows that there is a smaller power, more patients on the
superior treatment and a larger bias observed due to the additional uncertainty in
the random delay. Furthermore, it is interesting to note that although we expect the
percentage of patients on the superior treatment (% on sup) to be 50% when the
expected delay length is 75, as it is for the fixed delay of 75, it is actually closer to
70% for the CRDP and 79% for the DP (see the middle plot in Figure 4.2.5).
The reason for this is that we will have some simulation runs where there is no
delay, by random chance, in which case we are back to the standard (CR)DP design
and will have high values for % on sup, and other runs where there is complete delay,
in which case we are at the other extreme of pure randomisation and will consequently
have values close to 50% on sup (and everything in between as well). Therefore, the
estimates for the % on sup will lie somewhere in between. Similarly for the bias,
which we expect to be 0 when the expected delay length is 75, but it is actually
higher. Moreover, recall that the variance of a geometric random variable is given by
(1 − r)/r2. This means that the variability increases as r decreases or, equivalently,
as the expected delay length increases. Thus, the large amount of variability ob-
served, particularly for longer expected delay lengths, is what we would expect from
a geometric random variable.






















● ● ● ●

















































































































Figure 4.2.5: The changes in power, % of patients on the superior treatment and
the average bias of the treatment effect estimator for the CRDP design as the
fixed/expected delay length increases, when n = 75, θA = 0.5 and θB = 0.1 (esti-
mated over 100, 000 simulations).
To confirm our justification that these differences are indeed due to the increased
variability prevalent in the random delay, we consider the actual distributions of the
simulations (in the form of histograms) rather than simply summarising the results
as means which we have been doing thus far. Since there is a very large difference
between the % on sup obtained for the fixed and random delays when the delay is 75,
we will illustrate the corresponding histograms for this case in Figure 4.2.6.
% patients on superior treatment






















(a) CRDP with fixed delay
% patients on superior treatment
















(b) CRDP with random delay
Figure 4.2.6: Histograms showing the distribution of the 100, 000 simulations for the
% of patients on the superior treatment when the fixed/expected delay length is 75,
n = 75, θA = 0.5 and θB = 0.1.
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From Figure 4.2.6a, which corresponds to a fixed delay, we see that the distribution
looks approximately normal with most of the 100, 000 simulations centred around
50%, as expected. However, from Figure 4.2.6b, we see that the distribution covers
a much wider range of values (with some of the simulations producing values below
20% and above 90%). Further, it is skewed to the right with most of the simulations
concentrated around 70%. This clearly illustrates the increased variability in the
results when there is a random delay and thus justifies the differences observed in the
performance measures.
Comparison to DRPWR
We now compare the performance of the (CR)DP in trials with a random delay to the
DRPWR, as we did in Section 4.2.1 for trials with fixed delays. Similarly, we consider
how the performance measures vary with the expected delay length for (i) a treatment
difference and (ii) no treatment difference. For an alternative illustration of how the
DRPWR (with random delay) behaves for a wider range of scenarios under different
expected delay lengths, see Figure 4.5.4 in Appendix 4.5.
(i) Scenario 1: θA = 0.5 and θB = 0.1
Power. The first plot in Figure 4.2.7 shows the changes in power for the (CR)DP
and DRPWR as the expected delay length increases. As in the fixed delay case, the
greatest changes in power for the (CR)DP designs occur for shorter expected delay
lengths, although now at a slower rate. For CRDP, the power remains constant for
delays expected to be greater than 65, but for DP it continues increasing for all of
the expected delay lengths plotted. The power of the DRPWR, on the other hand,
remains relatively stable for all expected delay lengths and attains values very close
to those obtained when there is a fixed delay.
Relative to the DRPWR, the (CR)DP designs have smaller power for all expected
delay lengths. Again, this difference is much more prominent for DP. For example,
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when the delay length is expected to be 5, the power is 8% smaller for CRDP and 53%
smaller for DP compared to the DRPWR. For expected delays over 40, the difference
in power between the DRPWR and CRDP is expected to be at most 3%.
Patient benefit. The second plot in Figure 4.2.7 compares how the percentage
of patients allocated to the superior treatment varies as the expected delay length
increases for the (CR)DP and DRPWR. Again, we see that the % on sup for the
(CR)DP decreases at a slower rate than when the delay is fixed, but at a faster rate
than the DRPWR which only decreases by a small amount (2.7%) as the expected
delay increases from 0 to 100. Moreover, the rate of change for these designs remains
relatively constant. Compared to the DRPWR, the (CR)DP allocates significantly
more patients to the superior treatment for all expected delay lengths considered. In
particular, for an expected delay length of 5, DP and CRDP allocate approximately
30% and 20% more patients, respectively, to the superior arm than the DRPWR,
which is a huge improvement and is the same as what we observed in the fixed delay
case.
Bias. The third plot in Figure 4.2.7 illustrates the changes in the average bias
of the treatment effect estimator as the expected delay length varies. Overall, for
the CRDP design, the trend in bias appears to be decreasing, which is much more
apparent for the DP. The bias values corresponding to the DRPWR do not change
much with the expected delay and lie slightly closer to 0 than the CRDP for all
expected delay lengths. However, it must be remembered that the scale of this plot is
very small so the differences in the bias between the DRPWR and CRDP are trivial.
Both the DRPWR and CRDP consistently outperform the DP, but the differences
are considerably greater for shorter expected delays. For example, when the expected
delay length is 5, the bias of the DP is ten times larger than that of the CRDP.
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Figure 4.2.7: The changes in power, % of patients on the superior treatment and the
average bias of the treatment effect estimator for the (CR)DP and DRPWR as the
expected delay length increases, when n = 75, θA = 0.5 and θB = 0.1 (estimated over
100, 000 simulations).
(ii) Scenario 2: θA = θB = 0.5
The corresponding plots for no treatment difference are shown in Figure 4.2.8.
The first plot illustrates the changes in type I error rates for the (CR)DP and
DRPWR as the expected delay increases. After an initial increase for (CR)DP, the
type I error rate then seems to decrease slightly (at a slower rate than it did in the fixed
delay case). The type I error for the DRPWR seems to remain relatively constant
around 0.077.
The % on sup and bias values, illustrated in the second and third plots of Fig-
ure 4.2.8, behave as one would expect, that is, randomly jumping near 50% and 0,
respectively.
4.2.3 Discussion
In the first part of this chapter, we have evaluated how the (CR)DP design performs
in two-armed trials with both fixed and random delays. This is an important ques-
tion in practice which has been raised several times whenever presenting the CRDP
design. To summarise, we have found that we gain slightly in terms of power and bias
through the delay, so in that sense delay could be viewed as a positive attribute (which
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Figure 4.2.8: The changes in type I error, % of patients on the superior treatment
and the average bias of the treatment effect estimator for the (CR)DP and DRPWR
as the expected delay length increases, when n = 75 and θA = θB = 0.5 (estimated
over 100, 000 simulations).
seems somewhat counter-intuitive), but we lose in terms of patient benefit which is
the main advantage of using such response-adaptive designs over alternatives. How-
ever, this loss is not overly concerning and for a relatively large delay length of 25,
for example, which is one third of the sample size, the percentage of patients on the
superior treatment when θA = 0.5 and θB = 0.1 is still approximately 23% higher
for CRDP than the traditional approach of fixed randomisation. Further, when com-
pared to the performance of the most commonly proposed rule for delayed response
scenarios (Hardwick et al., 2006), namely the DRPWR, there are still considerable
improvements with respect to the patient benefit for (CR)DP.
Therefore, this evaluation has shown that the (CR)DP designs already perform
well in trials with delayed responses since they continue to maintain their patient ben-
efit advantages over other designs for a range of (expected) delay lengths. Simulation
studies for other RAR designs in the literature, mostly urn models, have similarly
shown that they still reduce the expected number of failures and allocate more pa-
tients to the better treatment(s) when responses are delayed (Rosenberger and Lachin,
2016, Chapter 12). More specifically, for short to moderate delays, (CR)DP incurs
only a slight loss in patient benefit (relative to the no delay case) which again reflects
what has been found in the literature for other response-adaptive designs (see the pa-
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pers cited in Section 4.1 for examples). Thus, the main message to convey from this
simulation study is that (CR)DP is fairly robust to delays, whether fixed or random,
with only a small loss in patient benefit for moderate delay lengths.
4.3 Adjusting (CR)DP for Fixed Delays
As we have seen above, (CR)DP already performs quite well in the presence of de-
layed responses with slight gains in power and a loss in patient benefit as the delay
length increases. As such, there is not much room for improvement. However, since
the patient benefit is the primary motivation behind using such bandit-based designs
(see e.g. Rosenberger and Lachin, 1993; Hardwick, 1995), ideally we want to retain
this feature as much as possible. Therefore, the second part of this chapter investi-
gates whether we can minimise this loss by utilising the pipeline information in the
adaptations rather than simply ignoring it as we were doing above and as most adap-
tive designs in the literature do. For the remainder of this chapter, we focus on the
setting of a constant arrival rate and a fixed response/follow-up time.
4.3.1 Modifying the Time Horizon of (CR)DP
In Section 4.2, the time horizon used in the MDP formulation of the (CR)DP design
was of size T = n, i.e. equivalent to the number of patients in the trial. However, when
we implement this design with a fixed delay of length d, the state representing the
number of unobserved patients remaining in the trial will stay the same for the first d
patients because no observations accrue during this stage. Therefore, these patients
are simply randomised (with equal probability) between the treatments, giving rise to
an initial equal randomisation phase. It is only once we begin to receive observations,
i.e. from time d+1 onwards, that (CR)DP allocates patients adaptively. This suggests
that for a trial of size n, it may only be worthwhile to use the (CR)DP algorithm to
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allocate patients d+ 1 to n, that is, for n− d of the allocation decisions.
Therefore, we first investigate how the (CR)DP algorithm performs when it is
implemented with the adjusted time horizon of T = n− d. Not only does this mean
that we generate a smaller array of optimal actions, which is computationally quicker
and requires less memory, but this will allow us to understand whether there are any
non-negligible gains when optimising over the smallest possible time horizon instead.
Figure 4.3.1 illustrates the performance measures of CRDP across all scenarios
when using a time horizon (TH) of n − d for a range of delay lengths, which we
refer to as the CRDP-TH design (represented by the dashed lines). For comparative
purposes, the CRDP when using a time horizon of n is also superimposed onto these
plots. In terms of the power (top left plot in Figure 4.3.1), we see that there is very
little difference between the two designs, with CRDP-TH lying slightly above CRDP
for shorter delay lengths. For the percentage of patients on the superior arm (top right
plot in Figure 4.3.1), the differences are more pronounced and, interestingly, CRDP is
found to outperform CRDP-TH for all delay lengths (excluding 0 and 75 where both
designs are equivalent). A possible reason for this is discussed below. Further, since
CRDP-TH results in less imbalance between the two treatment groups than CRDP,
the corresponding bias and MSE values are also slightly smaller for CRDP-TH, as
illustrated in the bottom two plots of Figure 4.3.1.
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Figure 4.3.1: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the CRDP
and CRDP-TH designs when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different delay
lengths (estimated over 1, 000, 000 simulations).
We now discuss why CRDP is shown to attain a larger percentage of patients on
the superior arm compared to CRDP-TH with the aid of allocation plots in Figures
4.3.2 and 4.3.4. Recall that in Figure 3.4.6 of Chapter 3, we saw that, for the no delay
case, the average allocation probability to the superior treatment oscillates markedly
for the final 15 patients in order to satisfy the constraint, and thus the CRDP makes
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an important number of allocations to the inferior arm towards the end of the trial.
However, when the CRDP time horizon T is equal to the trial size n and there is a
delay of length d, the final d decisions are redundant. Thus, this final exploration
phase, which is illustrated by the dashed green lines in Figures 4.3.2a and 4.3.2b,
is ignored. Nevertheless, CRDP will continue to allocate the required number of
patients, as specified by the constraint, to the inferior arm. In fact, on average, it will
“over-satisfy” the constraint because the number of allocations made to the inferior
arm during the initial equal randomisation stage (as a result of the delay) will, on
average, exceed those that are no longer being made at the end. This is evident from
Figures 4.3.2a and 4.3.2b where it is clear that the proportion of times the superior
(inferior) treatment is allocated during the “redundant” phase in green is substantially
greater (smaller) than that during the equal randomisation phase.
In contrast, by using the smallest possible time horizon of n − d instead, there
will be even more allocations, on average, to the inferior arm because the exploration
phase towards the end of the trial is still incorporated (as in the no delay case) (see
the red lines in Figures 4.3.2a and 4.3.2b). Hence, we see a smaller percentage of
patients on the superior treatment, and thus higher power, for CRDP-TH compared
to CRDP with the longer time horizon of 75.
Note that the patient allocation plots in Figure 4.3.2 also illustrate the effect of
changing the delay length d on the average allocation probabilities when using CRDP
and CRDP-TH. For example, the black line in Figure 4.3.2a shows the average alloca-
tion probability to the superior treatment under the CRDP design with time horizon
equal to the trial size T = 75, a fixed delay of d = 5 and a degree of constraining equal
to 15% of the total sample size (approximately 12 patients on each arm). We see that
near the end of the trial, by around patient number 60, the proportion of times the
superior treatment is allocated decreases in order to satisfy the constraint. However,
when the delay length is increased to d = 15, Figure 4.3.2b shows that there is no


























































































































































(b) d = 15
Figure 4.3.2: Probability of allocating a patient to the superior treatment when θA =
0.5 and θB = 0.9 in a trial of size n = 75 (estimated over 1, 000, 000 simulations).
The black and red lines correspond to the CRDP design with time horizons T = n
and T = n− d, respectively. The dashed green lines illustrate what the remaining d
allocations would look like if the CRDP was continued.
longer this decrease near the end of the trial because, in this case, it is likely that
the minimum requirement on each arm will have already been fulfilled (owing to the
longer delay length, and consequently the longer initial equal randomisation phase).
The plots for CRDP-TH (in red) similarly show that as the delay length increases,
the need to allocate as many patients to the inferior treatment at the end of the trial
is reduced.
Since we expect CRDP-TH to make a greater number of allocations to the inferior
arm than CRDP, it is not clear whether the observed differences in Figure 4.3.1 are
due to the change in time horizon, or the fact that CRDP-TH is effectively satisfying
a stricter constraint. Therefore, to isolate the impact of the time horizon alone on
the performance of the design, we remove the constraint and randomisation from the
design, and revert back to the original DP design. The corresponding performance
measures illustrated in Figure 4.3.3 and allocation plots in Figure 4.3.4 show that DP
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and DP-TH behave the same, and thus there are no non-negligible gains to be made
from modifying the time horizon.
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Figure 4.3.3: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the DP
and DP-TH designs when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different delay
lengths (estimated over 1, 000, 000 simulations).
Next, we propose a more sophisticated way of accounting for fixed delays by in-
corporating data on the pipeline patients into the MDP model associated with the
(CR)DP design.
































































































































(b) d = 15
Figure 4.3.4: Probability of allocating a patient to the superior treatment when θA =
0.5 and θB = 0.9 in a trial of size n = 75 (estimated over 1, 000, 000 simulations).
The black and red lines correspond to the DP design with time horizons T = n and
T = n− d, respectively.
4.3.2 Incorporating the Pipeline Information into (CR)DP
Model Formulation
Following Chapter 3, we consider a clinical trial where the patients arrive sequen-
tially, one-by-one, and are allocated to either treatment A or B. We model the
patient responses as independent Bernoulli random variables giving rise to binary
outcomes, either a success or failure. In contrast with the model presented in Chap-
ter 3, however, patient responses are now observed only after a fixed delay of length
d ∈ Z≥0 (where d = 0 recovers the immediate response case). As before, we assign
non-informative uniform prior distributions to θA and θB, the unknown success prob-
abilities of treatments A and B respectively. Since this is a conjugate prior for the
Bernoulli likelihood, the resulting posterior distribution follows a Beta distribution
with parameters summarising the initial prior information plus the observed infor-
mation to date. Note that for simplicity of exposition, we specify the model for the
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two-arm case, yet the principles used can easily be generalised to multi-arm trials.
Similar to the approach taken in Chick et al. (2017), it is useful to think about
this problem as being composed of the following three stages. It may also be helpful
to refer to the diagram in Figure 5.2.1 of Chapter 5 for the general case.
Stage 1: allocations. This corresponds to the initial equal randomisation stage
of the trial in which the first d patients are randomly allocated, with equal probability,
to either treatment A or B. No responses are observed during this stage due to the
delay of length d, and so these patients enter the pipeline to form, what Eick (1988b)
referred to as, an information bank.
Stage 2: allocations and observations. During this stage, (i) patients continue
to be randomised to a treatment arm and added to the pipeline, and (ii) responses
from the pipeline patients are observed and used to update the states. The pipeline
remains of fixed length d throughout this stage.
Stage 3: observations. This comprises the end of the trial after all n patients
have been allocated. However, updating continues to take place as the remaining
pipeline responses are observed.
As in Chapter 3, we formulate the problem as an MDP defined in discrete time
in which each time period is indexed by t ∈ {0, 1, . . . , n}, representing both time
and the number of patients that have been treated (since at time t, we have treated
t patients). Recall that a time period refers to the time between two allocation
decisions, which will be of a fixed length throughout the trial since we are assuming
that the recruitment rate is constant. The elements of the MDP corresponding to the
fixed delay version of the CRDP model, which we will henceforth refer to as FCRDP
for convenience, are now defined.
The state space, zt, which summarises all of the information available at time
t when the current patient is about to be allocated (Eick, 1988b), now includes an
additional parameter, uA,t, representing the number of pipeline patients on treatment
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A, that is, those patients that have been allocated to treatment A but have not yet
responded. This additional parameter increases the dimension, and therefore the
complexity, of the problem. Although we do not need to explicitly include another
parameter in the state space for the number of pipeline patients on treatment B, since
it is derived from information we already know (uB,t = d − uA,t), we include it here
for completeness.
The remaining states, as before, include the number of patients in the trial remain-
ing to be treated, ñ = n − t, and the number of successes and failures observed on
each treatment to date (plus the prior information), denoted by s̃A,t, f̃A,t, s̃B,t, f̃B,t.
Note that we can exclude one of s̃A,t, f̃A,t, s̃B,t or f̃B,t from the state space because
sA,t + fA,t + sB,t + fB,t + d = t but, again, we include it here for clarity of exposition.
Thus, the vector of states can be summarised as
zt = (uA,t, uB,t, s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ).
At each t ∈ {0, 1, . . . , T}, where T = n is the time horizon (equivalent to the total
number of patients within the trial), an action at is chosen from the randomised set
of actions, A = {1, 2}, such that at = 1 denotes allocating the next patient (patient
t + 1) to treatment A with probability p and treatment B with probability 1 − p,
and at = 2 denotes allocating patient t + 1 to treatment B with probability p and
treatment A with probability 1− p (where 0.5 ≤ p ≤ 1 for a two-armed trial).
The non-zero transition probabilities, P(zt+1 | zt, at), representing the evolution
of the states from time t to t + 1 under action at, for each of the different stages of
the problem are as follows:
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Stage 1.
(i) When at = 1:
zt+1 =
 (uA,t + 1, uB,t, s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ− 1) w.p. p,(uA,t, uB,t + 1, s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ− 1) w.p. 1− p.
(ii) When at = 2:
zt+1 =
 (uA,t + 1, uB,t, s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ− 1) w.p. 1− p,(uA,t, uB,t + 1, s̃A,t, f̃A,t, s̃B,t, f̃B,t, ñ− 1) w.p. p.
Stage 2.
(i) When at = 1:
zt+1 =

































Note that uA,t remains the same in the first two transitions because the pa-
tient being allocated and the patient responding are both on treatment A, and
similarly for treatment B in the latter two transitions.
(ii) When at = 2:
As above but with the probabilities p and 1− p exchanged.
CHAPTER 4. EXTENSION TO DELAYED RESPONSES 113
Finally, the expected one-period (or immediate) reward after transitioning from
state zt to zt+1 under action at is given by Rat(zt). Here, the one-period reward
corresponds to the first-in-pipeline patient who was allocated d time-steps ago (at
time t − d), not the patient that was previously allocated (at time t), as in the
CRDP model described in Chapter 3. Note that the reward depends on the objective
function of interest, which in this case is to maximise the expected total number of
patient successes in the trial, whereby we obtain a reward of 1 for a success and 0 for a
failure. Since we do not know which treatment the first-in-pipeline patient received, we







. To keep track of which treatment each pipeline patient received,
rather than just the number of pipeline patients on each treatment, a parameter would
need to be introduced into the state space for every pipeline patient. Consequently,
the problem would quickly become computationally infeasible as d increased.
Stage 1. For t ∈ {0, . . . , d}, no reward accrues since there are no patient responses
observed during this time.
Stage 2. For t ∈ {d+ 1, . . . , n},
(i) When at = 1:
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(ii) When at = 2:




































The rewards are equivalent in this case because the response from the first-in-
pipeline patient will be the same regardless of which action is taken for the
subsequent patient.
Stage 3. When ñ = 0,









 −n, if uA,t + sA,t + fA,t < ` or uB,t + sB,t + fB,t < `,0, otherwise,
which serves as a penalty to avoid choosing states that give rise to fewer than the




expected predicted number of successes for the pipeline patients.
The Bellman equation, defined in (2.2.2) of Chapter 2, immediately follows as the
expected one-period rewards, defined above, plus the expected (undiscounted) future
rewards. As in Chapter 3, the objective is to maximise the expected total reward over
the entire time horizon. This is solved exactly using backward induction (Sections
2.2.3 and 3.6.1) to obtain the optimal treatment allocation policy of the FCRDP
design. The performance of this design is evaluated in the following section.
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Simulation Results
We implement the proposed FCRDP design, along with the analogous version for the
DP (which we refer to as the FDP), via simulation. For consistency, we illustrate the
performance of F(CR)DP in a two-armed trial with 75 patients and a fixed delay of
length d for the same scenarios that have been considered throughout this chapter.
Results for other sample sizes and delay lengths showed similar patterns and the
conclusions do not change.
First, we focus on how, if at all, the performance measures of FCRDP, indicated
by the dashed lines in Figure 4.3.5, vary relative to CRDP, represented by the solid
lines, for a selection of fixed delay lengths. Analogous results for DP versus FDP are
presented in Figure 4.5.5. The top left plot in Figure 4.3.5 shows that the power of
FCRDP is slightly smaller than that of CRDP, particularly for smaller delay lengths
(see delay lengths of 5 and 10, for example). This is more obvious for the FDP design;
see Figure 4.5.5. An alternative representation is provided in Figure 4.4.1 where the
differences in power between FDP (blue line) and DP (green line) are greater than
the corresponding differences between FCRDP (red line) and CRDP (black line).
The % on sup, displayed in the top right plot of Figure 4.3.5, is larger for FCRDP
than CRDP for all delay lengths > 0, excluding 75 where both designs are equivalent
(see also Figure 4.4.1). For example, when θB = 0.1 and d = 25 (see blue line), an
additional 1% of patients, on average, will receive the superior treatment. The larger
% on sup for the proposed design is also reflected in the corresponding results for
FDP (see Figures 4.4.1 and 4.5.5). Such gains are extremely desirable in practice
(Rosenberger and Hu, 2004), particularly for trials involving life-threatening diseases.
The changes in the bias and MSE values are illustrated in the bottom two plots
of Figure 4.3.5. The bias values following the FCRDP design appear to be slightly
deflated relative to those for CRDP, at least for the smaller delay lengths, whereas
the MSE values are slightly inflated. Since the scale of this plot is extremely small,
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these observed differences are negligible.


















































































































































































































































































































































































Figure 4.3.5: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the CRDP
and FCRDP designs when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different fixed
delay lengths (estimated over 1, 000, 000 simulations).
Effect of Random Delays on F(CR)DP
Next, in the same way as we did for (CR)DP in Section 4.2.2, we investigate how
the F(CR)DP design performs when the delays in response are instead random. The
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results are presented in Figure 4.3.6 (see dashed lines), alongside those for CRDP
(solid lines), and illustrated for the case of geometric response times with expected
delay lengths as indicated.
We observe that, relative to CRDP, FCRDP continues to consistently improve the
percentage of patients allocated to the superior arm, even when the delay is random.
For example, in a trial where n = 75, θB = 0.1 and the delay is expected to be of length
25 (see blue line), an additional 2% of patients, on average, will receive the superior
treatment when implementing FCRDP over CRDP. Note that these differences tend
to increase with the expected delay length. Similarly to when the delays were fixed,
the corresponding changes in power, bias and MSE are minimal.
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Figure 4.3.6: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the CRDP
and FCRDP designs when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different expected
delay lengths (estimated over 1, 000, 000 simulations).
4.4 Summary
The purpose of this chapter was to gain insight into how the CRDP design, proposed
in Chapter 3, behaves when responses are observed after a delay. In Section 4.2, we
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demonstrated that the benefits of the CRDP, namely, a large number of patients on
the superior treatment, are slightly reduced when there is a delay in observing the
response. However, overall, CRDP was shown to be fairly robust to delays.
Section 4.3 provided two suggestions of how to account for a fixed delay with a view
to ameliorate the associated loss in patient benefit. The first, in Section 4.3.1, was a
näıve approach (referred to as CRDP-TH) which involved altering the time horizon
of the corresponding MDP. Although this was actually shown to reduce the patient
benefit further for CRDP, some important issues, such as the underlying interaction
between the delay and constraint, were raised. Furthermore, when removing the
constraint and randomisation, modifying the time horizon had practically no effect
on the performance measures. An interesting topic for further research, which will
help make the results more interpretable, is how to appropriately adjust the degree of
constraining within the CRDP formulation to ensure that it remains the same for each
design. One way to achieve this for the CRDP-TH design is to subtract the expected
number of patients that are on the inferior arm during the final d allocations from the
current degree of constraining. These translate to responses which the current design
is “blind” to because they only become available after all allocations have been made,
hence why the constraint ends up being stricter than desired.
The second approach, referred to as FCRDP and described in Section 4.3.2, in-
volved formally extending the associated MDP to incorporate information on the
pipeline patients. Therefore, rather than only using the responses once they become
available, as in the previous designs, patients are still able to contribute valuable infor-
mation even whilst in the pipeline. F(CR)DP was shown to consistently outperform
(CR)DP, in terms of patient benefit, for all delay lengths with minimal impact on the
associated power, bias and MSE.
Although the increase in patient benefit was found to be small, at least for
the simulation scenarios considered here, this may be critically important in trials
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where treatment failures are particularly undesirable, or even fatal (as in some life-
threatening diseases), (Hu and Rosenberger, 2006, Chapter 8). Therefore, the value
of such results should not be underestimated, especially since we are obtaining this
worthwhile improvement at no extra cost simply by implementing a different algo-
rithm to allocate the patients.
The key information gleaned from this chapter is summarised in Figure 4.4.1,
which presents the results of (CR)DP and F(CR)DP, alongside those of standard
fixed randomisation and DRPWR, all on the same plot for a specific scenario over the
entire range of delay lengths.
The F(CR)DP model is formulated assuming that patients arrive sequentially and
have a fixed response time, thus giving rise to a fixed number of patients in the
pipeline. This is somewhat restrictive in a clinical trial setting where responses of
different patients often arrive randomly. Consequently, we then evaluated how the
F(CR)DP design behaves when the delay in response is instead random, and com-
pared it to the performance of (CR)DP with random delay. The results showed that
the improvements in patient benefit, achieved by F(CR)DP, persist even when im-
plemented in a random delay setting. When implementing the random delay setting,
we assumed that the delay in response is independent of the treatment. However, in
practice, different treatments are likely to give rise to different delay lengths. There-
fore, further investigation is required to consider the performance of (CR)DP and
F(CR)DP when the response distributions vary for each treatment.
In the following chapter, we explore whether generalising the F(CR)DP model to
allow for a random number of patients in the pipeline may enhance the performance
of the design for the random delay setting even further.









































































Figure 4.4.1: The changes in power, % of patients on the superior treatment and the
average bias of the treatment effect estimator for (CR)DP, F(CR)DP, DRPWR and
fixed randomisation as the fixed delay length increases, when n = 75, θA = 0.1 and
θB = 0.5 (estimated over 1, 000, 000 simulations).
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4.5 Appendix
4.5.1 Performance Measures for DP with Fixed Delay
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Figure 4.5.1: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the DP
design when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different fixed delay lengths
(estimated over 100, 000 simulations).
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4.5.2 Performance Measures for DP with Random Delay






































































































































































































































































































































Figure 4.5.2: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the DP
design when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different expected delay lengths
(estimated over 100,000 simulations).
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4.5.3 Performance Measures for DRPWR with Fixed Delay


































































































































































































































































Figure 4.5.3: The changes in power (and type I error), % of patients on the supe-
rior treatment, the average bias and MSE of the treatment effect estimator for the
DRPWR when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different fixed delay lengths
(estimated over 100, 000 simulations).
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4.5.4 Performance Measures for DRPWR with Random De-
lay














































































































































































































































































Figure 4.5.4: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the DR-
PWR when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different expected delay lengths
(estimated over 100, 000 simulations).
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4.5.5 Performance Measures for DP vs. FDP
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Figure 4.5.5: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the DP
and FDP designs when n = 75, θA = 0.5 and θB ∈ (0.1, 0.9) for different fixed delay
lengths (estimated over 1, 000, 000 simulations).
Chapter 5
Extension to Random Arrivals
5.1 Introduction
This chapter generalises the F(CR)DP model, proposed in Chapter 4, to the more
realistic setting of when there is a random, rather than fixed, number of patients in
the pipeline. This encompasses a wide variety of trial contexts, including those with
a: (i) constant inter-arrival time and fixed time to response, in which case the model
simplifies to F(CR)DP, (ii) constant inter-arrival time and random time to response,
(iii) random inter-arrival time and fixed time to response, or (iv) random inter-arrival
time and random time to response.
Random arrivals of patients are most representative of clinical trial practice, es-
pecially in the rare disease setting where there is unlikely to be a constant influx
of patients. Moreover, since we are concerned with a binary outcome, interest is in
whether the response has been observed by a fixed follow-up time after treatment.
Thus, we present and illustrate the methodology proposed in this chapter for the most
pertinent trial setting of random arrivals with a fixed follow-up time. Nonetheless, it
can still be easily applied to all of the aforementioned contexts. This is in contrast
to many response-adaptive designs in the literature which, as Ahuja and Birge (2016)
127
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point out as a limitation, “may not be fully applicable in all trial contexts . . . e.g.
when time to observation of the primary endpoint is a random variable”.
Even those methods that have been developed specifically with delay in mind are
not designed for all settings (i)–(iv). For example, although the (group sequential)
designs proposed by Hampson and Jennison (2013) do allow for a random number
of patients in the pipeline, they rely on there being a fixed delay in response and
cannot accommodate stochastic delays, thus they cannot be applied to settings (ii)
or (iv). It has already been mentioned in Chapter 4 that the model by Chick et al.
(2017) is proposed under the assumption of a constant arrival rate and fixed time to
response, thus only applies to setting (i). Further, although the bandit-based designs
by Hardwick et al. (2006) are proposed for a binary trial with random arrivals and
a random response time, their designs hinge on the assumption of Poisson arrivals
and exponential response times. This is not the case for our design which is not
limited/restricted to a specific arrival or response distribution.
5.2 Model Formulation
Recall that the MDP formulation consists of a state space, a set of actions, transition
probabilities and rewards. Each of these components will now be defined for the
random delay version of the CRDP model, which we will henceforth refer to as RCRDP
for convenience.
Although we present this model in the two-armed setting for simplicity, it is im-
portant to note that the principles used extend to the multi-armed setting (as with
the CRDP and FCRDP models defined in Chapters 3 and 4, respectively).
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5.2.1 Decision Epochs and State Space
In general, decision epochs refer to the points in time at which decisions are made
based upon the current state of the system (Puterman, 2014). In the current context,
we define the decision epochs t ∈ [0, n− 1] to be the time when patient t + 1 arrives
and is allocated to a treatment (where arrival time and allocation time are assumed
to be analogous). For example, decision epoch t = 0 corresponds to the arrival and
allocation of the first patient which defines the start of the trial. Refer to the timeline
in Figure 5.2.1 which illustrates the decision epochs as black crosses. Note that
the patient allocated at each decision epoch will immediately enter the appropriate
pipeline.
Since n is finite, we have a finite horizon problem in which no decisions are made
after the final nth patient is allocated at decision epoch n− 1 (this is often referred to
as an n−1 period problem). However, for completeness and the purpose of evaluating
the final state of the system, we also include an “imaginary” epoch n in the model
(represented by the dashed vertical line in Figure 5.2.1) at which point the observation
of the last patient (and any other remaining pipeline observations) will be available.
The state space for this problem now includes two additional parameters, uA,t
and uB,t, which represent the number of pipeline patients on treatments A and B,
respectively, just before patient t+ 1 is allocated at decision epoch t. Therefore, uA,t
and uB,t can take values from 0 to t since it is now possible for pipeline A or pipeline
B to include all of the allocated patients. Thus, the state vector, which summarises
all of the information available just before decision epoch t, is given by
zt = (uA,t, uB,t, sA,t, fA,t, sB,t, fB,t, ñ) if 0 ≤ t ≤ n− 1, (5.2.1)
where sA,t, fA,t, sB,t, fB,t are the total numbers of successes and failures observed on
each treatment to date, and ñ = n− t is the number of patients in the trial remaining
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to be treated. Note that the addition of epoch n at the end (in which no actual
decision is made) leads to the definition of zn = (0, 0, sA,n, fA,n, sB,n, fB,n, 0) (where
sA,n + fA,n + sB,n + fB,n = n).
5.2.2 Action Set
The set of randomised actions, A = {1, 2}, remains as it was for CRDP and FCRDP
in Chapters 3 and 4, respectively. That is, at = 1 denotes allocating patient t + 1 at
decision epoch t to treatment A with probability p and treatment B with probability
1− p, and at = 2 denotes allocating patient t + 1 to treatment B with probability p
and treatment A with probability 1− p (where 0.5 ≤ p ≤ 1 for a two-armed trial).
5.2.3 State Transitions
We now need to define all the possible state transitions that can occur under action
at during time period t, i.e. the random time between decision epochs t and t + 1,
before we specify their corresponding probabilities, P(zt+1 | zt, at). This requires the
introduction of the following notation.
Let Kt ∈ {0, . . . , uA,t + uB,t + 1} be the random number of responses observed (or
equivalently, the number of patients leaving the pipeline) during period t (which could
include the patient allocated at decision epoch t if they respond before the arrival of
the next patient). We will denote the total number of patients in the pipeline just be-
fore decision epoch t by dt, so that dt = uA,t+uB,t. Out of the Kt = kt total responses
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where mt is an indicator variable taking the value 1 if patient t + 1 is allocated to
treatment A at decision epoch t, or 0 if patient t + 1 is allocated to treatment B at
decision epoch t.
To aid with the understanding and interpretation of the model set-up, we consider
the schematic in Figure 5.2.1 which clearly illustrates the ordering of events. In
particular, we first update the state vector zt and only then do we make an allocation
decision (represented by the crosses). This means that if an arrival and an observation
(of a different patient) happen at the same time, we first incorporate the observation
and then make the allocation. We see that at epoch t = 1 (when we allocate patient
2): uA,1 = 1 since patient 1 was allocated to treatment A and has not yet responded
so remains in pipeline A; uB,1 = 0; k1 = 2 because we observe a total of two responses
during period 1; r1 = (1, 1, 0, 0) because we observe one success and one failure from
A during period 1; m1 = 1 because patient 2 is allocated to treatment A. At epoch
t: kt = 3 since we have a total of three observations during period t; rt = (1, 0, 0, 2)
because we observe one success from A and two failures from B during period t;
mt = 0 because patient t+ 1 is allocated to treatment B. Just before patient t+ 2 is
allocated at epoch t+1: uA,t+1 = uA,t−1 since we observe one success from treatment
A during period t, and uB,t+1 = uB,t+1−2 since we first add patient t+1 (at epoch t)
to pipeline B and subsequently observe two failures from treatment B during period
t. Note that it is possible for patient t+ 1 allocated at epoch t to also respond during
period t, as depicted in the diagram for patients 2, t+ 1 and n.
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Figure 5.2.1: Schematic of model set-up showing the order in which events occur.
5.2.4 Transition Probabilities
We now turn our attention to the calculation of the transition probabilities which are
conditional on the state and action at the current decision epoch t and determine the
state of the system at the next decision epoch t+ 1. Under at = 1, these are given by:
P(zt+1 | zt, at = 1) =
1∑
m=0




P(Rt = rt | zt, at = 1,mt = m) · P(mt = m | zt, at = 1)
= P(Rt = rt | zt, at = 1,mt = 0) · (1− p) +
P(Rt = rt | zt, at = 1,mt = 1) · p,
where P(mt = 0 | zt, at = 1) = 1− p and P(mt = 1 | zt, at = 1) = p. We can simplify
this further by noting that we do not need to condition on action at if we know the
value of mt. Thus, we have
P(zt+1 | zt, at = 1) = P(Rt = rt | zt,mt = 0) · (1− p) + P(Rt = rt | zt,mt = 1) · p.
(5.2.3)
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The transition probabilities under at = 2 are defined similarly to (5.2.3), but with the
randomisation probabilities p and 1− p exchanged, that is,
P(zt+1 | zt, at = 2) = P(Rt = rt | zt,mt = 0) · p+ P(Rt = rt | zt,mt = 1) · (1− p).
(5.2.4)
We now show how the components of the transition probabilities in (5.2.3) and
(5.2.4) can be calculated. Since P(Rt = rt | zt,mt = 0) and P(Rt = rt | zt,mt = 1)
are derived in exactly the same way, we will only show how P(Rt = rt | zt,mt = 1)
is calculated. For clarity, we will use · to represent zt and mt = 1 from hereafter.
By conditioning on KA,t = kA,t and KB,t = kB,t, and applying the law of total





P (Rt = rt | KA,t = kA,t, KB,t = kB,t, zt) · P (KA,t = kA,t, KB,t = kB,t | ·) ,
(5.2.5)
where the first term in equation (5.2.5) simplifies as
P (Rt = rt | KA,t = kA,t, KB,t = kB,t, zt)
=







t | KA,t = kA,t, KB,t = kB,t, zt) ,











and, by conditional independence, the first line in (5.2.6) becomes
P (RsAt = r
sA










for j ∈ {A,B},
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where, recall from Chapter 3, that s̃j,t and f̃j,t represent the posterior number of
successes and failures, respectively, on each arm j (i.e. including the prior pseudo-
observations). To calculate the second expression in (5.2.5), namely, the joint proba-
bility of KA,t and KB,t conditional on zt and mt = 1, we first note that KA,t and KB,t
are not independent because they are both constrained by the total number of patients
in the pipeline, dt (thus knowledge of kA,t influences what values kB,t can take, and vice
versa). Since kA,t + kB,t = kt, it is helpful to re-express P (KA,t = kA,t, KB,t = kB,t | ·)
as
P (KA,t = kA,t, Kt = kA,t + kB,t | ·) =
P (KA,t = kA,t | Kt = kA,t + kB,t, ·) · P (Kt = kA,t + kB,t | ·) . (5.2.8)
The first term in equation (5.2.8) gives the probability of receiving kA,t responses
from treatment A given that the total number of responses observed during period t
is kA,t + kB,t, and can be calculated as follows. We will consider what happens to this
probability in the cases when: (i) patient t+ 1 is observed during period t (i.e. before
arrival of patient t+ 2), and (ii) patient t+ 1 is not observed during period t.
(i) First, if patient t + 1 is observed, this implies that all other patients in the
pipeline must have been observed1, that is, kA,t = uA,t + 1 and kB,t = uB,t. Thus, in
1Patients will be observed in the same order as they are allocated owing to the fixed follow-up
time.
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this case
P (KA,t = kA,t | Kt = kA,t + kB,t, ·) = P (KA,t = uA,t + 1 | Kt = uA,t + uB,t + 1, ·) = 1.
(5.2.9)
Note that if kB,t 6= uB,t, the above probability will be 0.
(ii) Now, suppose that patient t+ 1 is not observed, that is, kA,t ≤ uA,t. Then, we
obtain the following probability







· uA,t − 1
uA,t + uB,t − 1
·
. . . · uA,t − kA,t + 1
uA,t + uB,t − kA,t + 1
· uB,t
uA,t + uB,t − kA,t
· . . . · uB,t − kB,t + 1
uA,t + uB,t − kA,t − kB,t + 1
,
(5.2.10)














This is the probability mass function of a hypergeometric distribution with parameters
uA,t + uB,t, kA,t + kB,t and uA,t.
The calculation of the second term in equation (5.2.8), i.e. P (Kt = kA,t + kB,t | ·),
is now discussed. First, we introduce some further notation. Suppose that we have
obtained a total of xt = sA,t+fA,t+ sB,t+fB,t observations just before decision epoch
t. Further, let τi denote the random inter-arrival time of patient i ∈ {1, . . . , n} (where
τ1 = 0) and δ be some constant representing the fixed follow-up time (which is the
same for every patient). Thus, it follows that
∑xt
i=1 τi is the arrival time of patient xt
and
∑xt
i=1 τi + δ is the corresponding observation time.
The possible events that can happen during period t (i.e. the random time between
two allocations) are as follows:
(i) The first pipeline patient, i.e. patient xt + 1, is observed. This happens at time









(dt + 1) The final pipeline patient, which is the patient allocated most recently at









These allow us to derive the conditions required to observe kt responses. In par-
ticular:
• No responses (kt = 0) will be observed during period t if and only if patient
xt + dt + 2 is allocated before the first-in-pipeline patient, patient xt + 1, is






τi + δ, i.e.
xt+dt+2∑
i=xt+2
τi < δ. (5.2.12)
• kt = lt responses will be observed during period t, where 1 ≤ lt ≤ dt, if and only
if patient xt + dt + 2 is allocated both after the lt
th pipeline patient, i.e. patient






τi + δ, i.e.
xt+dt+2∑
i=xt+lt+1











Note that if patient xt + lt does not respond, this implies that all other pipeline
patients thereafter must not respond since their responses are ordered owing to
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the fixed follow-up time of each patient.
• If every pipeline patient is observed during period t, we will obtain kt = dt + 1
observations. This will happen if and only if patient xt+dt+2 is allocated after







τi + δ, i.e. τxt+dt+2 ≥ δ. (5.2.14)
At this point, we are now in a position where the corresponding probabilities
of the events in (5.2.12), (5.2.13) and (5.2.14) can be derived for a specified inter-
arrival distribution. We outline this in Example 1 below before showing that we
can, in fact, condition on further information to make these probabilities closer to
their true values which could be obtained if we knew the exact arrival (treatment)
times. For illustrative purposes, and in keeping with related literature (e.g. Biswas
and Coad, 2005; Hardwick et al., 2006; Zhang and Rosenberger, 2007), we will assume
from hereon that the inter-arrival times τi are independent and identically distributed
(i.i.d.) exponential random variables with rate parameter equal to λ for all i ∈
{1, . . . , n}. However, note that the same principles easily apply to other distribution
types. Moreover, it is important to keep in mind that these probabilities are inherently
conditioned upon the information provided by the current state vector zt, but we omit
this explicit dependence from the following calculations for simplicity.
Example 1: No Further Conditioning
• Let W =
xt+dt+2∑
i=xt+2
τi. Since this is the sum of dt + 1 i.i.d. exponential random
variables, it follows that W ∼ Gamma(dt + 1, λ). Thus, from (5.2.12), the
probability of observing no responses during period t is given by
P(W < δ) =
γ(dt + 1, δλ)
Γ(dt + 1)
, (5.2.15)
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that is, the cumulative distribution function of W , where γ is the lower incom-
plete gamma function and Γ is the gamma function.




τi ∼ Gamma(dt − lt + 1, λ). It follows that the probability of
observing lt responses during period t, where 1 ≤ lt ≤ dt, is equivalent to





fX,Y (x, y) dx dy =
(δλ)dt−lt+1
Γ(dt − lt + 2)
·exp(−δλ),
(5.2.16)
where fX,Y is the joint probability density function of X and Y .
• Finally, to calculate the probability of (5.2.14), that is, of observing all dt + 1
responses during period t, we require P(Z ≥ δ), where Z = τxt+dt+2 ∼ Exp(λ),
which is given by
1− FZ(δ) = exp(−δλ), (5.2.17)
where FZ is the cumulative distribution function of Z evaluated at δ.
We now need to check that the probabilities in (5.2.15), (5.2.16) and (5.2.17) sum
to one. We have
dt+1∑
kt=0
P(Kt = kt) =








Γ(dt − kt + 2)
}
· exp(−δλ). (5.2.18)
Applying the recurrence relation γ(dt + 1, δλ) = dt · γ(dt, δλ) − (δλ)dt · exp(−δλ)
(see e.g. Jameson, 2016, p.300) iteratively, we can express γ(dt + 1, δλ) in terms of
γ(1, δλ) as follows





Γ(dt − kt + 2)
}
·exp(−δλ), (5.2.19)
where γ(1, δλ) = 1 − exp(−δλ). Substituting (5.2.19) into equation (5.2.18) and
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simplifying gives the value 1, as required.
Further Conditioning
To make the calculations of P (Kt = kt | ·) more efficient, we note that there is ad-
ditional information which can be conditioned upon. In particular, recall that the
current state at epoch t is given by the vector zt (refer to the schematic in Figure
5.2.1) from which the total number of observations, xt, and patients in the pipeline, dt,
by epoch t can be deduced. Therefore, by conditioning on zt (which we do throughout
calculation of the transition probabilities), this implies that the allocation of patient
xt + dt + 1 (i.e. the patient allocated most recently at epoch t) must happen after
we have observed xt responses, but before we have observed xt + 1 responses. This






τi + δ i.e.
xt+dt+1∑
i=xt+1
























C represents the ideal conditioning which makes full use of the available information
contained in zt and is therefore the version that we implement
2. This will result
in a better approximation to the true transition probabilities, and hence optimal
solution, which would be attained if we conditioned on the exact arrival times of the
pipeline patients. However, introducing arrival times into zt would make the problem
2For illustrative purposes, and to show the natural development of ideas, we present the initial
event we conditioned upon, along with the derivation of the corresponding marginal probabilities, in
Example 2 of Appendix 5.5.1.
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intractable.
As previously mentioned, the exact evaluation of the corresponding probabilities
will depend upon the distributional assumption of τi. Although analytical evaluation
may be feasible for some distributions, not all distributions will give rise to prob-
abilities that can be expressed in closed-form (as seen for the exponential case in
Example 1 above and Example 2 of Appendix 5.5.1, which rely on the incomplete
gamma function). Therefore, the probabilities of the events in (5.2.12), (5.2.13) and
(5.2.14) when conditioned on C will be approximated using Monte Carlo simulation
so that our implementation remains as general as possible.
5.2.5 Expected One-Period Rewards
To complete the formulation of the MDP, we need to define the expected one-period
(or immediate) rewards after transitioning from state vector zt to zt+1 under action
at, which we denote by Rat(zt). This depends on the objective function of interest
which, in this case, is to maximise the expected total number of patient successes
in the trial3 (formally defined in Chapter 3), whereby we obtain a reward of 1 for a
success and 0 for a failure. The expected one-period reward for periods 0 ≤ t ≤ n− 2
























t ) · P(Rt = rt | ·),
(5.2.22)
where we refer the reader to equation (5.2.5) for the calculation of P(Rt = rt | ·).
After the final patient has been allocated at epoch t = n− 1, i.e. when ñ = 0, we
use the information accrued during the trial to predict how many of the remaining
uA,n−1 + uB,n−1 + 1 pipeline patients will have a success. Consequently, the expected
3Note that this approach applies to objective functions beyond the bandit objective of maximising
reward.
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one-period reward for period n− 1 under mt is
Rmt(zt) = (uA,t +mt) ·
s̃A,t
s̃A,t + f̃A,t




for t = n− 1, where
ε =
 −n, if uA,t +mt + sA,t + fA,t < ` or uB,t + 1−mt + sB,t + fB,t < `,0 otherwise,
which serves as a penalty to avoid the design choosing states that give rise to fewer
than the desired number of allocations on each arm, `. This avoids extreme imbalance
between the treatment arms (refer to Section 3.2.3).
It follows that the corresponding expected one-period rewards under action at = 1
and at = 2, respectively, for periods 0 ≤ t ≤ n− 1 are of the form
Rat=1(zt) = p · Rmt=1(zt) + (1− p) · Rmt=0(zt) and
Rat=2(zt) = (1− p) · Rmt=1(zt) + p · Rmt=0(zt),
(5.2.24)
with Rmt replaced by (5.2.22) for 0 ≤ t ≤ n − 2 and (5.2.23) for t = n − 1. We
will take the randomisation probability p to be 0.9 in the following simulations (as in
Chapter 3).
5.2.6 Obtaining the Optimal Solution
The Bellman equation, defined in (2.2.2) of Chapter 2, immediately follows as the
expected one-period rewards, defined in (5.2.24), plus the expected (undiscounted)
future rewards. As in Chapters 3 and 4, the corresponding optimisation problem is to
maximise the expected total reward over the entire finite time horizon for a uniform
prior distribution on each arm at t = 0, which is solved exactly using backward
induction (described in Section 2.2.3 and Appendix 3.6.1). This gives rise to the
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optimal treatment allocation policy which prescribes the optimal action to use in
every possible combination of states for all t, along with the corresponding maximum
expected total reward. For example, when the system is in state zt = (uA,t = 5, uB,t =
8, sA,t = 2, fA,t = 4, sB,t = 3, fB,t = 3, ñ = 35) just before epoch t = 25, the optimal
action obtained from the RCRDP design is a25 = 2. For a trial with n = 60 patients,
treatment success probabilities (θA, θB) = (0.5, 0.7), exponential inter-arrival times
with rate parameter λ = 20 and a follow-up time of δ = 1, this is interpreted as
follows. If there are 13 patients in the pipeline (5 on A and 8 on B), 12 patients
which have currently been observed (2 successes from arm A, 4 failures from arm A,
3 successes from arm B and 3 failures from arm B) with 35 patients remaining to be
treated, then the 26th patient will be randomised to arm B with probability 0.9 (and
arm A with probability 0.1).
5.3 Simulation Results
We implement the RCRDP design assuming that patients arrive via a Poisson pro-
cess with rate λ or, equivalently, that the inter-arrival times follow i.i.d. exponential
distributions, τi ∼ Exp(λ) (i = 1, . . . , n), with mean 1/λ. As patients arrive, they are
immediately allocated to either treatment A or B based on data accrued so far. After
a follow-up time of δ has elapsed, the patient’s outcome (either a success or failure)
is observed and used to update the states accordingly. We assume that the patient
arrival rate λ and follow-up time δ is known. Note that this delay structure is purely
for illustrative purposes and the RCRDP design can be applied to any appropriate
arrival and/or response time distribution. As an example, results for a small trial with
inter-arrival times determined by the discrete analogue of the exponential distribution
instead, i.e. the geometric distribution, are illustrated in Appendix 5.5.2.
We present the simulation results for a trial with 60 patients and treatment success
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probabilities as used in previous chapters, namely, θA = 0.5 and θB ∈ (0.1, 0.9).
Wason et al. (2019) highlight that “methodological papers often do not consider the
rate of enrolment versus the length of follow-up for outcomes when quantifying the
efficiency advantages of adaptive designs.” However, we do consider this here by
fixing the follow-up time at δ = 1 and varying the arrival rates, which we take to be
λ = 10, 20, 30, 50. This means that if a unit of time is interpreted as one week, say,
then λ patients are expected to enter the trial per week, each of which are followed
up exactly one week later. Also included are the results corresponding to values of
λ→ 0 and λ→∞, which represent the two extreme situations of immediate response
(IR) and equal fixed randomisation (FR), respectively.
For comparative purposes, we plot the analogous results for CRDP (introduced in
Chapter 3) and FCRDP (introduced in Chapter 4) alongside those for RCRDP, all
of which are the average of 1, 000, 000 simulation runs. These are displayed in Figure
5.3.1 which is discussed below. Moreover, to check that the differences between CRDP,
FCRDP and RCRDP are not attributed to any underlying interaction between the
delay length, constraint and randomisation (refer to Chapter 4), we also consider the
optimal version of each design which has the constraint and randomisation removed.
These are referred to as DP, FDP and RDP, and the corresponding results are pre-
sented in Appendix 5.5.3 where they are shown to exhibit similar patterns to those
observed for CRDP, FCRDP and RCRDP, respectively.
First note that as the arrival rate λ increases, the expected inter-arrival time
decreases and, since the follow-up time remains fixed, the number of patients in the
pipeline will accumulate. In other words, the “delay” length increases with λ.
The top left plot in Figure 5.3.1 shows that there is practically no difference
between the power values obtained for all three versions of the design. As λ (and
hence the delay length) increases, we see that the power also increases which reaffirms
what was found in Chapter 4. When λ = 50 (see red line), the resulting power is
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approximately the same as that achieved by FR (i.e. when λ→∞).
In terms of the percentage of patients allocated to the superior treatment (top
right plot in Figure 5.3.1), which is indicative of patient benefit, we observe that
RCRDP offers an improvement over CRDP for all values of λ (excluding the two
extremes in which RCRDP reduces to FR and CRDP). For example, when θB = 0.1
and λ = 20 (see blue line), an additional 1% of patients, on average, will receive the
superior treatment. Similarly for an arrival rate which is half the trial size, λ = 30
(see green line). However, when RCRDP (see black, dot-dashed lines) is compared to
FCRDP (see coloured, dashed lines), the difference between their performance is very
small.
Further note that as λ increases, the patient benefit decreases (which is what we
expect from Chapter 4). In particular, the best case occurs when all responses have
been observed immediately so that full information is retained (see pink line), whilst
the “worst” case occurs when no responses have been observed until after all patients
have been allocated, i.e. FR (see grey line).
The additional gains in patient benefit achieved by RCRDP over CRDP are also
clearly demonstrated in Figure 5.5.1 of Appendix 5.5.2 for the geometric case.
The bottom two plots in Figure 5.3.1 illustrate the changes in the average bias and
MSE of the treatment effect estimator, which decrease as the arrival rate λ increases.
The observed differences in bias and MSE between the designs are negligible (note
the extremely small scale of the plot), with RCRDP and FCRDP almost identical.
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Figure 5.3.1: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the CRDP,
FCRDP and RCRDP designs when n = 60, θA = 0.5, θB ∈ (0.1, 0.9), τi ∼ Exp(λ)
and δ = 1 (estimated over 1, 000, 000 simulations). IR, immediate response and FR,
fixed randomisation.
5.4 Summary
In this chapter, we have built upon the ideas introduced in Chapters 3 and 4 to present
a general model, R(CR)DP, for the bandit problem with delayed information using
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the Bayesian MDP framework and solution by dynamic programming. Incorporating
delayed information provides a powerful modelling framework which can not only be
used for a greater variety of real life clinical trials but, as discussed in Caro and Yoo
(2010), “can be generalised to aid decision making in many [other] application areas.”
Examples include, but are not limited to, online advertising (Chapelle, 2014; Vernade
et al., 2017), dynamic assortment (Caro and Gallien, 2007) and bandwidth allocation
(Ehsan and Liu, 2004).
We illustrated the workings of RCRDP for random arrivals with fixed response
times (since this is most pertinent to clinical trials with a binary endpoint), but the
fundamental principles apply to the most general structure of random arrivals with
random response times (as in survival trials, for example, which are beyond the scope
of this thesis). In particular, the state space (and hence dimension/computational
complexity of the problem), action set, state transitions and specification of the cor-
responding Bellman equation will remain the same. The transition probabilities, and
consequently the reward function, will take a slightly different form because the order
in which responses are observed will no longer be known (which will affect the deriva-
tion of equation (5.2.8)). However, these can still be computed using Monte Carlo
simulation.
Moreover, although we implemented RCRDP assuming exponential inter-arrival
times, the underlying DP formulation will remain the same regardless of the arrival
and/or response distribution which can simply be adjusted within the Monte Carlo
simulation. This is an advantage over the DP solution implemented by Hardwick et al.
(2006, Approach II) which is more restrictive and applies specifically to the exponen-
tial delay model. In particular, Hardwick et al. (2006) comment that, “unfortunately,
optimising and evaluating different arrival and response delay models can involve sig-
nificantly different recursive equations, and the computational requirements can vary
dramatically.”
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The first approach suggested by Hardwick et al. (2006) is the optimal design for
the standard two-armed bandit problem with delay, based upon the DP approach.
The corresponding Bellman equation is stated in Hardwick et al. (2006, Appendix
A) and takes a similar form to ours. However, there is no explanation provided
as to how the probabilities t, q1, q2, equivalent to our P (KA,t = kA,t, KB,t = kB,t | ·),
P (RsAt = r
sA
t | KA,t = kA,t, zt), P (RsBt = rsBt | KB,t = kB,t, zt) (see equation (5.2.5)),
can be calculated. Furthermore, they do not implement this solution because, at
the time of publication, it was computationally infeasible. In contrast, we are able to
implement our DP solution to the bandit problem with delay (using the programming
language R) for sample sizes up to 100 on a standard laptop with 16GB of RAM. Recall
that this only needs to be computed once and can then be stored for future use.
Our results showed that RCRDP consistently improved patient benefit compared
to CRDP, with an inconsequential effect on the corresponding power, bias and MSE.
However, similar gains were also achieved by the FCRDP design, at least for the
setting considered here. Therefore, given the additional complexity and increased
computational requirements associated with RCRDP, the FCRDP design is prefer-
able4. It would be interesting to see if the FCRDP and RCRDP designs continue to
perform similarly for other inter-arrival distributions that do not possess the mem-
oryless property (e.g. the Weibull distribution), as well as for more general settings
involving random arrivals and random response times. This forms a topic for future
work.
The results also illustrated that the reformulation of the problem in terms of
random arrivals and a fixed follow-up time provides the same conclusions as those
obtained in Chapter 4 for the case of sequential arrivals and a random response time.
In this work, we have assumed that only information on the primary endpoint is
4This point has been highlighted in Wason et al. (2019), for example, which states that “it is also
important to carefully consider reducing the complexity of an adaptive design when the efficiency
gains are marginal”.
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available for updating the allocation probabilities. However, many clinical trials in-
clude a short-term or surrogate endpoint which is correlated with, and observed more
quickly than, the primary endpoint (e.g. Tamura et al., 1994). Therefore, an “alter-
native is to adapt on the basis of some surrogate measure” (Rosenberger and Lachin,
1993). This approach has been considered in the group sequential setting by Hamp-
son and Jennison (2013), for example, who demonstrated that the loss of efficiency
caused by a delayed response can be ameliorated by incorporating information on the
short-term endpoint. This raises the question of how data on a short-term endpoint
can be incorporated into the proposed designs. The inclusion of short-term endpoints
into RAR methods has not received much attention in the literature (Nowacki et al.,
2017) and hence provides an opportune area for further research.
An alternative approach that can be implemented to dilute the effects of delayed
responses is block (or cohort) RAR, in which the allocation probabilities are updated
only after groups of patients respond, rather than after each individual patient re-
sponds (Rosenberger and Lachin, 1993; Karrison et al., 2003; Sverdlov et al., 2012;
Perchet et al., 2016). A block RAR design, which is also less computationally intensive
than the DP-based designs discussed so far, is proposed in the following chapter.
5.5 Appendix
5.5.1 Example 2: Initial Version of Further Conditioning
As discussed in Section 5.2.4, obtaining the transition probabilities requires evaluation
of P (Kt = kt | ·), where kt = 0, . . . , dt + 1, for every possible value of dt. This can
be achieved by calculating the probabilities of the events defined in (5.2.12), (5.2.13)
and (5.2.14) (which was illustrated in Example 1 for exponential inter-arrival times).
However, we can condition on further information which will improve the accuracy
of the probability estimates. Here, we provide the initial version that was considered
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before implementing the stricter conditioning defined in (5.2.21). This example also
includes the exact derivation of the corresponding probabilities for exponential inter-
arrival times.
Initially, we conditioned on the fact that the allocation of patient xt + dt + 2 must






τi + δ, i.e.
xt+dt+2∑
i=xt+1
τi ≥ δ. (5.5.1)
• To calculate the probability that kt = 0, let W =
xt+dt+2∑
i=xt+2
τi. Since this is the sum
of dt + 1 i.i.d. exponential random variables, it follows that W ∼ Gamma(dt +
1, λ). Thus, from (5.2.12), the probability of no observations conditional on the
event in (5.5.1) is given by
P(W < δ | W + τxt+1 ≥ δ) =
P(W < δ,W + τxt+1 ≥ δ)
P(W + τxt+1 ≥ δ)
. (5.5.2)
To calculate the numerator of (5.5.2), let V = τxt+1 ∼ Exp(λ). Thus,










where fV,W is the joint probability density function of V and W .
The denominator of (5.5.2) is given by
P(W + V ≥ δ) = 1− P(W + V < δ) = 1− γ(dt + 2, δλ)
Γ(dt + 2)
, (5.5.4)
where V +W ∼ Gamma(dt+2, λ) and γ is the lower incomplete gamma function.
Therefore, from (5.5.3) and (5.5.4), it follows that the probability of obtain-
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ing no observations during period t is given by
(δλ)dt+1 · exp(−δλ)
Γ(dt + 2)− γ(dt + 2, δλ)
. (5.5.5)
• Next, we use the events defined in (5.2.13) to find the probability that kt = lt,




Y = τxt+lt+1 and Z =
xt+dt+2∑
i=xt+lt+2
τi, then the required probability can be expressed
as P {(Z < δ, Y + Z ≥ δ) | (X + Y + Z ≥ δ)}, which is equivalent to
P(Z < δ, Y + Z ≥ δ,X + Y + Z ≥ δ)
P(X + Y + Z ≥ δ)
=
P(Z < δ, Y + Z ≥ δ)
P(X + Y + Z ≥ δ)
. (5.5.6)
First, we calculate the numerator of (5.5.6) as follows





fY,Z(y, z) dy dz =
(δλ)dt−lt+1 · exp(−δλ)
Γ(dt − lt + 2)
. (5.5.7)
The denominator, i.e. the probability of the event (5.5.1) being conditioned
upon, has already been calculated in equation (5.5.4). Thus, it follows that the
probability of observing lt responses, where 1 ≤ lt ≤ dt, during period t is
given by
Γ(dt + 2) · (δλ)dt−lt+1 · exp(−δλ)
Γ(dt − lt + 2) · {Γ(dt + 2)− γ(dt + 2, δλ)}
. (5.5.8)
• Finally, to calculate the probability that all pipeline patients are observed during
period t, that is, we receive dt + 1 observations during period t, we require the
probability of the event in (5.2.14) conditional on the event in (5.5.1), which is































where P(τxt+dt+2 ≥ δ) = 1− P(τxt+dt+2 < δ) = exp(−δλ) and the denominator
is as calculated previously in (5.5.4). Therefore, the probability of obtaining
dt + 1 observations during period t is given by
Γ(dt + 2) · exp(−δλ)
Γ(dt + 2)− γ(dt + 2, δλ)
. (5.5.9)
The probabilities in (5.5.5), (5.5.8) and (5.5.9) sum to one, as required.
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Figure 5.5.1: The changes in power (and type I error), % of patients on the superior
treatment, bias and MSE for RCRDP (dot-dashed line) and CRDP (solid line) with
geometric inter-arrival times when n = 40, δ = 30, θA = 0.5 and θB ∈ (0.1, 0.9)
(estimated over 100, 000 simulations).
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5.5.3 Results for the DP Variants with Exponential Inter-
Arrival Times
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Figure 5.5.2: The changes in power (and type I error), % of patients on the superior
treatment, the average bias and MSE of the treatment effect estimator for the DP,
FDP and RDP designs when n = 60, θA = 0.5, θB ∈ (0.1, 0.9), τi ∼ Exp(λ) and





Multi-Armed Clinical Trials with
Normally Distributed Outcomes
Whereas the previous two chapters have focused on the dynamic programming ap-
proach to the bandit problem for binary endpoints within a two-arm clinical trial,
this chapter considers the alternative Gittins index approach to the bandit problem
for normally distributed endpoints within a multi-armed trial. Furthermore, we now
consider the use of block randomisation rather than sequential randomisation.
6.1 Introduction
Response-adaptive randomisation (RAR) has been widely developed ever since the
idea was first suggested by Thompson (1933) (Hu and Rosenberger, 2006). The usual
motivation behind RAR is to achieve a patient benefit objective, e.g. to reduce ex-
posure to inferior treatments by skewing the allocation towards superior treatments
154
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based on observed responses. Incorporating such an objective into a trial design is
particularly important when the disease under study is rare — in which case a sub-
stantial proportion of patients in the population will be included in the trial — and
when an inferior treatment could result in a fatal outcome.
Despite the vast array of RAR procedures proposed in the literature, most of them:
(a) assume binary responses, (b) are defined for trials with only two treatments, and
(c) are myopic. However, many clinical trials have continuous primary outcomes and
include more than two (i.e. multiple) arms. Wason and Trippa (2014) report that 39%
of all multi-arm clinical trials published in four major medical journals during 2012 had
normally distributed primary outcomes. Although most RAR procedures for binary
responses are not easily extended to the continuous case, particularly those based
on urn models (Atkinson and Biswas, 2014), several RAR procedures for continuous
outcomes have been proposed (e.g. Zhu and Hu, 2009); a review of these can be found
in Atkinson and Biswas (2014, Chapter 4), and Biswas and Bhattacharya (2016).
Moreover, a “shortage of RAR methodology to handle cases with multiple treatments”
(Zhang et al., 2011) persists, despite the fact that RAR has the greatest potential
for efficiency and patient benefit gains in multi-armed trials (Berry, 2011), which
considerably limits its use in practice.
Furthermore, almost all procedures in the RAR literature (for binary or contin-
uous outcomes) use only past observations (allocations and responses) to influence
the decision for the next patient, without considering the number of patients remain-
ing to be treated (inside or outside the trial) or the information they could provide.
Such myopic strategies are not optimal in general (Berry and Fristedt, 1985). An
optimal approach, in terms of patient benefit, is based on the multi-armed bandit
problem (MABP) which considers all possible sequences of trial observations, and
the sequence that maximises patient response is selected. As a result, the traditional
dynamic programming approach used to solve the MABP is much more computation-
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ally intensive than myopic procedures, which is the predominant reason why the latter
have been favoured in the literature. Recent work proposing non-myopic bandit-based
RAR procedures for binary responses includes Villar et al. (2015b), Williamson et al.
(2017), and Villar and Rosenberger (2018). We will refer to non-myopic procedures
as forward-looking hereafter to be consistent with the terminology used in previous
papers.
Examples of forward-looking adaptive allocation rules for continuous endpoints
relevant to this chapter are Coad (1991b), Wang (1991a), Coad (1995) and Smith and
Villar (2018), all of which use the Gittins index for normally distributed outcomes.
However, the main limitation of these designs from a clinical trials perspective is their
deterministic nature. Randomisation is essential in order to remove various sources of
bias and it additionally provides a basis for inference (Rosenberger and Lachin, 2016).
Motivated by the above considerations, we propose a novel bandit-based allocation
rule that (a) applies to continuous outcomes, assumed to be normally distributed; (b)
applies when the outcome variance is assumed unknown; (c) is defined for multi-armed
trials; (d) is forward-looking and thus is orientated towards a patient benefit objective;
(e) is computationally feasible, and (f) is randomised. Additionally, we investigate
the impact on patient benefit of dichotomising a continuous endpoint, which is a
widely adopted approach in clinical research that has received considerable attention
in the literature (Royston et al., 2006). A common reason for this practice is to deal
with complete responses and missing data (due to death or dropout, for example)
since these naturally fall into success and failure categories, respectively. However,
dichotomisation comes at an efficiency cost (either a reduced power or larger sample
size) (Lavin, 1981; Wason et al., 2011).
Dealing with complete responses and missing data poses an extra challenge that is
exclusive to the implementation of RAR in a trial. The imputation method suggested
in Karrison et al. (2007), which is the only one that has shown moderate uptake in
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practice (Wason and Jaki, 2016), imputes unobserved responses using the distribution
of data collected at the end of the trial and therefore, the imputed data cannot be
used to perform any adaptations. In this chapter, we suggest a simple modification
of the procedure by Karrison et al. (2007) which permits the use of RAR to allocate
patients dynamically during the trial.
In Section 6.2, we present our forward-looking rule for continuous endpoints with
unknown variance using a simple example to illustrate its implementation. In Section
6.3, we report extensive comparative simulation studies in the context of a real phase
II cancer trial. We discuss the costs of dichotomisation in Section 6.4, and present our
method to accommodate missing data due to deaths, dropouts and complete responses
in Section 6.5. We draw conclusions in Section 6.6.
6.2 The Forward-Looking Gittins Index (FLGI) Rule
for Continuous Endpoints
We now define a RAR procedure for continuous endpoints, assumed to be normally
distributed, which augments the Forward-Looking Gittins Index (FLGI) rule pro-
posed in Villar et al. (2015b) for binary endpoints. Following the notation in that
paper, we consider a clinical trial that will test the effectiveness of K experimental
treatments against a control treatment on a sample of T patients, with K and T
fixed. Patients are labelled by t (t = 1, . . . , T ) and treatments by k (k = 0, . . . , K),
where k = 0 denotes the control. The response of patient t allocated to treatment k
is a random variable denoted by Yk,t, now assumed to follow a normal distribution,
Yk,t ∼ N(µk, σ2k). Without loss of generality, we also assume that a larger response is
desired and that σ2k is unknown.
In order to derive our FLGI rule, we need to obtain the Gittins index for the MABP
associated with this trial design problem. A detailed explanation of the problem’s
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assumptions and its exact formulation appears in Appendix 6.7.1. The Gittins index
for a treatment with posterior mean ỹk,t and posterior standard deviation s̃k,t, after
having observed nk,t responses from treatment k, G(ỹk,t, s̃k,t, nk,t), can be written as
G(ỹk,t, s̃k,t, nk,t) = ỹk,t + s̃k,tG(0, 1, nk,t + 2, d), (6.2.1)
where G(0, 1, nk,t + 2, d) denotes the Gittins index value of a standardised bandit
problem with posterior mean 0, posterior standard deviation 1, nk,t observations, an
implicit (prior) sample size of 2 (refer to Appendices 6.7.1 and 6.7.3 for details), and
discount factor 0 ≤ d < 1. In this chapter, we choose d as recommended in Wang
(1991b) (Appendix 6.7.2 provides further details).
Notice that in this case we have two unknown parameters, µk and σ
2
k, which we
























0. The choice of prior and its effect on performance measures is explored in Appendix
6.7.3. As in Smith and Villar (2018), we implement the solution in (6.2.1) at a very
low computational cost by calculating the values of G(0, 1, nk,t + 2, d) in advance1 and
interpolating from Table 8.3 in Gittins et al. (2011, p.263). Details on how to compute
these indices, first computed by Jones (1975), can be found in Gittins et al. (2011,
Chapters 7 and 8).
In order to derive a response-adaptive rule that will sequentially randomise the
next b patients among the K + 1 treatments at stage j (j = 1, . . . , J), given the data
up to and including block j−1, according to what the Gittins index rule would do, we
assume that patients are enrolled in groups, or blocks, of size b over J stages, so that
J × b = T . Using (6.2.1) and the Gittins index rule, which states that it is optimal to
allocate the treatment with the highest index value (breaking ties at random), we can
compute the FLGI probabilities for the case of a normally distributed endpoint (with
1These values are provided in Table 6.7.1.
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unknown variance) using equation (3) in Villar et al. (2015b). The main difference
here is that the optimal action probabilities in equation (3) of Villar et al. (2015b)
can no longer be matched to the probabilities of the (binary) outcome and must be
computed for different ranges of the continuous outcome.
Example
To illustrate the proposed rule, we derive the FLGI probabilities for the simplest possi-
ble case of a two-arm trial testing a control treatment (k = 0) against an experimental
treatment (k = 1) with a block of size two (b = 2).
For both k, we assume the following hierarchical (conjugate) prior structure at























. Suppose further that both patients are randomly allocated to the
control treatment in the first block of the trial, resulting in responses y0,1 = 3.1 and
y0,2 = −0.4. Thus, the three relevant parameters required to obtain the corresponding
Gittins index for the control treatment are: the posterior mean ỹ0,2 = 0.675, the
posterior standard deviation s̃0,2 = 1.727, and the number of observations n0,2 = 2
(see equation (6.7.1) in Appendix 6.7.1). For the experimental treatment, the relevant
parameters are: ỹ1,2 = 0, s̃1,2 = 1, and n1,2 = 0. From equation (6.2.1), setting d =
0.995 and using Table 6.7.1 of Appendix 6.7.1, the Gittins index for the control and
experimental treatment, respectively, is G0(0.675, 1.727, 2) = 0.675 + 1.727×1.8126 =
3.805 and G1(0, 1, 0) = 0 + 1× 65.5848 = 65.585.
Figure 6.2.1 illustrates how the FLGI probabilities for block two, given the data
in block one, are computed via a probability tree. Given that the experimental treat-
ment has the unique maximum Gittins index, the first patient of the second block
is allocated to the experimental treatment with probability 1. When the second pa-
tient of the second block is to be allocated, we need to have observed the (random)
outcome of the first patient in this block, denoted by Y1,3, in order to update the
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indices and determine the optimal action. The updated prior parameters for the ex-
perimental treatment, as a function of the observed information on this treatment












n1,3 = 1. Thus, the index for the experimental treatment can be expressed as a func-











G1(0, 1, 3, 0.995), with G1(0, 1, 3, 0.995) = 4.6049.
For the control treatment, we have no new information and so its index remains
unchanged at G0(Ỹ0,3, S̃0,3, n0,3) = 3.805. According to the Gittins index rule, it is op-
timal to allocate the control treatment to the second patient in the block if and only if
G1(Ỹ1,3, S̃1,3, n1,3) < G0(Ỹ0,3, S̃0,3, n0,3), which happens when −0.9508 < Y1,3 < 0.5862.
Since Y1,3 is a standard normal random variable, this happens with probability 0.5503,
that is, P(Y1,3 ≤ 0.5862) − P(Y1,3 ≤ −0.9508) = 0.5503. If Y1,3 < −0.9508 or
Y1,3 > 0.5862, which happens with probability 0.4497, then G1(Ỹ1,3, S̃1,3, n1,3) >
G0(Ỹ0,3, S̃0,3, n0,3) and the second patient in the second block is optimally allocated to
the experimental treatment. Notice that if Y1,3 = −0.9508 or Y1,3 = 0.5862, the index
values are equal and it is optimal to allocate any of the two treatments. In theory,
this would happen with probability 0 since Yk,t is a continuous variable. However, in
practice, if this were to happen, we would randomise with probability 0.5. Hence, the
normal FLGI procedure would randomise both patients in this block to receive the
experimental treatment with probability 1+(1×0.4497)
2
= 0.7249, and the control treat-
ment with probability 0+(1×0.5503)
2
= 0.2751. Continuing this example for larger block
sizes using Monte Carlo simulation, the allocation probabilities to the experimental
and control arm, respectively, are (0.6565, 0.3435) for b = 3, (0.5151, 0.4849) for b = 4,
(0.4370, 0.5630) for b = 5, and (0.3051, 0.6949) for b = 10.
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aGI1,3 = 1
G1 (0,1,0) = 65.585
















G0 (0.675,1.727,2) = 3.805





























Figure 6.2.1: The FLGI rule and a probability tree of all trial histories using the
Gittins index rule when K + 1 = 2, b = 2, d = 0.995, the outcome Yk,t is normally
distributed with unknown mean and variance, and parameters (ỹk,2, s̃k,2, nk,2) are given
by (0.675, 1.727, 2) for k = 0 and (0, 1, 0) for k = 1. Bold text indicates the allocated
treatment under the Gittins index rule {aGIk,t}. Note that the FLGI probabilities in
this case are 0.7249 and 0.2751 for the experimental and control arm, respectively.
(For simplicity of the illustration, we have omitted the branch corresponding to the
cases Y1,3 = −0.9508 or Y1,3 = 0.5862 since, theoretically, this would happen with
probability 0).
6.3 Simulation Study
6.3.1 Alternative Designs and Performance Measures
Next, we will report simulations that compare the FLGI for a normally distributed
endpoint (with unknown variance) against the following existing randomisation pro-
cedures:
(1) Equal Randomisation2 (ER), where each patient is randomly allocated to one
2Note that this is referred to as fixed randomisation in previous chapters. The two terms are
taken to be synonymous throughout this thesis.
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of the K + 1 arms with equal probability, 1/(K + 1). ER is predominant in practice
(implemented, for example, by permuted-block randomisation), thus it will be used
as a reference to compare all designs.
(2) Modified Zhang and Rosenberger (MZR), introduced by Zhang and Rosen-
berger (2006) and later modified by Biswas and Bhattacharya (2009) to allow for
negative mean responses. The rule aims at minimising the total of inverse mean




c if {µ0, µ1 > 0 and ρc < c} or
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or {µ0 < 0, µ1 > 0} ,
ρc if {µ0, µ1 > 0, c ≤ ρc ≤ 1− c} ,
1− c if {µ0, µ1 > 0, ρc > 1− c} or
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or {µ0 > 0, µ1 < 0} ,










and c ∈ [0, 1/2]. The initial parameter esti-
mates are obtained by allocating the first nER patients using ER. After that, estimates
of the unknown parameters µk and σk are sequentially updated based on the current
data available.
(3) Constrained Gittins Index (GI) Rule is a procedure based on Gittins indices
proposed by Wang (1991a) and further studied by Coad (1991b, 1995). However,
unlike the FLGI, Constrained GI is not implemented in terms of probabilities, and
hence is not randomised. This is a practical limitation and explains why Constrained
GI has been neglected as a comparator within the RAR literature. The rule is defined
as follows: if nc0,t < n1,t, allocate the next patient to arm 0; if n
c
1,t < n0,t, allocate
the next patient to arm 1; else, allocate the next patient to the treatment with the
largest Gittins index (randomising if they are equal). The parameter c ≥ 1 is a tuning
parameter; c = 1 corresponds to ER, and the Gittins index is eventually recovered as
c→∞. Following Wang (1991a), we fix c = 2 in our simulations.
(4) Thompson Sampling (TS) randomises patients to arms based on their posterior
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probability of being the “best” arm. Specifically, we consider a version of Thompson
sampling suggested by Thall and Wathen (2007), where the probability of allocating
treatment k to patients in block j is computed as
P
(




maxi µi = µk | x̃(j−1)b
)c ,
where x̃t = (ỹ0,t, s̃0,t, n0,t, . . . , ỹK,t, s̃K,t, nK,t) and c = (j−1)b/2T is a tuning parameter
that recovers ER when c = 0 and TS when c = 1.
(5) Trippa et al. (2012) Procedure (TP) randomises patients similarly to TS,
but also protects allocation to the control arm. We have implemented TP as in Villar
et al. (2015b)3.
(6) Controlled FLGI (CFLGI) is a variant of the FLGI design proposed in Villar
et al. (2015b) which, similarly to TP, protects the allocation to the control arm by
ensuring that the corresponding allocation probability is always at least 1/(K + 1).
(7) Gwise et al. (2011) propose a design for comparing K + 1 arms with het-
eroscedasticity. After an initial ER phase, patient t + 1 is allocated to arm k with
probability
σ̂2k,t/nk,t
σ̂20,t/n0,t + · · ·+ σ̂2K,t/nK,t
,
where σ̂2k,t is the estimated sample variance of the first nk,t responses on arm k.
Note that MZR and Constrained GI are fully sequential and will only be imple-
mented in the two-armed case (see Coad (1995) for the multi-arm version of Con-
strained GI). TP and CFLGI apply only to the multi-armed case. For all of the rules
which require specification of a joint prior distribution on µk and σ
2
k, we take the
same approach as with the FLGI. For the index-based designs, a discount factor of
d = 0.995 is used, and the allocation probabilities defined in the FLGI designs, TS
and TP are computed using their empirical estimates from 100 Monte Carlo repli-
3Refer to Section 2.1.3 for a description of TP.
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cates. Additionally, we implement the doubly adaptive biased coin design by Hu and
Zhang (2004)4 with the target allocation proportions taken to be the corresponding
FLGI probabilities for b = T under the null and alternative hypotheses, H0 and H1,
defined below.
To evaluate the performance of all designs, we consider patient benefit and the
usual inferential measures. The former includes: (a) the expected proportion of pa-
tients in the trial allocated to the superior treatment, E(p∗), and (b) the percentage
change in expected total outcome for rule r (ETOr) relative to the theoretical expected
total outcome for ER (ETOER), computed as 100× (ETOr − ETOER)/ETOER and
denoted in the tables of results by RelETO%. For the inferential measures, we focus
on standard operating characteristics, including: power, 1 − β; type I error rate, α;
and bias in the maximum likelihood estimator of the treatment effect, E(∆̂ − ∆),
with ∆ = µk − µ0 and ∆̂ = (µ̂k − µ̂0). For the multi-armed case, we report both the
marginal power (i.e. power to reject H0,k∗ , where k∗ is the best arm) and the bias
for the best experimental arm under H1. Note that under H0, we take k∗ to be the
control arm.
We consider the following hypotheses: H0 : µ0 = µk ∀ k versus the one-sided
alternatives, H1,k : µ0 < µk for some k > 0 considered the best arm. We will use the
test statistic Tk =
(






for k = 1, . . . , K, where Y k and σ̂
2
k are
the sample mean and sample variance, respectively, of arm k at the end of the trial.
In the multi-armed case, we consider the joint distribution of T1, . . . , TK and use a
critical value, t1−α, to achieve a family-wise type I error rate (FWER) close to the
specified α, where FWER is defined as the probability of obtaining at least one false
positive, or type I error, within the family of null hypotheses H0.
4Refer to (2.1.1) for details.
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6.3.2 A Two-Armed Trial
To motivate this scenario, we use the example in Karrison et al. (2007) of a two-
armed phase II cancer trial, in which the primary endpoint is the ratio of tumour
size at the time of follow-up to that at baseline for patient t under treatment k, that
is, the change in tumour size, denoted by Ck,t. After a log-transformation, Ck,t is
continuous and approximately normally distributed, as shown by Lavin (1981). In
keeping with our assumption that a larger outcome is desirable, we add a minus sign
to re-express the endpoint as a measure of tumour reduction. Under the assumption
that Y0,t = − log(C0,t) ∼ N(0.155, 0.642) and Y1,t = − log(C1,t) ∼ N(0.529, 0.642),
the total sample size required to detect this treatment difference with approximately
80% power at the α = 0.05 significance level and assuming complete observations is
T = 72.
Results
Table 6.3.1 displays the results from 50, 000 replications of the trial when we assume
unknown variance. As expected, under H0 all the designs are equal in terms of patient
benefit (RelETO% ≈ 0 and E(p∗) ≈ 0.50). The main difference between designs under
the null is the variability of the allocations, represented by the standard deviations
(s.d.) of p∗, with ER and FLGI (for b = 1) being the least and most variable,
respectively. As the block size increases, changes in the allocation probabilities are
based on more data and the FLGI becomes less variable. The index-based procedures
tend to be more variable because they aim at maximising patient response. For
example, the Constrained GI also has a large variability which is comparable to that
of the FLGI. For the MZR design, the variability of the allocations decreases as the
size of the initial ER period, nER, increases. The variability of the FLGI is also
markedly reduced when implemented using Hu and Zhang (2004), labelled as FLGI-
HZ in Table 6.3.1. In terms of the bias of the treatment effect estimator, all are (on
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average) unbiased under H0. Note that we have used adjusted t-critical values to
control type I error rates for all designs following the approach used in Smith and
Villar (2018). The (unreported) type I error inflation incurred for the FLGI when
using the usual t0.95 critical value is approximately 11% for b = 1 and it decreases as
the block size grows, as expected. A similar level and pattern of inflation occurs for
TS.
The results under H1, in which we are testing for superiority of arm 1 (the ex-
perimental arm), show more contrasts amongst designs. First, we focus on the FLGI
design and the effect of varying the block size on the power versus patient benefit
trade-off. When b = 1, the FLGI design is statistically identical to the fully sequen-
tial Gittins index rule and so favours patient response. At the other extreme, when
b = T , the FLGI design is equivalent to ER and therefore favours power. Thus, consis-
tent with the findings for the binary case, Table 6.3.1 shows that as b increases under
H1, the patient benefit measures (and corresponding standard deviations) decrease,
whilst the power increases (at a faster rate) which illustrates the natural tension be-
tween these two conflicting goals. This relationship is depicted visually in Figure 6.5.1
for T = 128.
In terms of the patient benefit measures, the index-based designs (namely the
FLGI and Constrained GI) perform the best out of all the designs considered. Relative
to ER, for a moderate block size of b = 9, the FLGI allocates approximately 34% more
patients to the superior treatment (equivalent to 25 patients). Moreover, the expected
total tumour size reduction is just over 37% greater than that obtained when using
ER. Even for a large block size of b = 36, the FLGI allocates approximately 21%
more patients to arm 1 and achieves an expected total tumour size reduction 23%
larger than ER. All other block sizes for the FLGI have a total tumour size reduction
at least 30% greater than ER, on average. The Constrained GI is shown to perform
similarly to the FLGI when b = 9. TS has a total tumour size reduction rate of at
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least 20% greater than ER for small b, on average, whereas MZR falls below this for
all nER.
As mentioned above, the cost of these patient benefit gains is a severe reduction
in the power compared to that of ER. However, this is ameliorated as b increases or
by implementing the FLGI probabilities using Hu and Zhang (2004). The ER design
attains an unbiased treatment effect estimator, as expected, with the largest relative
bias exhibited by the FLGI design when b = 1 (i.e. the GI design). This makes
sense because this is the design with the biggest imbalance in favour of arm 1. As
a result, µ̂0 will be substantially underestimated giving rise to an overestimated ∆̂
(and positive bias of treatment effect). As b increases, and consequently the number
of observations on arm 0 increases, the bias (and associated standard deviations) of
the treatment effect estimator decreases.
These results emphasise the very important point that, in a two-armed setting,
none of the designs are uniformly better than the others for every performance mea-
sure since each design is tailored towards a different competing objective. This makes
direct comparisons between such designs infeasible and motivates our main interest
in the multi-armed case.
Table 6.3.1 also shows the results attained by the FLGI rule when assuming the cor-
rect variance in both arms (see FLGI-known). As expected, FLGI-known marginally
outperforms the FLGI with unknown variance in terms of patient benefit (and re-
duces the power) due to the additional uncertainty present in the latter. However, in
practice, this is unrealistic since the true variance of the outcome is seldom known at
the start of a trial. Therefore, in Tables 6.3.2 and 6.3.3, we illustrate the effect of as-
suming an incorrect variance (on one, or both, of the arms) on the performance of the
FLGI relative to when assuming an unknown variance. Although misspecifying the
variance does not always have a negative impact on the results, and the performance
may be comparable to that when assuming an unknown variance (as in Scenarios
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(i)–(iv)), it is important to be aware that it can sometimes lead to a considerable
loss in patient benefit. This is evident in Scenario (vii) of Table 6.3.3, for example,
where 6.4% fewer patients are allocated to the superior treatment (for b = 1) as a
consequence of underestimating σ21. As such, the robustness and flexibility attained
by the FLGI with unknown variance makes this design more suited to practice.
µ0 = µ1 = 0.155 µ0 = 0.155, µ1 = 0.529
Design t1−α α E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) 1− β E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.)
ER b = 1 1.654 0.0518 0.4999 (0.06) -0.19 (5.45) -0.0005 (0.15) 0.7884 0.5005 (0.06) 0.20 (5.66) -0.0013 (0.15)
FLGI-known b = 1 1.991 0.0526 0.4997 (0.33) -0.06 (5.42) -0.0004 (0.49) 0.2290 0.8823 (0.16) 41.69 (7.01) 0.2167 (0.45)
b = 2 1.969 0.0505 0.5002 (0.32) 0.34 (5.42) -0.0003 (0.44) 0.2701 0.8777 (0.16) 41.27 (6.85) 0.1870 (0.41)
b = 6 1.911 0.0481 0.4987 (0.29) -0.03 (5.45) 0.0010 (0.34) 0.3599 0.8605 (0.14) 39.38 (6.59) 0.1147 (0.30)
b = 9 1.864 0.0492 0.4983 (0.28) -0.15 (5.43) 0.0008 (0.30) 0.4235 0.8483 (0.13) 38.14 (6.53) 0.0843 (0.26)
b = 18 1.766 0.0513 0.5017 (0.24) 0.14 (5.44) -0.0010 (0.23) 0.5653 0.8074 (0.12) 33.72 (6.30) 0.0389 (0.20)
b = 36 1.682 0.0495 0.5000 (0.19) 0.26 (5.45) 0.0001 (0.17) 0.7124 0.7139 (0.09) 23.25 (5.98) 0.0087 (0.17)
FLGI b = 1 2.1820 0.0525 0.5013 (0.29) -0.15 (5.43) 0.0013 (0.29) 0.3289 0.8712 (0.12) 40.62 (6.39) 0.0955 (0.27)
b = 2 2.159 0.0497 0.5016 (0.28) 0.21 (5.45) 0.0014 (0.28) 0.3432 0.8651 (0.12) 39.95 (6.41) 0.0902 (0.26)
b = 6 2.118 0.0477 0.4985 (0.27) 0.18 (5.42) -0.0008 (0.26) 0.3790 0.8521 (0.12) 38.48 (6.36) 0.0801 (0.25)
b = 9 2.045 0.0514 0.5011 (0.26) -0.01 (5.41) 0.0019 (0.25) 0.4236 0.8412 (0.12) 37.13 (6.36) 0.0698 (0.24)
b = 18 1.898 0.0517 0.5008 (0.24) -0.04 (5.42) 0.0005 (0.22) 0.5277 0.8047 (0.12) 33.30 (6.23) 0.0356 (0.20)
b = 36 1.733 0.0505 0.4997 (0.18) 0.01 (5.43) -0.0009 (0.18) 0.6973 0.7128 (0.09) 23.23 (6.00) 0.0097 (0.17)
FLGI-HZ (γ = 2) b = 1 1.658 0.0509 0.5000 (0.05) 0.12 (5.43) 0.0008 (0.15) 0.6510 0.7784 (0.04) 30.46 (5.51) 0.0001 (0.18)
b = 2 1.660 0.0509 0.5003 (0.05) -0.14 (5.44) 0.0004 (0.15) 0.6499 0.7786 (0.04) 30.61 (5.54) -0.0007 (0.18)
b = 6 1.688 0.0487 0.5001 (0.05) 0.16 (5.42) 0.0000 (0.15) 0.6417 0.7781 (0.04) 30.40 (5.54) -0.0001 (0.18)
b = 9 1.661 0.0529 0.4994 (0.05) 0.43 (5.43) 0.0017 (0.15) 0.6501 0.7777 (0.04) 30.27 (5.52) -0.0004 (0.18)
b = 18 1.684 0.0490 0.4999 (0.05) 0.11 (5.41) 0.0003 (0.15) 0.6570 0.7644 (0.04) 28.99 (5.54) -0.0011 (0.18)
b = 36 1.665 0.0516 0.5000 (0.05) 0.10 (5.41) 0.0017 (0.15) 0.7779 0.5865 (0.05) 9.57 (5.64) 0.0003 (0.15)
TS b = 1 1.751 0.0496 0.4999 (0.11) -0.1108 (5.44) -0.0001 (0.17) 0.7425 0.6961 (0.11) 21.35 (6.14) 0.0302 (0.19)
b = 2 1.739 0.0497 0.4997 (0.11) -0.0431 (5.41) -0.0016 (0.17) 0.7479 0.6934 (0.11) 21.27 (6.11) 0.0290 (0.19)
b = 6 1.741 0.0513 0.4994 (0.11) 0.3098 (5.44) -0.0001 (0.17) 0.7489 0.6825 (0.10) 19.88 (6.14) 0.0257 (0.18)
b = 9 1.729 0.0499 0.5000 (0.10) 0.1311 (5.42) 0.0001 (0.17) 0.7547 0.6747 (0.10) 18.95 (6.13) 0.0229 (0.18)
b = 18 1.722 0.0494 0.5008 (0.10) 0.4446 (5.42) 0.0013 (0.16) 0.7602 0.6509 (0.10) 16.40 (6.11) 0.0184 (0.17)
b = 36 1.697 0.0507 0.4999 (0.08) 0.4332 (5.41) 0.0013 (0.16) 0.7726 0.6040 (0.10) 11.45 (6.07) 0.0095 (0.16)
CGI (c = 2) 1.887 0.0496 0.4871 (0.28) 0.19 (5.42) 0.0004 (0.24) 0.4298 0.8294 (0.11) 37.59 (6.19) 0.0340 (0.21)
MZR nER = 2 1.794 0.0516 0.5005 (0.19) 0.2794 (5.41) 0.0002 (0.19) 0.7471 0.6569 (0.12) 17.15 (5.76) 0.0229 (0.17)
nER = 6 1.780 0.0507 0.4998 (0.17) 0.3487 (5.43) 0.0001 (0.18) 0.7632 0.6414 (0.10) 15.47 (5.49) 0.0202 (0.16)
nER = 11 1.751 0.0508 0.5001 (0.14) -0.2534 (5.41) 0.0007 (0.17) 0.7755 0.6173 (0.08) 12.86 (5.29) 0.0155 (0.16)
Gwise nER = 2 1.877 0.0495 0.4997 (0.13) -0.08 (5.43) 0.0012 (0.18) 0.7193 0.4999 (0.13) -0.11 (6.47) -0.0013 (0.18)
nER = 6 1.697 0.0482 0.5003 (0.06) -0.08 (5.45) -0.0000 (0.15) 0.7833 0.5005 (0.06) 0.02 (5.67) -0.0013 (0.15)
nER = 11 1.705 0.0492 0.4999 (0.06) 0.07 (5.41) 0.0007 (0.15) 0.7837 0.5000 (0.06) -0.20 (5.66) 0.0000 (0.15)
Table 6.3.1: Comparison of performance measures for a two-armed trial using different
designs when the variance is assumed unknown (with the exception of FLGI-known)
and T = 72, averaged over 50,000 trial replications. Note that the true variance of
the response is σ2k = 0.64
2 for k ∈ {0, 1}.
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µ0 = µ1 = 0.155 µ0 = 0.155, µ1 = 0.529
b t1−α α E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) 1− β E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.)






1 2.001 0.0509 0.4983 (0.27) -0.04 (3.84) 0.0013 (0.26) 0.4722 0.9215 (0.07) 46.01 (4.34) 0.1430 (0.29)
2 1.977 0.0505 0.5010 (0.26) 0.17 (3.83) -0.0007 (0.24) 0.5422 0.9142 (0.07) 45.22 (4.32) 0.1209 (0.26)
6 1.925 0.0525 0.4986 (0.24) 0.12 (3.85) 0.0009 (0.20) 0.6642 0.8952 (0.07) 43.29 (4.33) 0.0771 (0.21)
9 1.887 0.0518 0.5002 (0.23) 0.07 (3.82) -0.0004 (0.18) 0.7241 0.8814 (0.07) 41.77 (4.30) 0.0545 (0.18)
18 1.798 0.0509 0.4999 (0.21) 0.14 (3.83) 0.0010 (0.15) 0.8406 0.8370 (0.07) 36.90 (4.29) 0.0224 (0.14)
36 1.698 0.0500 0.5006 (0.16) -0.03 (3.83) -0.0005 (0.12) 0.9341 0.7331 (0.06) 25.53 (4.19) 0.0050 (0.12)






1 2.280 0.0502 0.5014 (0.30) -0.04 (3.84) 0.0017 (0.21) 0.4301 0.9177 (0.07) 45.60 (4.33) 0.0641 (0.20)
2 2.209 0.0484 0.4987 (0.29) 0.04 (3.83) -0.0013 (0.20) 0.4713 0.9131 (0.07) 45.15 (4.32) 0.0602 (0.20)
6 2.132 0.0491 0.4987 (0.28) 0.01 (3.81) -0.0017 (0.19) 0.5520 0.9008 (0.07) 43.88 (4.35) 0.0537 (0.19)
9 2.080 0.0505 0.4991 (0.27) 0.04 (3.84) -0.0007 (0.18) 0.5958 0.8894 (0.07) 42.55 (4.33) 0.0427 (0.18)
18 1.897 0.0516 0.5004 (0.24) 0.04 (3.84) -0.0004 (0.16) 0.7604 0.8466 (0.07) 37.95 (4.29) 0.0186 (0.15)
36 1.751 0.0501 0.5000 (0.19) -0.22 (3.83) -0.0002 (0.12) 0.9110 0.7401 (0.06) 26.33 (4.18) 0.0035 (0.12)
(iii) FLGI-known with σ20 = σ
2
1 = 2× 0.642
1 1.940 0.0505 0.4998 (0.37) -0.04 (7.69) 0.0024 (0.81) 0.1517 0.8106 (0.27) 34.25 (10.54) 0.2656 (0.74)
2 1.924 0.0481 0.4997 (0.36) 0.13 (7.64) -0.0015 (0.72) 0.1719 0.8116 (0.26) 34.29 (10.29) 0.2279 (0.66)
6 1.865 0.0484 0.4999 (0.33) -0.28 (7.70) -0.0008 (0.54) 0.2233 0.8018 (0.23) 33.06 (9.85) 0.1441 (0.48)
9 1.790 0.0529 0.4998 (0.31) -0.21 (7.69) -0.0009 (0.45) 0.2730 0.7935 (0.21) 32.21 (9.55) 0.1068 (0.40)
18 1.747 0.0514 0.4998 (0.27) 0.49 (7.70) 0.0006 (0.33) 0.3454 0.7593 (0.18) 28.34 (9.10) 0.0487 (0.30)
36 1.677 0.0497 0.5003 (0.20) -0.03 (7.66) 0.0050 (0.25) 0.4532 0.6837 (0.14) 20.27 (8.53) 0.0108 (0.24)
(iv) FLGI with σ20 = σ
2
1 = 2× 0.642
1 2.386 0.0518 0.5013 (0.32) -0.04 (7.69) 0.0009 (0.45) 0.1944 0.8117 (0.21) 34.37 (9.55) 0.1326 (0.41)
2 2.323 0.0501 0.4975 (0.31) -0.21 (7.64) -0.0037 (0.43) 0.2047 0.8088 (0.21) 33.57 (9.50) 0.1292 (0.4)
6 2.255 0.0502 0.5008 (0.29) 0.05 (7.68) 0.0000 (0.40) 0.2184 0.7945 (0.20) 32.22 (9.37) 0.1117 (0.38)
9 2.138 0.0525 0.5004 (0.28) -0.07 (7.69) 0.0016 (0.38) 0.2413 0.7827 (0.19) 31.01 (9.27) 0.0936 (0.35)
18 1.888 0.0514 0.4974 (0.25) -0.02 (7.63) -0.0028 (0.32) 0.3346 0.7511 (0.17) 27.18 (8.97) 0.0517 (0.29)
36 1.753 0.0480 0.5002 (0.19) 0.13 (7.69) -0.0012 (0.25) 0.4470 0.6748 (0.13) 19.11 (8.48) 0.0145 (0.24)
Table 6.3.2: Comparing the performance measures of FLGI-known, when the vari-
ance is incorrectly assumed to be 0.642, against those obtained from FLGI when the
variance is assumed unknown (but with an initial estimate, s̃2k,0, of 0.64
2). The true
variance of the response is actually half or double 0.642, as indicated. These results
are averaged over 50, 000 replications for a two-armed trial of size T = 72.
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µ0 = µ1 = 0.155 µ0 = 0.155, µ1 = 0.529
b t1−α α E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) 1− β E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.)





1 1.9900 0.0502 0.4284 (0.30) 0.03 (4.61) 0.1030 (0.38) 0.1828 0.9203 (0.09) 45.84 (4.32) 0.2522 (0.41)
2 1.9710 0.0487 0.4358 (0.29) -0.35 (4.60) 0.0902 (0.35) 0.2200 0.9102 (0.09) 44.85 (4.32) 0.2038 (0.37)
6 1.9170 0.0487 0.4587 (0.27) 0.26 (4.63) 0.0583 (0.28) 0.3399 0.8857 (0.09) 42.06 (4.35) 0.1271 (0.28)
9 1.8730 0.0508 0.4666 (0.26) -0.08 (4.65) 0.0477 (0.24) 0.4222 0.8703 (0.09) 40.49 (4.36) 0.0952 (0.24)
18 1.7890 0.0532 0.4836 (0.23) 0.09 (4.68) 0.0280 (0.19) 0.5893 0.8240 (0.09) 35.37 (4.43) 0.0427 (0.18)
36 1.7060 0.0533 0.4992 (0.18) 0.07 (4.70) 0.0131 (0.15) 0.7697 0.7237 (0.08) 24.42 (4.56) 0.0117 (0.15)





1 2.425 0.0489 0.4822 (0.31) -0.07 (4.72) 0.0341 (0.26) 0.2655 0.8897 (0.11) 42.51 (4.58) 0.1104 (0.26)
2 2.331 0.0524 0.4789 (0.30) -0.07 (4.69) 0.0323 (0.25) 0.2969 0.8833 (0.11) 41.94 (4.59) 0.1044 (0.25)
6 2.266 0.0485 0.4752 (0.28) 0.05 (4.74) 0.0282 (0.24) 0.3431 0.8674 (0.11) 40.08 (4.62) 0.0927 (0.24)
9 2.185 0.0510 0.4722 (0.28) -0.37 (4.72) 0.0263 (0.23) 0.3861 0.8562 (0.11) 38.81 (4.62) 0.0813 (0.23)
18 1.977 0.0489 0.4721 (0.25) 0.06 (4.75) 0.0197 (0.19) 0.5261 0.8158 (0.10) 34.69 (4.60) 0.0418 (0.19)
36 1.778 0.0511 0.4786 (0.19) -0.04 (4.72) 0.0120 (0.15) 0.7429 0.7226 (0.09) 24.28 (4.60) 0.0111 (0.15)
(vii) FLGI-known with σ20 = 0.64
2, σ21 = 2× 0.642
1 1.981 0.0489 0.5892 (0.34) 0.30 (6.45) -0.1878 (0.65) 0.2669 0.7882 (0.29) 31.44 (11.25) 0.0885 (0.64)
2 1.941 0.0524 0.5747 (0.34) 0.33 (6.51) -0.1584 (0.59) 0.3005 0.7958 (0.27) 32.39 (10.90) 0.0819 (0.55)
6 1.855 0.0519 0.5517 (0.31) 0.01 (6.53) -0.1035 (0.45) 0.3741 0.8034 (0.23) 33.30 (10.18) 0.0586 (0.40)
9 1.821 0.0482 0.5422 (0.30) -0.03 (6.56) -0.0806 (0.38) 0.4119 0.7995 (0.21) 32.71 (9.84) 0.0454 (0.33)
18 1.735 0.0489 0.5194 (0.26) -0.34 (6.59) -0.0469 (0.28) 0.5105 0.7758 (0.17) 30.16 (9.15) 0.0197 (0.24)
36 1.665 0.0475 0.5007 (0.20) -0.04 (6.63) -0.0225 (0.22) 0.6098 0.6982 (0.12) 21.74 (8.20) 0.0004 (0.20)
(viii) FLGI with σ20 = 0.64
2, σ21 = 2× 0.642
1 2.238 0.0517 0.5204 (0.32) -0.05 (6.70) -0.0480 (0.38) 0.2806 0.8522 (0.19) 38.78 (9.50) 0.0774 (0.34)
2 2.207 0.0484 0.5249 (0.31) 0.24 (6.65) -0.0433 (0.37) 0.2885 0.8507 (0.18) 38.63 (9.40) 0.0710 (0.32)
6 2.095 0.0509 0.5290 (0.29) -0.06 (6.69) -0.0377 (0.34) 0.3353 0.8405 (0.17) 37.31 (9.28) 0.0637 (0.30)
9 2.039 0.0491 0.5297 (0.28) -0.07 (6.71) -0.0367 (0.33) 0.3554 0.8299 (0.16) 36.31 (9.14) 0.0501 (0.28)
18 1.839 0.0497 0.5284 (0.25) 0.05 (6.72) -0.0296 (0.27) 0.4708 0.7943 (0.14) 32.01 (8.71) 0.0220 (0.23)
36 1.700 0.0489 0.5222 (0.19) 0.15 (6.70) -0.0182 (0.21) 0.6050 0.7017 (0.11) 21.95 (8.05) 0.0030 (0.20)
Table 6.3.3: Continuation of Table 6.3.2, except now the true variances are heteroge-
neous, as indicated.
6.3.3 A Multi-Armed Trial
We now use the phase II cancer trial setting described in Karrison et al. (2007) as a
case study. The primary endpoint is again the change in tumour size from baseline
to eight weeks. Patients were randomly assigned to one of three treatment arms: 150
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mg of erlotinib plus placebo; 150 mg of erlotinib plus 200 mg of sorafenib; or 150 mg
of erlotinib plus 400 mg of sorafenib. We will refer to these as the control, low dose
and high dose, respectively.
Based on data from previous trials, the log ratio of tumour sizes is assumed to have
a mean of 0.05 for the control (k = 0), −0.07 for the low dose (k = 1) and −0.13 for the
high dose (k = 2), with a common standard deviation of 0.346. To be consistent with
our earlier assumption that larger responses are desirable, we instead consider tumour
reduction. Therefore, we assume that Y0,t ∼ N(−0.05, 0.3462), Y1,t ∼ N(0.07, 0.3462)
and Y2,t ∼ N(0.13, 0.3462). We simulate a trial of size T = 120, which should have at
least 80% power using a one-sided test at α = 0.10 when no correction for multiplicity
is considered. In our simulations, we will ensure a one-sided test at the α = 0.10
FWER level, and since we adjust for multiplicity, the power will fall slightly below
80%, illustrating the effect of correcting for multiplicity on power.
Results
Under the null, the only relevant difference amongst designs is the variability of result-
ing allocations, with the rules performing the best in terms of patient benefit being the
most variable. Results under the alternative hypothesis are illustrated in Figure 6.3.1
and provided in full (for both H0 and H1) in Table 6.3.4. Figure 6.3.1 shows a star
plot summarising the key features of each design (for blocks 1, 15, 40, and 60) where
the most desirable values lie towards the outer edge of the star plot with the least
favourable values towards the centre. We see that ER performs very well with respect
to power, average bias and variability, but poorly with respect to patient benefit for
all block sizes, whilst in contrast the FLGI design performs poorly with respect to
power, average bias and variability but the best with respect to patient benefit. The
CFLGI and TS design have values lying near to the outer edge of the star plot for all
measures, thus showing that they perform well with respect to all of the performance
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measures. Although CFLGI and TS have similar performances, they are not directly
comparable as they attain different compromises between the competing objectives.
Rather than having a flat probability protection for the control arm during the trial,
the definition of the CFLGI rule could be adjusted in a similar way to TS and TP,
which we expect would result in an advantage over TS in terms of patient benefit,



































































































































































Figure 6.3.1: The trade-offs between the expected proportion of patients allocated to
the superior arm, E(p∗), power, average absolute bias of the treatment effect estimator
and variability of patient allocations for the different designs, including normal FLGI
and normal FLGI with missing data (MD), for block sizes b = (1, 15, 40, 60) in a
three-armed trial of size T = 120 (assuming unknown variance).
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µ0 = µ1 = µ2 = −0.05 µ0 = −0.05, µ1 = 0.07, µ2 = 0.13
Design t1−α α E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) 1− β E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.)
ER b = 1 1.595 0.0997 0.3332 (0.04) -0.28 (3.79) -0.0007 (0.08) 0.7608 0.3333 (0.04) -0.07 (3.87) -0.0002 (0.08)
FLGI b = 1 1.731 0.0992 0.3331 (0.20) 0.03 (3.77) 0.0006 (0.12) 0.4936 0.6122 (0.23) 88.13 (4.34) 0.0212 (0.13)
b = 2 1.718 0.0994 0.3336 (0.20) -0.09 (3.79) 0.0002 (0.12) 0.5121 0.6087 (0.22) 87.48 (4.35) 0.0209 (0.13)
b = 4 1.737 0.0979 0.3343 (0.19) 0.10 (3.79) 0.0001 (0.12) 0.5100 0.6024 (0.22) 86.04 (4.35) 0.0203 (0.13)
b = 8 1.741 0.0954 0.3323 (0.19) -0.47 (3.79) -0.0003 (0.11) 0.5235 0.5938 (0.21) 83.52 (4.35) 0.0198 (0.12)
b = 15 1.709 0.1018 0.3337 (0.18) -0.03 (3.79) 0.0001 (0.11) 0.5582 0.5824 (0.21) 80.94 (4.34) 0.0191 (0.12)
b = 20 1.725 0.1001 0.3342 (0.18) 0.00 (3.78) 0.0004 (0.11) 0.5608 0.5716 (0.20) 77.82 (4.32) 0.0166 (0.11)
b = 40 1.662 0.1009 0.3342 (0.17) -0.35 (3.80) -0.0004 (0.10) 0.6100 0.5296 (0.18) 66.48 (4.26) 0.0047 (0.10)
b = 60 1.591 0.1009 0.3337 (0.15) -0.05 (3.80) 0.0004 (0.09) 0.6697 0.4835 (0.16) 51.91 (4.16) -0.0013 (0.09)
FLGI-HZ (γ = 2) b = 1 1.603 0.0972 0.3333 (0.04) 0.37 (3.79) -0.0001 (0.08) 0.6157 0.5137 (0.05) 67.11 (3.84) -0.0001 (0.10)
b = 2 1.592 0.0996 0.3334 (0.04) -0.41 (3.80) -0.0002 (0.08) 0.6161 0.5137 (0.05) 67.19 (3.85) -0.0005 (0.10)
b = 4 1.587 0.1009 0.3332 (0.04) 0.08 (3.79) 0.0000 (0.08) 0.6209 0.5134 (0.05) 66.96 (3.84) 0.0002 (0.10)
b = 8 1.600 0.0979 0.3331 (0.04) 0.79 (3.79) -0.0002 (0.08) 0.6162 0.5133 (0.05) 67.03 (3.84) -0.0004 (0.10)
b = 15 1.585 0.0994 0.3332 (0.04) -0.18 (3.80) -0.0006 (0.08) 0.6207 0.5131 (0.05) 66.86 (3.85) -0.0002 (0.10)
b = 20 1.605 0.0991 0.3334 (0.04) -0.32 (3.80) -0.0001 (0.08) 0.6187 0.5115 (0.05) 66.74 (3.87) -0.0001 (0.10)
b = 40 1.587 0.1014 0.3334 (0.04) 0.29 (3.80) -0.0002 (0.08) 0.6839 0.4827 (0.06) 53.2 (3.93) 0.0003 (0.09)
b = 60 1.598 0.1000 0.3335 (0.05) 0.25 (3.79) 0.0004 (0.08) 0.7665 0.4240 (0.05) 19.34 (4.08) 0.0000 (0.08)
CFLGI b = 1 1.530 0.1012 0.2894 (0.16) -0.01 (3.80) -0.0236 (0.10) 0.7254 0.4780 (0.18) 30.41 (4.12) -0.0171 (0.09)
b = 2 1.533 0.1009 0.2922 (0.16) 0.11 (3.78) -0.0223 (0.10) 0.7272 0.4756 (0.17) 30.28 (4.12) -0.0164 (0.09)
b = 4 1.520 0.1017 0.2949 (0.16) -0.06 (3.79) -0.0209 (0.10) 0.7324 0.4734 (0.17) 30.20 (4.09) -0.0157 (0.09)
b = 8 1.522 0.1027 0.2960 (0.15) -0.55 (3.80) -0.0203 (0.10) 0.7366 0.4685 (0.17) 29.11 (4.07) -0.0144 (0.09)
b = 15 1.530 0.0988 0.2976 (0.15) 0.04 (3.80) -0.0190 (0.10) 0.7361 0.4615 (0.16) 27.68 (4.09) -0.0133 (0.09)
b = 20 1.534 0.1020 0.2981 (0.15) -0.53 (3.80) -0.0180 (0.09) 0.7328 0.4554 (0.16) 26.79 (4.07) -0.0130 (0.09)
b = 40 1.538 0.1006 0.3029 (0.14) 0.20 (3.78) -0.0134 (0.09) 0.7425 0.4331 (0.14) 20.98 (4.03) -0.0105 (0.08)
b = 60 1.540 0.1005 0.3077 (0.13) -0.26 (3.79) -0.0082 (0.08) 0.7552 0.4094 (0.12) 15.80 (4.02) -0.0070 (0.08)
TP b = 1 1.582 0.1009 0.3116 (0.09) 0.11 (3.78) -0.0127 (0.09) 0.7822 0.3403 (0.06) -5.75 (3.82) -0.0019 (0.08)
b = 2 1.580 0.0991 0.3119 (0.09) 0.08 (3.80) -0.0128 (0.09) 0.7791 0.3402 (0.05) -6.68 (3.82) -0.0028 (0.08)
b = 4 1.571 0.0997 0.3121 (0.09) 0.05 (3.79) -0.0128 (0.09) 0.7824 0.3400 (0.05) -5.57 (3.81) -0.0019 (0.08)
b = 8 1.579 0.0991 0.3130 (0.09) -0.33 (3.78) -0.0121 (0.09) 0.7820 0.3393 (0.05) -6.07 (3.83) -0.0016 (0.08)
b = 15 1.570 0.1009 0.3148 (0.08) 0.45 (3.78) -0.0107 (0.09) 0.7793 0.3381 (0.05) -6.31 (3.84) -0.0023 (0.08)
b = 20 1.576 0.0982 0.3146 (0.08) -0.34 (3.79) -0.0098 (0.08) 0.7781 0.3370 (0.05) -6.02 (3.82) -0.0020 (0.08)
b = 40 1.567 0.1042 0.3174 (0.08) -0.11 (3.80) -0.0069 (0.08) 0.7792 0.3331 (0.05) -6.68 (3.91) -0.0013 (0.08)
b = 60 1.574 0.1021 0.3131 (0.07) -0.35 (3.78) -0.0051 (0.08) 0.7738 0.3214 (0.06) -11.58 (3.95) -0.0011 (0.08)
TS b = 1 1.629 0.1024 0.3331 (0.09) 0.09 (3.78) 0.0002 (0.09) 0.7313 0.4589 (0.10) 47.23 (4.08) 0.0141 (0.10)
b = 2 1.651 0.0985 0.3340 (0.09) -0.10 (3.78) 0.0009 (0.09) 0.7223 0.4574 (0.10) 46.67 (4.07) 0.0132 (0.10)
b = 4 1.641 0.0986 0.3337 (0.09) 0.18 (3.80) 0.0006 (0.09) 0.7267 0.4557 (0.10) 46.10 (4.08) 0.0138 (0.10)
b = 8 1.620 0.1028 0.3336 (0.08) 0.10 (3.79) 0.0000 (0.09) 0.7366 0.4513 (0.10) 44.76 (4.07) 0.0124 (0.09)
b = 15 1.626 0.1012 0.3327 (0.08) 0.38 (3.78) -0.0005 (0.09) 0.7349 0.4443 (0.09) 43.38 (4.07) 0.0121 (0.09)
b = 20 1.632 0.1006 0.3330 (0.08) 0.01 (3.78) -0.0001 (0.09) 0.7344 0.4390 (0.09) 41.59 (4.06) 0.0110 (0.09)
b = 40 1.635 0.0980 0.3329 (0.07) 0.00 (3.79) -0.0003 (0.08) 0.7410 0.4191 (0.08) 34.82 (4.05) 0.0093 (0.09)
b = 60 1.609 0.1016 0.3328 (0.07) 0.03 (3.78) -0.0006 (0.08) 0.7478 0.3979 (0.08) 27.29 (4.02) 0.0055 (0.09)
Gwise nER = 2 1.778 0.0998 0.3343 (0.08) 0.50 (3.82) 0.0003 (0.09) 0.7101 0.3336 (0.08) 0.12 (4.12) 0.0002 (0.09)
nER = 4 1.620 0.1011 0.3334 (0.05) -0.32 (3.78) 0.0001 (0.08) 0.7599 0.3328 (0.05) -0.13 (3.89) -0.0006 (0.08)
nER = 8 1.618 0.1010 0.3332 (0.04) -0.09 (3.78) -0.0001 (0.08) 0.7627 0.3332 (0.04) -0.01 (3.9) -0.0003 (0.08)
Table 6.3.4: Comparison of performance measures for a three-armed trial using dif-
ferent designs when the variance is assumed unknown and T = 120, averaged over
50,000 trial replications. Note that the true variance of the response is σ2k = 0.346
2
for k ∈ {0, 1, 2}.
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6.4 Dichotomisation: Patient Benefit and Efficiency
Cost
Phase II cancer trials, such as the ones considered above, are traditionally conducted
as single arm studies using a binary response rate as the primary endpoint, which is
formed by splitting the underlying continuous data (change in tumour size) into two
groups (success or failure of a treatment), that is, dichotomising. This dichotomisation
is often based on the Response Evaluation Criteria in Solid Tumors (Eisenhauer et al.,
2009) which categorises the change in tumour size and number of lesions into four
levels: complete response, partial response, stable disease, and progressive disease. A
treatment is considered a success if patients experience either a partial or complete
response (i.e. at least a 30% reduction in the total diameter of target lesions), and a
failure otherwise. If new lesions appear, or non-target lesions grow beyond a certain
percentage, this is also classed as a treatment failure.
Dichotomising continuous data is a widely adopted approach in clinical research.
However, this comes at the cost of losing power as well as raising issues such as where
exactly the dichotomisation cutpoint should be. For further implications, see Cohen
(1983) and Maccallum et al. (2002). Within the literature, there is a strong focus
on the loss of efficiency associated with dichotomising a continuous variable, but no
mention of the cost to patients in the trial. Therefore, we will use the same two-
armed example as in Section 6.3.2 to compare the performance, in terms of patient
benefit measures, of the continuous FLGI to the binary FLGI proposed in Villar
et al. (2015b). However, since the binary FLGI compares response rates, we increase
the total sample size from T = 72 to 128, as this is the size required to detect an
improvement from 20% to 40% with 80% power using a one-sided test at the α = 0.05
level; a 77% increase on that required for the continuous case.
Figure 6.5.1 shows the efficiency costs of dichotomising a continuous endpoint. A
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trial of size 128 achieves almost 100% power to detect the target treatment difference
when using a continuous endpoint, as opposed to 80% power when using a binary
one. Moreover, Figure 6.5.1 also illustrates that there is an important patient benefit
cost of using a binary endpoint instead of a continuous one when using RAR. In
particular, the normal FLGI (all versions) has not only a higher power level, but also
a considerably higher expected proportion of patients on the best arm for every block
size in a trial of size 128.
6.5 Imputing Complete Responses and Dropouts
The patient benefit cost associated with dichotomising requires an important practi-
cal consideration to be taken into account when interpreting it. To implement any
response-adaptive design in practice, particularly in cancer trials like those used in
this chapter, we need an online imputation method to account for patients who (a)
die or dropout of the trial before the follow-up time, or (b) have a complete response
(since this causes the log ratio to be undefined). Two approaches have been proposed
to impute these cases in Karrison et al. (2007) and Jaki et al. (2013), a review of
which is provided by Wason and Jaki (2016).
So far, we have assumed that all patients generate an observable response, which
is clearly not realistic. Whereas deaths/dropouts and complete responses are easily
imputed in the binary case, there is no obvious way of translating these outcomes
into continuous variables. Building upon the solution in Karrison et al. (2007), where
the best and worst possible outcomes are used to impute complete responses and
deaths/dropouts, respectively, we instead randomise from the upper tail of the (theo-
retical) distribution under H1 if we observe a complete response, and from the lower
tail of the null distribution to account for deaths or dropouts, regardless of which
treatment the patient received. Thus, this approach allows for a response-adaptive
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algorithm to be used by computing the missing values online as the trial progresses.
Furthermore, choosing the missing values randomly, as opposed to using the same
values every time, is perhaps a better reflection of reality or, at the very least, a
reflection of the distributional assumptions made to determine the size of the study
based on power considerations. Alternatively, we could estimate the best and worst
possible outcomes based on the interim data observed after each block. However, in
practice, if the deaths, dropouts or complete responses occur early on in the trial,
there would be too few, or possibly no, observations available to accurately represent
these values.
Figure 6.5.1 shows the results for the normal FLGI when we implement our online
imputation method assuming that we observe a 4% rate of deaths or dropouts and
a 1% rate of complete responses. This is illustrated under the assumption of both
a known and unknown variance, labelled as FLGI-known with missing data (MD)
and FLGI with MD, respectively. These rates are consistent with values reported
in Karrison et al. (2007). Figure 6.5.1 shows that, as expected, this missing data
assumption decreases both the efficiency and patient benefit advantages, relative to
the FLGI with complete observations, for both the known and unknown variance
cases. Nevertheless, the imputed continuous FLGI procedure continues to greatly
outperform the binary FLGI with respect to both criteria. Figure 6.3.1 suggests that
similar conclusions also apply for the multi-armed missing data case (see FLGI with
MD).
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Figure 6.5.1: The trade-off between the expected proportion of patients allocated to
the superior arm, E(p∗), and power for the: Binary ER, Normal ER, Binary FLGI,
Normal FLGI and Normal FLGI with Missing Data (MD) imputed in an online fashion
for block sizes b = (1, 2, 4, 8, 16, 32, 64, 128) in a two-armed trial of size T = 128. The
latter two designs are shown when assuming both an unknown variance and known
(correct) variance (dashed line and labelled as FLGI-known).
6.6 Discussion
The RAR literature contains relatively few procedures for a continuous endpoint as-
sumed to be normally distributed with unknown variance, fewer still that are defined
for the multi-armed case and none that are forward-looking. We propose the first
forward-looking RAR algorithm applicable to this case which is orientated towards
an optimality criterion with respect to patient benefit.
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In this chapter, we have shown that using a continuous endpoint instead of di-
chotomising can offer efficiency, but also patient benefit advantages, when combined
with RAR. An implication of not dichotomising could be a lack of robustness to de-
partures from the assumed response distribution. For example, if assuming responses
are normally distributed but the observed data is non-normal, how much of an impact
would this have on the performance measures of the proposed design, and would the
aforementioned advantages over the dichotomisation approach persist? This forms an
area of further work.
Implementing a RAR procedure, such as the FLGI, in the context of phase II
cancer trials requires dealing with missing data from patients in an online fashion. The
näıve imputation method suggested in this work, based on the method by Karrison
et al. (2007), shows that there are still important benefits even if a low rate of missing
observations is anticipated. Further work is needed to develop imputation methods
that can be used in combination with RAR.
An important advantage of our proposed method is that it can be implemented
without assuming a fixed, known, and common variance. In fact, the FLGI with
unknown variance can learn about the variance simultaneously as it learns about
the treatment means, and update the randomisation probabilities accordingly. Addi-
tionally, the method can incorporate covariates in the way suggested by Villar and
Rosenberger (2018).
The motivation of our algorithm is in the setting of clinical trials, but it applies
to sequential allocation problems more generally. Future research could consider the
issue of estimation following the sequential tests used in combination with these novel
designs, similar to work in Coad (1991a, 1994).
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6.7 Appendix
6.7.1 The MABP and FLGI for Normally Distributed End-
points
In this Appendix, we provide a more detailed description of the MABP for normally
distributed endpoints, its solution by the Gittins index (GI) and an additional example
of the Forward-Looking Gittins Index (FLGI) probabilities for normally distributed
endpoints with a known variance.
Recall that the MABP in this case involves a multi-armed clinical trial that will
test the effectiveness of K experimental treatments against a control treatment on
a sample of T patients, with K and T fixed and known in advance. Patients are
labelled by t (t = 1, . . . , T ) and treatments by k (k = 0, . . . , K), where k = 0 denotes
the control. The response of patient t allocated to arm k is a random variable denoted
by Yk,t and assumed to follow a normal distribution Yk,t ∼ N(µk, σ2k). Without loss of
generality, we also assume that a larger response is preferable and that σ2k is known.
In order to derive the FLGI rule, we first need to obtain the GI for a normally
distributed variable and the MABP associated with this trial design problem. For
this purpose, we assume the following. (i) Each unknown parameter µk has a prior
distribution πk,0 at the start of the trial (before any observation has been made)






. Note that the form of the prior
when both µk and σ
2
k are unknown is provided below. (ii) Patients enter the trial
one-by-one and responses are observed immediately after treatment. We will remove
these assumptions when we formulate the FLGI rule. (iii) Only one treatment can be
allocated per patient and we let ark,t be a binary indicator variable denoting whether
patient t + 1 is assigned to treatment k for patient allocation rule r or not, given
the information available on all treatments. (iv) Given the conjugacy of the prior and
normally distributed responses, prior distributions are converted into normal posterior
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distributions for each µk via Bayes’ Theorem. After treating patient t, if nk,t responses
from treatment k have been observed (each denoted by yk,i with i ∈ {1, . . . , nk,t} and





















i=1 yk,i is the sample
mean and n0k is the implicit sample size from the prior information (Spiegelhalter et al.,
2004, p. 62). The posterior distribution, πk,t, can be identified by the parameters ỹk,t
(posterior mean) and n0k + nk,t, which we subsequently refer to as the state (of the
bandit) (Gittins et al., 2011). Note that when the variance is unknown, an additional
parameter, s̃2k,t, denoting the posterior variance of patient t on arm k, is required
to identify πk,t and in this case, we need to specify a joint prior distribution for
µk and σ
2
k at the start of the trial. We take this to be the normal-inverse-gamma
distribution (where the variance follows an inverse-gamma distribution and the mean,
conditional on the variance, has a normal distribution). Consequently, the marginal
prior distribution for µk has a Student’s t-distribution. When we observe an outcome
yk,t+1 from patient t+ 1 on arm k, the state (ỹk,t, s̃k,t, n
0
k + nk,t) is updated as follows
(
(n0k + nk,t)ỹk,t + yk,t+1









n0k + nk,t + 1
) 1
2




The MABP is to find a patient allocation rule r that attains the maximum expected
patient response given the initial information about the treatments before the start

















k), x̃0 = {xk,0}
K
k=0 is the initial joint state with all the
prior parameters, R is the set of admissible allocation rules, Er[·] denotes expectation
under allocation rule r, and 0 ≤ d < 1 is a discount factor. In MABPs, rewards are
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geometrically discounted so that an infinite horizon can be considered, i.e. patient t’s
response yields a reward of dtYk,t for some k. In practice, a solution that depends on
d, such as the GI, can be adapted to solve an undiscounted problem with a specific
finite horizon, as explained in Edwards et al. (2017, Definition 6.6).
The exact solution to (6.7.2), obtained via dynamic programming, uses a backward
induction algorithm which becomes computationally infeasible very quickly as T and
K grow. The GI solution, first introduced by Gittins and Jones (1979), eliminates
this computational infeasibility by ensuring that the optimal solution to (6.7.2) can be
obtained by simply allocating every patient to the arm with the highest GI. Similarly
to equation (6.2.1) for the unknown variance case, the GIs, G(ỹk,t, σk, nk,t), for the
known variance case in (6.7.2) can be expressed as
G(ỹk,t, σk, nk,t) = ỹk,t + σkG(0, 1, n0k + nk,t, d), (6.7.3)
where G(0, 1, n0k +nk,t, d) denotes the GI value of a standardised bandit problem with
posterior mean 0, standard deviation 1, implicit sample size n0k, nk,t observations and
discount factor d (Gittins et al., 2011, Theorem 7.13). These were first computed
in Jones (1975). Table 6.7.1 shows indices corresponding to the unknown variance
case, as used in Sections 6.2–6.5, based on those presented in Gittins et al. (2011,
Table 8.3).
We implement the solution in (6.7.3) at a very low computational cost by calcu-
lating the values of G(0, 1, n0k + nk,t, d) in advance and interpolating from the tables
printed in Gittins et al. (2011, pp. 261–262). Details on how to compute these indices
using value iteration can be found in Gittins et al. (2011, Chapters 7 and 8). Using
(6.7.3) and the GI rule, we can compute the FLGI probabilities for normally dis-
tributed endpoints (with known variance) using equation (3) in Villar et al. (2015b).
We now assume that instead of enrolling patients one-by-one, patients are enrolled
in groups of size b over J stages, so that J × b = T . Our response-adaptive rule will
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sequentially randomise the next b patients among the K + 1 treatments at stage j
(j = 1, . . . , J) given the data up to and including block j − 1 according to what the
GI rule would do.
Example
We now illustrate the rule’s implementation using an example for the case of known
variances. We calculate the FLGI probabilities using the simplest possible case of a
two-arm trial testing a control treatment (k = 0) against an experimental treatment
(k = 1) with a block of size two (b = 2) and a known, common variance of σ2k =
σ2 = 1. We assume a prior of µk ∼ N(0, 1) so that the initial state, (ỹk,0, n0k), is
(0, 1) for both k = {0, 1}. Suppose further that both patients are allocated to the
control treatment in the first block of the trial resulting in responses y0,1 = 3.1 and
y0,2 = −0.4. The updated state after the first observation becomes (ỹ0,1, n00 + n0,1) =
(1.55, 2) and after the second observation becomes (ỹ0,2, n
0




(0.9, 3). Consequently, for the second block, the prior parameters for the control and
experimental treatment respectively are (0.9, 3) and (0, 1), i.e. µ0 ∼ N(0.9, 13) and
µ1 ∼ N(0, 1).
From equation (6.7.3), setting d = 0.995 and using Gittins et al. (2011, Table 8.1)5,





= 1.8493. For the experimental treatment, we only have the information
available from the initial state (since no observations have yet been observed on this





Given that the control treatment has the maximum GI, the first patient of the
second block (i.e. patient 3) is allocated to the control treatment with probability 1
since there is only one optimal action possible at this point. If we denote the ran-
dom outcome of this patient by Y0,3, then the updated state for the control treatment
5Note that Gittins et al. (2011, Table 8.1) provides values of (n0k+nk,t)(1−d)
1
2G(0, 1, n0k+nk,t, d).
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is (Ỹ0,3, n
0






. Thus, the corresponding index for the con-
trol treatment can be expressed as a function of the random outcome from patient









For the experimental treatment, we have no new information and so the corre-
sponding index remains unchanged at 1.8175. According to the GI rule, it will be
optimal to allocate the control treatment to the second patient of the second block if
and only if G0(Ỹ0,3, 1, 3) > G1(0, 1, 0) = 1.8175, that is, if Y0,3 > 1.4024. Since Y0,3 ∼
N(0.9, 1), we expect this to happen with probability P(Y0,3 > 1.4024) = 0.3077. If
Y0,3 < 1.4024, which happens with probability 0.6923, then G0(Ỹ0,3, 1, 3) < G1(0, 1, 0)
and the second patient of the second block is optimally allocated to the experimental
treatment. Notice that if Y0,3 = 1.4024, then there is a tie in the index values and
it is equally optimal to allocate any of the two treatments. Although theoretically
we expect this to happen with probability 0 (since we are dealing with a continuous
distribution), in practice this is possible and if it were to happen, we would simply
randomise with probability 0.5. Hence, the probability of a patient receiving either
the control or experimental treatment when using the normal FLGI procedure in this
block is 1+1×P(Y0,3>1.4024)
2
= 0.6538 and 0+1×P(Y0,3<1.4024)
2
= 0.3462, respectively. Figure
6.7.1 illustrates how the FLGI probabilities for block two, given the data in block one,
are computed via a probability tree.
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aGI0,3 = 1
G0(0.9,1,2) = 1.8493
G1(0, 1, 0) = 1.8175
aGI1,4 = 1










Figure 6.7.1: The FLGI rule and a probability tree of all trial histories using the GI
rule when K + 1 = 2, b = 2, d = 0.995 and the state at the start of the second block,
(ỹk,2, n
0
k + nk,2), is (0.9, 3) for arm k = 0 and (0, 1) for arm k = 1. Bold text indicates
the allocated treatment under the GI rule {aGIk,t}. (Note that for simplicity of the
illustration we have omitted the branch corresponding to the case when Y0,3 = 1.4024
since P(Y0,3 = 1.4024) = 0).
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d 0.5 0.6 0.7 0.8 0.9 0.95 0.99 0.995
n0k + nk,t
2 0.23984 1.04741 1.55545 2.81630 5.16921 10.14092 39.33433 65.58475
3 0.15620 0.21476 0.29804 0.43425 0.73571 1.16561 3.10200 4.60490
4 0.09486 0.13001 0.17914 0.25664 0.41606 0.61934 1.34279 1.81263
5 0.07058 0.09673 0.13323 0.19047 0.30608 0.44776 0.90524 1.17299
6 0.05679 0.07791 0.10742 0.15369 0.24666 0.35900 0.70542 0.89632
7 0.04779 0.06564 0.09061 0.12983 0.20866 0.30352 0.59010 0.74336
8 0.04135 0.05685 0.07858 0.11278 0.18165 0.26451 0.51233 0.64259
9 0.03649 0.05021 0.06948 0.09988 0.16128 0.23525 0.45557 0.57012
10 0.03268 0.04500 0.06234 0.08974 0.14527 0.21234 0.41187 0.51498
20 0.01611 0.02228 0.03106 0.04515 0.07444 0.11090 0.22299 0.28120
30 0.01072 0.01485 0.02076 0.03032 0.05049 0.07615 0.15786 0.20137
40 0.00804 0.01115 0.01560 0.02285 0.03829 0.05821 0.12347 0.15903
50 0.00643 0.00892 0.01250 0.01834 0.03086 0.04719 0.10189 0.13229
60 0.00536 0.00744 0.01043 0.01532 0.02586 0.03971 0.08697 0.11368
70 0.00459 0.00638 0.00895 0.01316 0.02225 0.03429 0.07599 0.09991
80 0.00402 0.00558 0.00784 0.01153 0.01953 0.03018 0.06755 0.08927
90 0.00357 0.00496 0.00697 0.01026 0.01741 0.02696 0.06084 0.08077
100 0.00321 0.00447 0.00627 0.00924 0.01570 0.02436 0.05538 0.07381
200 0.00161 0.00224 0.00314 0.00464 0.00793 0.01242 0.02944 0.04024
300 0.00107 0.00149 0.00210 0.00310 0.00531 0.00834 0.02015 0.02790
400 0.00080 0.00112 0.00157 0.00233 0.00399 0.00628 0.01534 0.02142
500 0.00064 0.00090 0.00126 0.00186 0.00319 0.00504 0.01239 0.01740
600 0.00054 0.00075 0.00105 0.00155 0.00266 0.00421 0.01040 0.01466
700 0.00046 0.00064 0.00090 0.00133 0.00228 0.00361 0.00896 0.01268
800 0.00040 0.00056 0.00079 0.00116 0.00200 0.00316 0.00787 0.01117
900 0.00036 0.00050 0.00070 0.00104 0.00178 0.00281 0.00702 0.00999
1000 0.00032 0.00045 0.00063 0.00093 0.00160 0.00253 0.00634 0.00903
Table 6.7.1: Gittins indices for a normal reward process with unknown variance where
d and n0k + nk,t denote the discount factor and total amount of information, respec-
tively. These values are based on those reported in Gittins et al. (2011, Table 8.3).
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6.7.2 Effect of Discount Factor on FLGI Performance
A practical consideration for our design is the choice of discount factor, d. We recom-
mend choosing d to be close to that obtained when applying the formula suggested
by Wang (1991b), namely, d = 1−1/T , where T is the trial size. Here, we discuss the
implications of not following this recommendation on the performance of the FLGI
(with known variance) by presenting results corresponding to d = 0, 0.5 and 0.99 in
Table 6.7.2. Note that the results for d = 0.995 (the discount factor used throughout)
are shown in (i) of Table 6.7.3. When d = 0, the design is analogous to a fully myopic
policy which treats every patient as if they are the last one in the trial. In contrast,
the closer d is to 1, the greater the influence that potential responses from future
participants have on allocation decisions made earlier in the trial, that is, the more
“forward looking” the design will be. Thus, we expect the patient benefit measures
to increase with d (up to a limit determined by the actual trial size), as illustrated in
Table 6.7.2. In particular, Table 6.7.2 shows that as d increases from 0 to 0.995 for
b = 1, E(p∗) increases by 0.164, which is equivalent to 11 more patients receiving the
superior arm, and the relative ETO increases by 17.77%. As a result of the greater
imbalance between the treatment arms for larger d, the bias of the treatment effect
estimator (under H1) is also increased.
Interestingly, for smaller d, we observe that the patient benefit measures increase
(up to around b = 9) followed by a decrease. This is due to an interaction between
the discount factor and block size, whereby the increase in block size counteracts
the myopic effect of a small d by forcing learning and consequently improving patient
benefit. However, as the block size continues to grow, the effect of the design becoming
more balanced supersedes the effect of the discount factor, causing the patient benefit
to now reduce. Therefore, when choosing d, it is important to consider which block
size will be used.
In terms of the power of the design, it increases somewhat with the size of d as
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illustrated by Table 6.7.2 which shows that the power exhibited for the FLGI when
d = 0 and b = 1 is 0.213 compared to 0.229 when d = 0.995. This makes sense because
increasing d from a value that is much smaller than its recommendation for a fixed T
reduces the myopic nature of the rule, meaning it will explore more of the arms (thus
increasing power) and make better choices (also increasing patient benefit).
The discount factor also affects the variability of the allocations, which decreases
considerably with the value of d under both H0 and H1. For example, Table 6.7.2
shows that under H1, the standard deviation (s.d.) of p∗ when d = 0 and b = 1 is
0.43, which is 2.7 times larger than the corresponding s.d. when d = 0.995. Given that
allocations under index-based designs (and response-adaptive designs more generally)
can already be very variable, it does not make sense to choose a discount factor which
exacerbates this even further.
A further practical drawback of using a discount factor that is too small is that
it will increase the likelihood of the design allocating all patients to only one of the
treatments (due to an under exploration). The number of times this occurred out of
the 50,000 trial realisations is reported in the “Discarded” column of Table 6.7.2. For
example, when d = 0 and b = 1, more than half of the 50,000 trial realisations under
H1 (namely 25,621) resulted in this extreme allocation. Therefore, for the purpose
of calculating the test statistic (and hence power) and bias values in these cases, we
randomly sampled an observation from the distribution corresponding to the missing
arm instead. In contrast, when d = 0.995, this problem did not occur in any of the
50,000 trial realisations (and similarly when d = 0.99).
Note that all of the aforementioned differences are most pronounced for smaller
block sizes (which is when the design is most adaptive) since as the block size grows
and the FLGI design becomes more balanced, the respective performance measures
eventually converge, irrespective of the value of d.
Overall, provided that d is near to the recommendation suggested by Wang (1991b),
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the performance of the FLGI will be similar — as illustrated by the results for d = 0.99
(Table 6.7.2) and d = 0.995 (Table 6.7.3(i)). However, choosing d to be too small in
relation to T can alter the behaviour of the design significantly. Moreover, if we
were to use this design in a rare disease context, where we envisage it would be best
suited, d should be chosen to be large enough so that we account for all of the patient
outcomes in the adaptations and hence ensure patient benefit for all.
µ0 = µ1 = 0.155 µ0 = 0.155, µ1 = 0.529
b z1−α α E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) Discarded 1− β E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) Discarded
d = 0 (Myopic)
1 1.827 0.050 0.498 (0.48) -0.14 (5.45) 0.00 (0.69) 14707 0.213 0.718 (0.43) 23.92 (12.49) 0.08 (0.68) 25621
2 1.829 0.049 0.497 (0.46) 0.02 (5.42) 0.00 (0.60) 7970 0.222 0.761 (0.39) 28.52 (11.53) 0.06 (0.60) 13789
4 1.799 0.050 0.501 (0.43) 0.12 (5.49) -0.00 (0.50) 2211 0.266 0.810 (0.32) 33.87 (10.13) 0.05 (0.48) 3889
6 1.776 0.050 0.499 (0.41) -0.24 (5.44) -0.00 (0.42) 598 0.312 0.832 (0.27) 36.44 (9.03) 0.05 (0.39) 1093
9 1.752 0.050 0.501 (0.38) 0.05 (5.41) -0.00 (0.33) 94 0.383 0.840 (0.22) 37.12 (8.06) 0.04 (0.31) 174
12 1.720 0.052 0.502 (0.35) 0.46 (5.43) -0.00 (0.29) 15 0.448 0.837 (0.19) 36.87 (7.44) 0.03 (0.26) 28
18 1.708 0.050 0.499 (0.31) -0.07 (5.45) 0.00 (0.24) 2 0.533 0.814 (0.15) 34.39 (6.80) 0.02 (0.22) 3
36 1.676 0.050 0.499 (0.21) 0.11 (5.40) 0.00 (0.18) 0 0.694 0.720 (0.10) 24.23 (6.05) 0.00 (0.17) 0
d = 0.5
1 1.819 0.050 0.497 (0.46) 0.02 (5.42) 0.00 (0.66) 4894 0.228 0.772 (0.39) 29.64 (11.38) 0.07 (0.66) 18359
2 1.818 0.049 0.501 (0.44) 0.03 (5.45) -0.00 (0.58) 2637 0.243 0.804 (0.35) 33.38 (10.54) 0.07 (0.58) 9769
4 1.770 0.054 0.497 (0.42) -0.15 (5.47) 0.00 (0.49) 669 0.287 0.832 (0.29) 36.20 (9.45) 0.07 (0.46) 2696
6 1.765 0.052 0.499 (0.40) -0.25 (5.45) -0.00 (0.41) 192 0.329 0.844 (0.25) 37.72 (8.60) 0.06 (0.38) 763
9 1.757 0.049 0.501 (0.37) 0.14 (5.45) -0.00 (0.33) 24 0.391 0.844 (0.21) 37.41 (7.80) 0.05 (0.30) 101
12 1.749 0.048 0.500 (0.34) -0.05 (5.39) -0.00 (0.29) 3 0.441 0.838 (0.18) 37.13 (7.26) 0.04 (0.26) 25
18 1.707 0.050 0.503 (0.30) -0.17 (5.43) -0.00 (0.24) 0 0.543 0.816 (0.15) 34.62 (6.70) 0.03 (0.22) 0
36 1.677 0.049 0.501 (0.21) -0.16 (5.43) -0.00 (0.18) 0 0.693 0.720 (0.10) 24.04 (6.09) 0.01 (0.17) 0
d = 0.99
1 1.981 0.050 0.498 (0.35) 0.08 (5.43) 0.00 (0.53) 0 0.209 0.882 (0.19) 41.94 (7.38) 0.22 (0.47) 0
2 1.944 0.051 0.502 (0.34) 0.08 (5.44) -0.00 (0.47) 0 0.255 0.879 (0.17) 41.44 (7.20) 0.19 (0.42) 0
4 1.907 0.051 0.501 (0.32) -0.31 (5.45) -0.00 (0.41) 0 0.313 0.871 (0.16) 40.62 (6.91) 0.14 (0.36) 0
6 1.885 0.049 0.500 (0.31) -0.20 (5.41) -0.00 (0.36) 0 0.349 0.865 (0.15) 39.95 (6.73) 0.11 (0.31) 0
9 1.850 0.049 0.501 (0.29) 0.36 (5.44) -0.00 (0.31) 0 0.409 0.851 (0.14) 38.38 (6.64) 0.08 (0.26) 0
12 1.816 0.051 0.499 (0.28) 0.16 (5.42) 0.00 (0.27) 0 0.467 0.839 (0.13) 37.11 (6.44) 0.06 (0.23) 0
18 1.758 0.050 0.499 (0.25) -0.10 (5.44) 0.00 (0.23) 0 0.556 0.811 (0.12) 33.89 (6.31) 0.04 (0.20) 0
36 1.684 0.051 0.499 (0.19) -0.03 (5.44) 0.00 (0.18) 0 0.710 0.716 (0.10) 23.45 (6.02) 0.01 (0.17) 0
Table 6.7.2: The effect of altering the discount factor, d, on the performance of the
FLGI for a two-armed trial when σ2k = 0.64
2 is assumed known and T = 72, averaged
over 50,000 trial replications. NB The “Discarded” column reports the number of
trials that resulted in an extreme allocation with all patients being allocated to only
one arm.
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6.7.3 Effect of Prior Information on FLGI Performance
In this Appendix, we investigate how sensitive the FLGI is to the choice of prior
on the location parameter µk when the variance is assumed known. Ultimately, the
choice of prior on µk determines which GI we start the allocation rule with. The
minimum amount of information we can assume, a priori, in order to initiate the GI
policy is n0k = 1 (known variance case) and n
0
k = 2 (unknown variance case) since the
GI is undefined for n0k = 0. This gives rise to a normal prior with large variance (see
Figure 6.7.2) which can be used as a so-called ‘non-informative’ prior (Spiegelhalter
et al., 2004, p. 62). All of the results presented thus far correspond to this ‘non-
informative’ prior so that we can report the effects on patient response and other
relevant statistical properties of the FLGI alone, without the influence of additional
prior information. However, we now turn our attention to using different priors in
conjunction with the FLGI. We use the results for the ‘non-informative’ prior (in
(i) of Table 6.7.3) as a reference, and therefore refer to it as a reference prior from
hereon (in keeping with the terminology used in Spiegelhalter et al. (1994, 2004), for
example).
Taking the two-armed example from Section 6.3.2 (but now assuming known vari-
ance), we follow the suggestion provided in Spiegelhalter et al. (2004, Chapter 5)
and consider two archetypal priors on µ1, namely, the sceptical and enthusiastic prior
(with the reference prior on µ0).
The sceptical prior attempts to formalise the belief that large treatment differences
are unlikely. In particular, the sceptical normal prior on µ1 is centred around the (null
hypothesis) value of 0.155 with only a small probability, say 5%, that the true value
exceeds the alternative hypothesis value of 0.529, i.e. P(µ1 > 0.529) = 0.05. This










= 0.529− 0.155, (6.7.4)
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where n01 is the implicit (prior) sample size and z0.05 = −1.645 is the fifth percentile
of the standard normal distribution. Rearranging equation (6.7.4) gives n01 ≈ 8.
Intuitively, this is equivalent to having eight patients’ worth of information (with null
mean) available at the start of the trial, that is, approximately 11% of the trial sample
size expressing scepticism and showing no treatment difference. The performance
measures of our design when starting with this prior on the experimental arm are
shown in (ii) of Table 6.7.3 for all block sizes, b.
The enthusiastic prior, on the other hand, is centred on the alternative hypothesis
value of 0.529 (with the same variance as the sceptical prior) and specifies that there
is little evidence of no treatment effect a priori, i.e. there is a 5% chance of observing a
value less than the null mean of 0.155. This corresponds to the following normal prior






, which is equivalent to having already observed
eight ‘enthusiastic’ responses before the start of the trial. The corresponding results
when starting with this prior on the experimental arm are displayed in (iii) of Table
6.7.3.
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µ0 = µ1 = 0.155 µ0 = 0.155, µ1 = 0.529
b z1−α α E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.) 1− β E(p∗) (s.d.) RelETO% (s.d.) Bias (s.d.)
(i) Reference (n00 = 1) vs. Reference (n
0
1 = 1)
1 1.991 0.053 0.500 (0.33) -0.06 (5.42) -0.00 (0.49) 0.229 0.882 (0.16) 41.69 (7.01) 0.22 (0.45)
2 1.969 0.051 0.500 (0.32) 0.34 (5.42) -0.00 (0.44) 0.270 0.878 (0.16) 41.27 (6.85) 0.19 (0.41)
4 1.949 0.046 0.502 (0.30) 0.32 (5.43) -0.00 (0.38) 0.313 0.870 (0.14) 40.30 (6.65) 0.15 (0.35)
6 1.911 0.048 0.499 (0.29) -0.03 (5.45) 0.00 (0.34) 0.360 0.861 (0.14) 39.38 (6.59) 0.11 (0.30)
9 1.864 0.049 0.498 (0.28) -0.15 (5.43) 0.00 (0.30) 0.423 0.848 (0.13) 38.14 (6.53) 0.08 (0.26)
12 1.825 0.050 0.502 (0.26) 0.11 (5.42) -0.00 (0.27) 0.478 0.834 (0.13) 36.68 (6.41) 0.06 (0.23)
18 1.766 0.051 0.502 (0.24) 0.14 (5.44) -0.00 (0.23) 0.565 0.807 (0.12) 33.72 (6.30) 0.04 (0.20)
36 1.682 0.050 0.500 (0.19) 0.26 (5.45) 0.00 (0.17) 0.712 0.714 (0.09) 23.25 (5.98) 0.01 (0.17)
(ii) Reference (n00 = 1) vs. Sceptical (n
0
1 = 8)
1 2.004 0.051 0.470 (0.32) 0.25 (5.44) 0.07 (0.43) 0.427 0.844 (0.18) 37.72 (6.51) 0.22 (0.41)
2 1.953 0.050 0.479 (0.31) -0.37 (5.43) 0.05 (0.38) 0.491 0.833 (0.17) 36.22 (6.46) 0.17 (0.34)
4 1.913 0.050 0.484 (0.29) -0.21 (5.43) 0.04 (0.33) 0.538 0.820 (0.17) 34.96 (6.38) 0.13 (0.29)
6 1.886 0.049 0.491 (0.28) -0.49 (5.43) 0.03 (0.31) 0.565 0.811 (0.16) 33.92 (6.44) 0.10 (0.26)
9 1.856 0.051 0.494 (0.27) -0.26 (5.45) 0.02 (0.28) 0.590 0.800 (0.16) 32.92 (6.40) 0.08 (0.24)
12 1.844 0.049 0.497 (0.26) 0.27 (5.43) 0.02 (0.25) 0.597 0.788 (0.15) 31.44 (6.41) 0.07 (0.22)
18 1.792 0.051 0.499 (0.24) -0.20 (5.42) 0.02 (0.22) 0.650 0.771 (0.14) 29.61 (6.32) 0.05 (0.20)
36 1.715 0.052 0.483 (0.18) 0.24 (5.43) 0.01 (0.18) 0.710 0.717 (0.12) 23.69 (6.09) 0.02 (0.17)
(iii) Reference (n00 = 1) vs. Enthusiastic (n
0
1 = 8)
1 1.964 0.047 0.315 (0.24) -0.00 (5.41) 0.14 (0.37) 0.176 0.920 (0.08) 45.86 (5.79) 0.24 (0.41)
2 1.908 0.052 0.323 (0.24) -0.44 (5.45) 0.13 (0.34) 0.234 0.911 (0.08) 44.80 (5.83) 0.20 (0.36)
4 1.892 0.049 0.329 (0.23) -0.02 (5.42) 0.11 (0.31) 0.275 0.902 (0.09) 43.88 (5.82) 0.17 (0.33)
6 1.872 0.050 0.332 (0.22) 0.24 (5.41) 0.10 (0.30) 0.313 0.896 (0.09) 43.38 (5.86) 0.15 (0.31)
9 1.864 0.048 0.337 (0.22) 0.15 (5.39) 0.09 (0.28) 0.348 0.887 (0.09) 42.32 (5.86) 0.13 (0.29)
12 1.834 0.052 0.338 (0.21) -0.10 (5.39) 0.08 (0.27) 0.388 0.878 (0.09) 41.37 (5.87) 0.12 (0.28)
18 1.804 0.054 0.338 (0.20) -0.19 (5.45) 0.07 (0.25) 0.444 0.865 (0.10) 39.83 (5.95) 0.10 (0.25)
36 1.761 0.050 0.324 (0.17) 0.08 (5.41) 0.05 (0.21) 0.515 0.836 (0.11) 36.62 (6.07) 0.05 (0.21)
Table 6.7.3: The effect of using archetypal priors on the performance of the FLGI
for a two-armed trial when σ2k = 0.64
2 is assumed known, T = 72 and d = 0.995,
averaged over 50,000 trial replications.
Conclusions
The main conclusions to draw from these experiments are that when using the FLGI
in the known variance case with a sceptical prior on the experimental arm, the power
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of the design increases whilst the patient benefit measures decrease relative to the
corresponding results when starting with the reference prior. This is what we would
expect to observe because the sceptical prior implies that there is a 0.95 probability
that µ1 lies below 0.529 (as depicted in Figure 6.7.2) which is incorrect under H1, and
as such it provides the FLGI algorithm with a ‘false start’. Thus, it takes longer for
the design to correctly identify the best arm, resulting in fewer patients allocated to
the superior arm but a larger power due to less imbalance.
In contrast, when starting with an enthusiastic prior on the experimental arm,
the reverse happens (as shown in (iii) of Table 6.7.3); the power decreases whilst the
patient benefit measures increase (relative to starting with the reference prior). Again,
this is not surprising because the enthusiastic prior specifies that the most likely value
of µ1 is 0.529 (as illustrated in Figure 6.7.2). Under H1, this is correct and so it gives
the algorithm a ‘head start’ in the right direction meaning it identifies the superior
arm quicker. Thus, less allocations are made to the control arm resulting in more
imbalance and hence reduced power. Under H0, however, this prior specification on
the experimental arm is incorrect and so the FLGI incorrectly allocates fewer patients
to the control arm, as observed in (iii) of Table 6.7.3 (where the control arm is taken
to be the ‘superior’ arm under H0). This explains why only ≈ 33% of patients in the
trial are allocated to the control arm for all block sizes under H0. Fewer observations
on the control arm leads to an underestimation of µ̂0 and consequently the treatment
effect estimator under H0 exhibits bias. It is also worth noting that the variability in
the allocations decreases when using the enthusiastic prior (relative to the reference
prior) since, under H1, the observed data and prior information match which reduces
the uncertainty of the allocations.
Overall, our recommendation is to be very cautious when incorporating prior in-
formation into bandit-based designs such as the FLGI because it influences the speed
at which the design updates and favours an arm (depending on how informative the
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prior is). Since these designs are so dynamic anyway, there is not as much to gain
from using prior information as there may be with less responsive designs. If the
prior specification is correct, then the incoming data will further enhance the effect
of the prior and the design will favour the superior arm sooner, whereas if the prior is
misspecified, the bandit may spend more time in the exploration phase or degenerate
to allocating all patients to one arm. However, it is likely that the incoming data
during the trial will eventually dilute the effect of the misspecified prior. How long
the design takes to correct for the misspecification depends on the value of n0k; the
greater its value, the more influence the prior will have. Therefore, if one wishes to
use prior information in conjunction with the FLGI, we suggest setting a small value
for n0k.
















Figure 6.7.2: Sceptical and enthusiastic prior densities with the reference prior de-
picted in black. The sceptics’ probability that the true mean response is greater than
0.529 (the alternative value) is 0.05, shown by the blue shaded region. The enthusi-
asts’ probability that the true mean response is less than 0.155 (the null value) is also
0.05, shown by the green shaded region.
Chapter 7
Conclusions and Further Work
7.1 Summary and Contributions
This thesis connects two lines of work, namely, bandit methodology and clinical trial
design. In particular, we have proposed a range of clinical trial designs which are
based upon solutions to the multi-armed bandit problem (MABP) and thus share the
same principal goal of maximising patient benefit within the trial. However, each
design is intended to address a different issue that has been suggested as preventing
such bandit-based designs from being implemented in practice. Below, we briefly
outline each design in turn and highlight their main contributions. The main points
are also summarised succinctly in Table 7.2.1.
7.1.1 Chapter 3, CRDP
In Chapter 3, we proposed the constrained randomised dynamic programming (CRDP)
design, so called because we introduced: (i) a constraint to force a minimum number
of patients on each arm, and (ii) randomisation into an otherwise deterministic de-
sign based on the optimal dynamic programming (DP) solution. Several performance
measures of the proposed design were evaluated and compared to alternative designs
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through extensive simulation studies using a recently published trial as motivation.
For simplicity, a two-armed trial with binary endpoints and immediate responses was
considered. Simulation results for the proposed design showed that: (i) the percent-
age of patients allocated to the superior arm is much higher than in the traditional
fixed randomised design; (ii) relative to the optimal DP design, the power is largely
improved upon and (iii) it exhibits only a very small bias and mean squared error of
the treatment effect estimator.
7.1.2 Chapter 4, FCRDP
CRDP, as with most response-adaptive designs, hinges on the limiting assumption of
patient responses being available before allocation of the next patient. This is one of
the greatest challenges, both for clinical trial practice (Rosenberger et al., 2012) and
the bandit literature (Caro and Yoo, 2010). Therefore, in Chapter 4, not only do we
study the impact of delayed responses on CRDP, but we take it one step further by
extending the design for the fixed delay case (e.g. constant arrivals and fixed response
time). This design is referred to as FCRDP. Simulation results revealed that CRDP
continues to offer patient benefit (albeit less than in the immediate response case)
even when the information during each adaptation is reduced due to the delay. It
is therefore relatively robust to delayed responses. Nevertheless, implementation of
FCRDP in the same scenarios showed that there are worthwhile patient benefit gains
to be made, with minimal impact on the corresponding power, bias and mean squared
error, by utilising the pipeline data in the updates of the allocation probabilities.
7.1.3 Chapter 5, RCRDP
Having a fixed number of patients in the pipeline is only representative of a small
number of trials. Therefore, in Chapter 5, we extend the CRDP design to the most
general case so that it can be applied to a greater variety of trials which encounter
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a random number of patients in the pipeline (including those with random arrivals
or random response times, or both). This aptly takes the initialism RCRDP. When
implemented for a hypothetical trial with exponential inter-arrival times and a fixed
follow-up time, RCRDP was shown to perform very similarly to FCRDP with respect
to all performance measures.
Conclusion of DP-Based Designs
Overall, CRDP and its delayed variants (with suggested degree of randomisation
p = 0.9 and constraining ` = 0.15n) were found to strike a balance between the
two conflicting objectives of patient benefit (individual ethics) and power (collec-
tive ethics), which is indicative of a “good clinical trial design” (Lee et al., 2010)
and “properly chosen RAR method” (Du et al., 2015). By adjusting the constraint
and/or degree of randomisation, CRDP provides a continuum of designs with DP
and fixed randomisation at the extremes. As such, the design can be tailored to suit
the individual objectives of the trial and attain the most appropriate balance. This
greatly increases the prospects of a DP-based design being implemented in clinical
trial practice.
One of the main practical limitations of the aforementioned DP-based designs is
their associated computational expense (Jiang et al., 2013) which grows exponentially
with the patient horizon (Villar et al., 2015a; Ahuja and Birge, 2019). However, this
is not as prohibitive as it is commonly perceived to be in the literature (Jacko, 2019b,
Section 7.1) which emphasises the importance of collaboration between disciplines.
In particular, the recent survey by Jacko (2019b) demonstrates that a computer with
32GB RAM is able to optimally solve the two-armed Bernoulli bandit problem up
to a trial size of 1440 or 4440, depending on whether storage of the optimal allo-
cation policy is or is not required, respectively (see also Jacko, 2019a, for details of
implementation).
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The augmentation of the state space to include the delay parameters in the FCRDP
and RCRDP designs increases the computational complexity even further. Conse-
quently, such designs can only be applied to relatively small-scale trials. Nevertheless,
for rare disease settings, which is where we anticipate that our proposed designs are
most pertinent, this does not pose a serious problem. For example, a review by Bell
and Smith (2014) found that 67% of rare disease trials had 0–50 patients, 19% had
between 51–100 patients and only 14% had more than 100 patients (with just 1% over
500 patients). Therefore, even with the additional complexity caused by the delay,
our designs maintain computational feasibility for the most commonly encountered
sample sizes in rare disease trials. Moreover, the ideas from Jacko (2019a) could be
applicable and useful for developing a code that can solve the delayed model for larger
trials than those considered in this thesis.
7.1.4 Chapter 6, FLGI
Motivated by the fact that the “RAR literature dealing with continuous outcomes is
much smaller and less developed” (Hu and Rosenberger, 2006; Flournoy et al., 2013)
and “the generalisation of [RAR] features to the multiple arm setting has been less
explored” (Viele et al., 2020), we propose a RAR design for multi-armed trials with
continuous outcomes that are assumed to be normally distributed with unknown,
non-homogeneous variances. This design is based on the Gittins index (GI) solution
to the MABP, which we refer to as FLGI (the “FL-” indicative of its forward-looking
nature). Compared to the DP solution, this approach is much simpler to commu-
nicate and be understood by all parties involved in the drug development process,
including trial stakeholders, participants, etc. (Pallmann et al., 2018). Moreover, it
avoids the computational burden associated with DP-based designs, thus can easily
be implemented in multi-armed trials, for example.
In contrast to previous chapters, we implement the GI-based design in a group
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sequential setting. This ameliorates the logistical difficulties of having to update
the randomisation probabilities after each patient has been observed (Chappell and
Karrison, 2006), which is another main reason cited for the limited uptake of RAR
designs (Karrison et al., 2003; Wason et al., 2019).
We illustrate the proposed procedure by simulations in the context of phase II
cancer trials, and compare its performance against a variety of existing designs. Re-
sults show that there are efficiency and patient benefit gains of using RAR designs,
such as FLGI, with a continuous endpoint instead of artificially dichotomising to form
a binary one. These gains persist even if an anticipated low rate of missing data is
imputed online using an approach suggested in this chapter. The effect of varying the
prior information, as well as the discount factor, on the performance of FLGI is also
evaluated. Additionally, we demonstrate that protecting allocation to the control arm
continues to substantially improve patient benefit, whilst achieving similar power to
the traditional FR, in multi-armed trials with normal outcomes.1
7.1.5 Areas Covered
Collectively, we have covered a broad range of topics from DP policies to index policies,
two-armed trials to multi-armed trials, binary endpoints to continuous endpoints,
sequential designs to group-sequential designs, ‘non-informative’ priors to informative
priors, as well as the problem of missing data through either delayed responses or loss
to follow-up. These are central to the development and application of bandit-based
designs to clinical practice. However, not all of these issues have been covered by
any one design which leaves scope for many natural extensions. In particular: the
generalisation of the DP-based designs to endpoints other than binary, the evaluation
of the DP-based designs in multi-armed settings, the application of the DP-based
designs to a group-sequential setting, the incorporation of prior information into the
1Different control allocations for RAR designs in a binary response, multi-armed setting have
recently been compared in Viele et al. (2020).
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DP-based designs (by eliciting expert opinion or using historical data from a related
trial, for example, see Hampson et al., 2014), the incorporation of delayed responses
into the GI-based design, the extension of FLGI to other endpoints (e.g. exponential),
etc. Note that such practicalities can be taken into account by: (i) evaluating the
original design via a simulation study which allows for the practicality of interest
(as in Section 4.2 when exploring the impact of delays on CRDP, for example), or
(ii) extending the modelling framework to incorporate the required practicality (as
in Chapter 5 when extending the CRDP model to incorporate delayed responses, for
example).
Moreover, there are several remaining challenges that we have not addressed in
this thesis, some of which have already been highlighted within the relevant chapters
so we do not repeat them here. We therefore conclude this thesis by suggesting some
general ideas for further work which are applicable to all of the proposed designs.
7.2 Areas of Further Work
7.2.1 Joint Efficacy/Toxicity Outcome
Throughout this thesis, we have restricted attention to the efficacy outcome as an
indication of whether the treatment has been successful or not. However, in practice,
treatment toxicities should be monitored concurrently (Lee et al., 2012). For example,
what if a treatment is efficacious yet causes an adverse reaction in the patient; should
this treatment still be considered a success? This motivates the joint evaluation of
both efficacy and toxicity, particularly for trials testing treatments with a high risk of
severe adverse side effects such as oncology trials. An example of an RAR design based
on a joint efficacy/toxicity outcome is proposed by Ji and Bekele (2009). Adapting
the bandit-based allocation rules proposed in this thesis to reflect both efficacy and
toxicity outcomes remains an open problem.
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7.2.2 Multiple Outcomes
Furthermore, as stated in Kaibel and Biemann (2019), response-adaptive MAB ap-
proaches, such as those developed in this thesis, also have the potential to deter-
mine randomisation probabilities for diseases based on multiple outcomes of interest.
Within the multi-objective MAB literature, the linear scalarised function (Eichfelder,
2008), which transforms the vector of multiple outcomes into a single outcome, is
a popular approach because of its simplicity (Yahyaa and Manderick, 2015). This
would also allow for the outcome variables to be weighted according to their rele-
vance, for example. Whether this is applicable to the clinical trial setting is an area
to be explored.
7.2.3 Alternative Objective Functions
The standard bandit objective, which we have considered throughout this thesis, is
to maximise the expected total reward (i.e. treatment effectiveness) over the time
horizon. However, in a clinical trial context, this may not necessarily be the most
desirable option since “controlling multiple properties of a design may not be easily
achieved through a single utility function” (Zhang et al., 2019). For example, a
treatment which works best on average may also exhibit considerable variability, thus
causing adverse side effects for some patients. In this case, a treatment which is
less effective on average, but has a smaller variability so that its behaviour is more
consistent amongst patients, may be preferred. Therefore, it may be better to explore
alternative objective functions, such as the mean-variance model (Markowitz, 1952).
The mean-variance bandit problem focuses on the problem of selecting the arm which
effectively trades off its expected reward with its variability. Two algorithms have
been proposed by Sani et al. (2012) to solve the mean-variance bandit problem and
it would be interesting to evaluate their performance in the clinical trial setting.
Other objectives that could be incorporated are economical (e.g. the cost of treat-
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ment, see Pertile et al. (2014) and Chick et al. (2017)), quality of life measures such
as invasiveness (e.g. implications of surgical intervention versus a vaccination), or
duration (e.g. is it better to undergo surgery once or receive life-long medication?).
7.2.4 Incorporation of Covariates
Our proposed designs were formulated under the assumption that patients allocated
to the same treatment will have the same expected response. However, in practice this
may be unreasonable if there are certain covariates (such as age and gender) which
influence their response (Zhang et al., 2007), for example. In this case, it may not
be appropriate to use responses from all preceding patients to determine the current
patient’s randomisation probability since only a particular subset of the available
responses may be clinically relevant. This motivates the use of covariate-adjusted
RAR which generalises RAR to include a patient’s covariate profile (Rosenberger and
Lachin, 2016). More specifically, this means that the randomisation probabilities will
not only depend on the history of patient responses, but also on the covariate infor-
mation of previous patients and the current patient. Hence, different randomisation
probabilities will be used for different patient subgroups (Meurer et al., 2012). This
contributes to the personalisation of treatment allocation during the trial, with more
patients receiving the treatment most appropriate for them (Qiao et al., 2019). As
increasing numbers of biomarkers are being identified, particularly in cancer research,
personalised medicine is gaining considerable attention, and hence there is a growing
need for novel trial designs which can make use of this additional information. Con-
sequently, how to incorporate covariate information into the proposed designs forms
a particularly topical and promising area of further research.
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7.2.5 Accounting for Patient Drift
Continuing with the theme of how to adequately reflect patient heterogeneity within
the proposed designs raises the question of how to implement such designs in the pres-
ence of underlying time trends caused by a systematic change in patient characteristics
during the trial. The possibility of so-called patient drift is another major criticism
of using RAR (see Rosenberger et al., 2012, Section 4.3) since if this is not taken into
consideration, the parameter estimates may be biased which would erroneously im-
balance the treatment allocation and inflate the type I error (e.g. Thall et al., 2015).
Sequential tests accounting for linear time trends have been proposed and investigated
in Coad (1991a,b), and the effect of time trends on several response-adaptive rules
has been examined in Coad (1992).
Time trends are more likely to occur in trials with a long duration, such as rare
disease trials in which the recruitment period typically extends over a very long time
(Villar et al., 2018). Since the rare disease setting is where the proposed bandit-based
designs are deemed to be most applicable, it would be useful to first investigate the
impact of time trends on these designs before suggesting how this could be accounted
for. This could also combine with the previous area of further research by including
a particular time trend as a covariate (see e.g. Rosenberger et al., 2001a).
7.2.6 Adding/Dropping Arms
“MABs offer the flexibility to add further treatments easily at any point in time”
(Kaibel and Biemann, 2019). Therefore, further extensions could also explore the
performance of bandit-based designs when additional arms are added to the trial.
This would be relatively straightforward to implement for the GI-based design since
the GI is independent of the number of arms (Villar et al., 2015a). Similarly, the in-
corporation of early stopping rules (for efficacy or futility) (see e.g. Du et al., 2015; Lee
et al., 2010) and optimal stopping times (see e.g. Chick et al., 2017) could potentially
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be investigated.
7.2.7 Dose-Finding Trials
Another direction for future research is applying and extending the concepts covered
in this thesis to the context of dose-finding trials, in which the primary goal is to
find the maximum tolerated dose (MTD) of a treatment. In dose-finding trials, the
different arms represent different dose levels of a treatment, and hence the arms are
now correlated. This induces additional computational complexity into the associated
MABP (relative to the classic MABP with independent arms) which is prohibitive in
most practical situations. However, since dose-finding trials are typically small in
size, the additional computational complexity may be manageable in this context. A
framework for dose-finding trials using the theory of bandit problems was suggested
by Leung and Wang (2002), and generalised to include multiple outcomes and early
termination by Fan and Wang (2006). More recently, the dose-finding problem has
also been posed as a MABP in Kano et al. (2019) and Aziz et al. (2019). In this
context, the trade-off is between finding the MTD and treating as many patients as
possible with the MTD (whilst avoiding allocation to toxic doses).
It is hoped that the ideas raised in this thesis will prompt further development of the
proposed designs and encourage more collaboration between researchers and practi-
tioners.
Proposed design Solution method Simulation setting Main limitations Main issues addressed
CRDP Dynamic Two arms, Immediate responses, Lack of randomisation,
Constrained randomised programming binary endpoint, computationally intensive, insufficient power,
dynamic programming sequential logistically difficult biased estimates
FCRDP Dynamic Two arms Sequential arrivals & Impact of delay,
CRDP adjusted for programming binary endpoint, fixed response time, extension to
fixed pipeline sequential computationally intensive, fixed delays
logistically difficult
RCRDP Dynamic Two arms, Computationally intensive, Extension to
CRDP adjusted for programming binary endpoint, logistically difficult random delays
random pipeline sequential
(C)FLGI Gittins Two & multiple Immediate responses Computational complexity,
(Controlled) Forward- index arms, normal lack of randomisation,
looking Gittins index endpoint with continuous endpoints,
unknown variance, dichotomisation, missing
group sequential data, effect of prior info.
Table 7.2.1: Overview of proposed designs.
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Kelly, F. P. (1981). Multi-armed bandits with discount factor near one: The Bernoulli
case. The Annals of Statistics , 9(5), 987–1001.
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A.,
Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., Alden, C. M., Liu, S., Tang,
X., Khuri, F. R., Tran, H. T., Johnson, B. E., Heymach, J. V., Mao, L., Fossella,
F., Kies, M. S., Papadimitrakopoulou, V., Davis, S. E., Lippman, S. M., and Hong,
W. K. (2011). The BATTLE trial: Personalizing therapy for lung cancer. Cancer
Discovery , 1(1), 44–53.
Korn, E. L. and Freidlin, B. (2011). Outcome-adaptive randomization: Is it useful?
Journal of Clinical Oncology , 29(6), 771.
Kuleshov, V. and Precup, D. (2000). Algorithms for the multi-armed bandit problem.
Journal of Machine Learning Research, 1, 1–32.
Langenberg, P. and Srinivasan, R. (1981). On the Colton model for clinical trials
with delayed observations — Normally-distributed responses. Biometrics , 37(1),
143–148.
Langenberg, P. and Srinivasan, R. (1982). On the Colton model for clinical trials
with delayed observations — Dichotomous responses. Biometrical Journal , 24(3),
287–296.
BIBLIOGRAPHY 218
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